Proposed Exemptions From Certain Prohibited Transaction Restrictions, 77594-77623 [2011-31741]
Download as PDF
77594
Federal Register / Vol. 76, No. 239 / Tuesday, December 13, 2011 / Notices
DEPARTMENT OF LABOR
Employee Benefits Security
Administration
Proposed Exemptions From Certain
Prohibited Transaction Restrictions
Employee Benefits Security
Administration, Labor.
ACTION: Notice of Proposed Exemptions.
AGENCY:
This document contains
notices of pendency before the
Department of Labor (the Department) of
proposed exemptions from certain of the
prohibited transaction restrictions of the
Employee Retirement Income Security
Act of 1974 (ERISA or the Act) and/or
the Internal Revenue Code of 1986 (the
Code). This notice includes the
following proposed exemptions: D–
11517, JPMorgan Chase & Co. and its
Current and Future Affiliates and
Subsidiaries (JPMorgan Chase); D–
11579, Delaware Charter Guarantee &
Trust Co. d\b\a\ Principle Trust
Company (Principle Trust); D–11628,
Aztec Well Servicing Company and
Related Companies Medical Plan Trust
Fund (the Plan); D–11669, Genzyme
Corporation 401(k) Plan (the Plan or the
Applicant); and Retirement Program for
Employees of EnPro Industries (the
Plan), D–11662 et al.
DATES: All interested persons are invited
to submit written comments or requests
for a hearing on the pending
exemptions, unless otherwise stated in
the Notice of Proposed Exemption,
within 45 days from the date of
publication of this Federal Register
Notice.
ADDRESSES: Comments and requests for
a hearing should state: (1) The name,
address, and telephone number of the
person making the comment or request,
and (2) the nature of the person’s
interest in the exemption and the
manner in which the person would be
adversely affected by the exemption. A
request for a hearing must also state the
issues to be addressed and include a
general description of the evidence to be
presented at the hearing. All written
comments and requests for a hearing (at
least three copies) should be sent to the
Employee Benefits Security
Administration (EBSA), Office of
Exemption Determinations, Room N–
5700, U.S. Department of Labor, 200
Constitution Avenue NW., Washington,
DC 20210. Attention: Application
No.ll, stated in each Notice of
Proposed Exemption. Interested persons
are also invited to submit comments
and/or hearing requests to EBSA via
email or fax. Any such comments or
requests should be sent either by email
srobinson on DSK4SPTVN1PROD with NOTICES2
SUMMARY:
VerDate Mar<15>2010
16:27 Dec 12, 2011
Jkt 226001
to: moffitt.betty@dol.gov, or by fax to
(202) 219–0204 by the end of the
scheduled comment period. The
applications for exemption and the
comments received will be available for
public inspection in the Public
Documents Room of the Employee
Benefits Security Administration, U.S.
Department of Labor, Room N–1513,
200 Constitution Avenue NW.,
Washington, DC 20210.
Warning: If you submit written
comments or hearing requests, do not
include any personally-identifiable or
confidential business information that
you do not want to be publiclydisclosed. All comments and hearing
requests are posted on the Internet
exactly as they are received, and they
can be retrieved by most Internet search
engines. The Department will make no
deletions, modifications or redactions to
the comments or hearing requests
received, as they are public records.
SUPPLEMENTARY INFORMATION:
Notice to Interested Persons
Notice of the proposed exemptions
will be provided to all interested
persons in the manner agreed upon by
the applicant and the Department
within 15 days of the date of publication
in the Federal Register. Such notice
shall include a copy of the notice of
proposed exemption as published in the
Federal Register and shall inform
interested persons of their right to
comment and to request a hearing
(where appropriate).
The proposed exemptions were
requested in applications filed pursuant
to section 408(a) of the Act and/or
section 4975(c)(2) of the Code, and in
accordance with procedures set forth in
29 CFR part 2570, subpart B (55 FR
32836, 32847, August 10, 1990).
Effective December 31, 1978, section
102 of Reorganization Plan No. 4 of
1978, 5 U.S.C. App. 1 (1996), transferred
the authority of the Secretary of the
Treasury to issue exemptions of the type
requested to the Secretary of Labor.
Therefore, these notices of proposed
exemption are issued solely by the
Department.
The applications contain
representations with regard to the
proposed exemptions which are
summarized below. Interested persons
are referred to the applications on file
with the Department for a complete
statement of the facts and
representations.
PO 00000
Frm 00002
Fmt 4701
Sfmt 4703
JPMorgan Chase & Co. and Its Current
and Future Affiliates and Subsidiaries
(JPMorgan Chase), Located in New
York, New York
Application Number D–11517
Proposed Exemption
The Department is considering
granting an exemption under the
authority of section 408(a) of the
Employee Retirement Income Security
Act of 1974 (ERISA or the Act) and
section 4975(c)(2) of the Internal
Revenue Code of 1986, as amended (the
Code), and in accordance with the
procedures set forth in 29 CFR part
2570, subpart B (55 FR 32836, 32847,
August 10, 1990).1
Section I. Sales of Auction Rate
Securities From Plans to JPMorgan
Chase: Unrelated to a Settlement
Agreement
If the proposed exemption is granted,
the restrictions of section 406(a)(1)(A)
and (D) and section 406(b)(1) and (2) of
the Act and the sanctions resulting from
the application of section 4975 of the
Code, by reason of section 4975(c)(1)(A),
(D), and (E) of the Code, shall not apply,
effective February 1, 2008, to the sale by
a Plan (as defined in section V(e)) of an
Auction Rate Security (as defined in
section V(c)) to JPMorgan Chase, where
such sale (an Unrelated Sale) is
unrelated to, and not made in
connection with, a Settlement
Agreement (as defined in section V(f)),
provided that the conditions set forth in
section II have been met.
Section II. Conditions Applicable to
Transactions Described in Section I
(a) The Plan acquired the Auction
Rate Security in connection with
brokerage or advisory services provided
by JPMorgan Chase;
(b) The last auction for the Auction
Rate Security was unsuccessful;
(c) Except in the case of a Plan
sponsored by JPMorgan Chase for its
own employees (a JPMorgan Chase
Plan), the Unrelated Sale is made
pursuant to a written offer by JPMorgan
Chase (the Offer) containing all of the
material terms of the Unrelated Sale,
including, but not limited to the most
recent rate information for the Auction
Rate Security (if reliable information is
available). Either the Offer or other
materials available to the Plan provide
the identity and par value of the
Auction Rate Security. Notwithstanding
the foregoing, in the case of a pooled
1 For purposes of this proposed exemption,
references to section 406 of ERISA should be read
to refer as well to the corresponding provisions of
section 4975 of the Code.
E:\FR\FM\13DEN2.SGM
13DEN2
Federal Register / Vol. 76, No. 239 / Tuesday, December 13, 2011 / Notices
srobinson on DSK4SPTVN1PROD with NOTICES2
fund maintained or advised by
JPMorgan Chase, this condition shall be
deemed met to the extent each Plan
invested in the pooled fund (other than
a JPMorgan Chase Plan) receives written
notice regarding the Unrelated Sale,
where such notice contains the material
terms of the Unrelated Sale, including,
but not limited to, the material terms
described in the preceding sentence;
(d) The Unrelated Sale is for no
consideration other than cash payment
against prompt delivery of the Auction
Rate Security;
(e) The sales price for the Auction
Rate Security is equal to the par value
of the Auction Rate Security, plus any
accrued but unpaid interest or
dividends; 2
(f) The Plan does not waive any rights
or claims in connection with the
Unrelated Sale;
(g) The decision to accept the Offer or
retain the Auction Rate Security is made
by a Plan fiduciary or Plan participant
or IRA owner who is independent (as
defined in section V(d)) of JPMorgan
Chase. Notwithstanding the foregoing:
(1) In the case of an individual
retirement account (an IRA, as described
in section V(e) below) which is
beneficially owned by an employee,
officer, director or partner of JPMorgan
Chase, or a relative of any such persons,
the decision to accept the Offer or retain
the Auction Rate Security may be made
by such employee, officer, director,
partner, or relative; or (2) in the case of
a JPMorgan Chase Plan or a pooled fund
maintained or advised by JPMorgan
Chase, the decision to accept the Offer
may be made by JPMorgan Chase after
JPMorgan Chase has determined that
such purchase is in the best interest of
the JPMorgan Chase Plan or pooled
fund; 3
2 This proposed exemption does not address tax
issues. The Department has been informed by the
Internal Revenue Service and the Department of the
Treasury that they are considering providing
limited relief from the requirements of sections
72(t)(4), 401(a)(9), and 4974 of the Code with
respect to retirement plans that hold Auction Rate
Securities. The Department has also been informed
by the Internal Revenue Service that if Auction Rate
Securities are purchased from a Plan in a
transaction described in sections I and III at a price
that exceeds the fair market value of those
securities, then the excess value would be treated
as a contribution for purposes of applying
applicable contribution and deduction limits under
sections 219, 404, 408, and 415 of the Code.
3 The Department notes that the Act’s general
standards of fiduciary conduct also would apply to
the transactions described herein. In this regard,
section 404 requires, among other things, that a
fiduciary discharge his duties respecting a plan
solely in the interest of the plan’s participants and
beneficiaries and in a prudent manner.
Accordingly, a plan fiduciary must act prudently
with respect to, among other things, the decision to
sell the Auction Rate Security to JPMorgan Chase
for the par value of the Auction Rate Security, plus
VerDate Mar<15>2010
16:27 Dec 12, 2011
Jkt 226001
(h) Except in the case of a JPMorgan
Chase Plan or a pooled fund maintained
or advised by JPMorgan Chase, neither
JPMorgan Chase nor any affiliate
exercises investment discretion or
renders investment advice within the
meaning of 29 CFR 2510.3–21(c) with
respect to the decision to accept the
Offer or retain the Auction Rate
Security;
(i) The Plan does not pay any
commissions or transaction costs with
respect to the Unrelated Sale;
(j) The Unrelated Sale is not part of an
arrangement, agreement or
understanding designed to benefit a
party in interest to the Plan;
(k) JPMorgan Chase and its affiliates,
as applicable, maintain, or cause to be
maintained, for a period of six (6) years
from the date of the Unrelated Sale,
such records as are necessary to enable
the persons described below in
paragraph (l)(1), to determine whether
the conditions of this exemption, if
granted, have been met, except that—
(1) No party in interest with respect
to a Plan which engages in an Unrelated
Sale, other than JPMorgan Chase and its
affiliates, as applicable, shall be subject
to a civil penalty under section 502(i) of
the Act or the taxes imposed by section
4975(a) and (b) of the Code, if such
records are not maintained, or not
available for examination, as required,
below, by paragraph (l)(1); and
(2) A separate prohibited transaction
shall not be considered to have occurred
solely because, due to circumstances
beyond the control of JPMorgan Chase
or its affiliates, as applicable, such
records are lost or destroyed prior to the
end of the six-year period;
(l)(1) Except as provided below in
paragraph (l)(2), and notwithstanding
any provisions of subsections (a)(2) and
(b) of section 504 of the Act, the records
referred to above in paragraph (k) are
unconditionally available at their
customary location for examination
during normal business hours by—
(A) Any duly authorized employee or
representative of the Department, the
Internal Revenue Service, or the U.S.
Securities and Exchange Commission;
or
(B) Any fiduciary of any Plan,
including any IRA owner, that engages
in a Sale, or any duly authorized
employee or representative of such
fiduciary; or
any accrued but unpaid interest or dividends. The
Department further emphasizes that it expects Plan
fiduciaries, prior to entering into any of the
proposed transactions, to fully understand the risks
associated with this type of transaction following
disclosure by JPMorgan Chase of all relevant
information.
PO 00000
Frm 00003
Fmt 4701
Sfmt 4703
77595
(C) Any employer of participants and
beneficiaries and any employee
organization whose members are
covered by a Plan that engages in the
Unrelated Sale, or any authorized
employee or representative of these
entities;
(2) None of the persons described
above in paragraph (l)(1)(B)–(C) shall be
authorized to examine trade secrets of
JPMorgan Chase, or commercial or
financial information which is
privileged or confidential; and
(3) Should JPMorgan Chase refuse to
disclose information on the basis that
such information is exempt from
disclosure, JPMorgan Chase shall, by the
close of the thirtieth (30th) day
following the request, provide a written
notice advising that person of the
reasons for the refusal and that the
Department may request.
Section III. Sales of Auction Rate
Securities From Plans to JPMorgan
Chase: Related to a Settlement
Agreement
If the proposed exemption is granted,
the restrictions of section 406(a)(1)(A)
and (D) and section 406(b)(1) and (2) of
the Act and the sanctions resulting from
the application of section 4975 of the
Code, by reason of section 4975(c)(1)(A),
(D), and (E) of the Code, shall not apply,
effective February 1, 2008, to the sale by
a Plan of an Auction Rate Security to
JPMorgan Chase, where such sale (a
Settlement Sale) is related to, and made
in connection with, a Settlement
Agreement, provided that the conditions
set forth in Section IV have been met.
Section IV. Conditions Applicable to
Transactions Described in Section III
(a) The terms and delivery and timing
of the Offer are consistent with the
requirements set forth in the Settlement
Agreement;
(b) The Offer or other documents
available to the Plan specifically
describe, among other things:
(1) How a Plan may determine: the
Auction Rate Securities held by the Plan
with JPMorgan Chase, the purchase
dates for the Auction Rate Securities,
and (if reliable information is available)
the most recent rate information for the
Auction Rate Securities;
(2) The number of shares and par
value of the Auction Rate Securities
available for purchase under the Offer;
(3) The background of the Offer;
(4) That participating in the Offer will
not result in or constitute a waiver of
any claim of the tendering Plan;
(5) The methods and timing by which
Plans may accept the Offer;
(6) The purchase dates, or the manner
of determining the purchase dates, for
E:\FR\FM\13DEN2.SGM
13DEN2
77596
Federal Register / Vol. 76, No. 239 / Tuesday, December 13, 2011 / Notices
srobinson on DSK4SPTVN1PROD with NOTICES2
Auction Rate Securities tendered
pursuant to the Offer;
(7) The timing for acceptance by
JPMorgan Chase of tendered Auction
Rate Securities;
(8) The timing of payment for Auction
Rate Securities accepted by JPMorgan
Chase for payment;
(9) The methods and timing by which
a Plan may elect to withdraw tendered
Auction Rate Securities from the Offer;
(10) The expiration date of the Offer;
(11) The fact that JPMorgan Chase
may make purchases of Auction Rate
Securities outside of the Offer and may
otherwise buy, sell, hold or seek to
restructure, redeem or otherwise
dispose of the Auction Rate Securities;
(12) A description of the risk factors
relating to the Offer as JPMorgan Chase
deems appropriate;
(13) How to obtain additional
information concerning the Offer; and
(14) The manner in which
information concerning material
amendments or changes to the Offer will
be communicated to affected Plans;
(c) The terms of the Settlement Sale
are consistent with the requirements set
forth in the Settlement Agreement; and
(d) All of the conditions in Section II
have been met with respect to the
Settlement Sale.
Section V. Definitions
For purposes of this proposed
exemption:
(a) The term ‘‘affiliate’’ means: Any
person directly or indirectly, through
one or more intermediaries, controlling,
controlled by, or under common control
with such other person;
(b) The term ‘‘control’’ means: The
power to exercise a controlling
influence over the management or
policies of a person other than an
individual;
(c) The term ‘‘Auction Rate Security’’
means a security that:
(1) Is either a debt instrument
(generally with a long-term nominal
maturity) or preferred stock; and
(2) Has an interest rate or dividend
that is reset at specific intervals through
a Dutch auction process;
(d) A person is ‘‘independent’’ of
JPMorgan Chase if the person is:
(1) Not JPMorgan Chase or an affiliate;
and (2) not a relative (as defined in
ERISA section 3(15)) of the party
engaging in the transaction;
(e) The term ‘‘Plan’’ means: An
individual retirement account or similar
account described in section
4975(e)(1)(B) through (F) of the Code (an
IRA); an employee benefit plan as
defined in section 3(3) of ERISA; or an
entity holding plan assets within the
meaning of 29 CFR 2510.3–101, as
modified by ERISA section 3(42); and
VerDate Mar<15>2010
16:27 Dec 12, 2011
Jkt 226001
(f) The term ‘‘Settlement Agreement’’
means: A legal settlement involving
JPMorgan Chase and a U.S. state or
federal authority that provides for the
purchase of an Auction Rate Security by
JPMorgan Chase from a Plan.
Effective Date: If granted, this
proposed exemption will be effective as
of February 1, 2008.
Summary of Facts and Representations
1. The applicant is JPMorgan Chase &
Co. (hereinafter, either JPMorgan Chase
or the Applicant), a financial holding
company incorporated under Delaware
law in 1968. JPMorgan Chase is a
leading global financial services firm,
with $2.0 trillion in assets, $165.4
billion in stockholders’ equity, and
operations in more than 60 countries as
of December 31, 2009.
2. The Applicant describes Auction
Rate Securities (ARS) and the
arrangement by which ARS are bought
and sold as follows. ARS are securities
(issued as debt or preferred stock) with
an interest rate or dividend that is reset
at periodic intervals pursuant to a
process called a Dutch Auction.
Investors submit orders to buy, hold, or
sell a specific ARS to a broker-dealer
selected by the entity that issued the
ARS. The broker-dealers, in turn, submit
all of these orders to an auction agent.
The auction agent’s functions include
collecting orders from all participating
broker-dealers by the auction deadline,
determining the amount of securities
available for sale, and organizing the
bids to determine the winning bid. If
there are any buy orders placed into the
auction at a specific rate, the auction
agent accepts bids with the lowest rate
above any applicable minimum rate and
then successively higher rates up to the
maximum applicable rate, until all sell
orders and orders that are treated as sell
orders are filled. Bids below any
applicable minimum rate or above the
applicable maximum rate are rejected.
After determining the clearing rate for
all of the securities at auction, the
auction agent allocates the ARS
available for sale to the participating
broker-dealers based on the orders they
submitted. If there are multiple bids at
the clearing rate, the auction agent will
allocate securities among the bidders at
such rate on a pro-rata basis.
3. The Applicant states that, under a
typical Dutch Auction process,
JPMorgan Chase is permitted, but not
obligated, to submit orders in auctions
for its own account either as a bidder or
a seller and routinely does so in the
auction rate securities market in its sole
discretion. JPMorgan Chase may place
one or more bids in an auction for its
own account to acquire ARS for its
PO 00000
Frm 00004
Fmt 4701
Sfmt 4703
inventory, to prevent: (a) A failed
auction (i.e., an event where there are
insufficient clearing bids which would
result in the auction rate being set at a
specified rate, resulting in no ARS being
sold through the auction process); or (b)
an auction from clearing at a rate that
JPMorgan Chase believes does not
reflect the market for the particular ARS
being auctioned.
4. The Applicant states that for many
ARS, JPMorgan Chase has been
appointed by the issuer of the securities
to serve as a dealer in the auction and
is paid by the issuer for its services.
JPMorgan Chase is typically appointed
to serve as a dealer in the auctions
pursuant to an agreement between the
issuer and JPMorgan Chase. That
agreement provides that JPMorgan
Chase will receive from the issuer
auction dealer fees based on the
principal amount of the securities
placed through JPMorgan Chase.
5. The Applicant states further that
JPMorgan Chase may share a portion of
the auction rate dealer fees it receives
from the issuer with other brokerdealers that submit orders through
JPMorgan Chase, for those orders that
JPMorgan Chase successfully places in
the auctions. Similarly, with respect to
ARS for which broker-dealers other than
JPMorgan Chase act as dealer, such
other broker-dealers may share auction
dealer fees with JPMorgan Chase for
orders submitted by JPMorgan Chase.
6. The Applicant represents that since
February, 2008, a significant majority of
auctions have been unsuccessful.
According to the Applicant, the current
state of the ARS market remains
illiquid. As a result, Plans holding ARS
may not have sufficient liquidity to
make benefit payments, mandatory
payments and withdrawals and expense
payments when due.4
7. The Applicant represents further
that, in certain instances, JPMorgan
Chase may have previously advised or
otherwise caused a Plan to acquire and
hold an ARS.5 In connection with
JPMorgan Chase’s role in the acquisition
and holding of ARS by various
JPMorgan Chase clients, including the
4 The Department notes that Class Exemption 80–
26 (45 FR 28545 (Apr. 29, 1980), as amended at 71
FR 17917 (Apr. 7, 2006)) permits interest-free loans
or other extensions of credit from a party in interest
to a plan if, among other things, the proceeds of the
loan or extension of credit are used only— (1) For
the payment of ordinary operating expenses of the
plan, including the payment of benefits in
accordance with the terms of the plan and periodic
premiums under an insurance or annuity contract,
or (2) for a purpose incidental to the ordinary
operation of the plan.
5 The relief contained in this proposed exemption
does not extend to the fiduciary provisions of
section 404 of the Act.
E:\FR\FM\13DEN2.SGM
13DEN2
srobinson on DSK4SPTVN1PROD with NOTICES2
Federal Register / Vol. 76, No. 239 / Tuesday, December 13, 2011 / Notices
Plans, JPMorgan Chase entered into
Settlement Agreements with certain
U.S. states and federal authorities.
Pursuant to these Settlement
Agreements, among other things,
JPMorgan Chase was required to send a
written offer to certain Plans that held
ARS in connection with the advice and/
or brokerage services provided by
JPMorgan Chase. As described in further
detail below, eligible Plans that
accepted the written offer were
permitted to sell the ARS to JPMorgan
Chase for cash equal to the par value of
such securities, plus any accrued
interest and/or dividends. According to
the Applicant, in connection with an
offer issued by JPMorgan Chase
pursuant to a Settlement Agreement,
JPMorgan Chase has purchased
approximately $2 billion dollars in ARS.
The Applicant states that, prospectively,
additional shares of ARS may be
tendered by Plans to JPMorgan Chase
pursuant to an offer issued by JPMorgan
Chase pursuant to a Settlement
Agreement. Accordingly, the Applicant
is requesting retroactive and prospective
relief for the Settlement Sales. With
respect to Unrelated Sales, the
Applicant states that to the best of its
knowledge, as of January 1, 2011, no
Unrelated Sale has occurred. However,
the Applicant is requesting retroactive
relief (and prospective relief) for
Unrelated Sales in the event that a sale
of ARS by a Plan to JPMorgan Chase has
occurred outside the Settlement process.
If granted, the exemption would be
effective as of February 1, 2008.
8. Specifically, the Applicant is
requesting exemptive relief for the sale
of ARS under two different
circumstances: (a) Where JPMorgan
Chase initiates the sale by sending to a
Plan a written offer to acquire the ARS,
notwithstanding that such offer is not
required under a Settlement Agreement
(i.e., an Unrelated Sale); and (b) where
JPMorgan Chase is required under a
Settlement Agreement to send to Plans
a written offer to acquire the ARS (i.e.,
a Settlement Sale). The Applicant states
that the Unrelated Sales and Settlement
Sales (hereinafter, either, a Covered
Sale) are in the interests of Plans. In this
regard, the Applicant states that the
Covered Sales would permit Plans to
normalize Plan investments. The
Applicant represents that each Covered
Sale will be for no consideration other
than cash payment against prompt
delivery of the ARS, and such cash will
equal the par value of the ARS, plus any
accrued but unpaid interest or
dividends. The Applicant represents
further that Plans will not pay any
VerDate Mar<15>2010
16:27 Dec 12, 2011
Jkt 226001
commissions or transaction costs with
respect to any Covered Sale.
9. The Applicant represents that the
proposed exemption is protective of the
Plans. The Applicant states that, except
in the case of a Plan sponsored by
JPMorgan Chase for its own employees
(a JPMorgan Chase Plan), each Covered
Sale will be made pursuant to a written
offer (an Offer); and the decision to
accept the Offer or retain the ARS will
be made by a Plan fiduciary or Plan
participant or IRA owner who is
independent of JPMorgan Chase.
Additionally, each Offer will be
delivered in a manner designed to alert
a Plan fiduciary that JPMorgan Chase
intends to purchase ARS from the Plan.
In connection with an Unrelated Sale,
the Offer will describe the material
terms of the Unrelated Sale, including
the most recent rate information for the
ARS (if reliable information is
available). Either the Offer or other
materials available to the Plan will
provide the identity and par value of the
ARS. Offers made in connection with a
Settlement Agreement will specifically
include, among other things: The
background of the Offer; the method and
timing by which a Plan may accept the
Offer; the expiration date of the Offer; a
description of certain risk factors
relating to the Offer; how to obtain
additional information concerning the
Offer; and the manner in which
information concerning material
amendments or changes to the Offer will
be communicated to affected Plans. The
Applicant states that, except in the case
of a JPMorgan Chase Plan or a pooled
fund maintained or advised by
JPMorgan Chase, neither JPMorgan
Chase nor any affiliate will exercise
investment discretion or render
investment advice with respect to a
Plan’s decision to accept the Offer or
retain the ARS.6 In the case of a
JPMorgan Chase Plan or a pooled fund
maintained or advised by JPMorgan
Chase, the decision to engage in a
Covered Sale may be made by JPMorgan
Chase after JPMorgan Chase has
determined that such purchase is in the
best interest of the JPMorgan Chase Plan
or pooled fund. The Applicant
represents further that Plans will not
waive any rights or claims in connection
with any Covered Sale.
10. The Applicant represents that the
proposed exemption, if granted, would
be administratively feasible. In this
regard, the Applicant notes that each
Covered Sale will occur at the par value
6 The Applicant states that while there may be
communication between a Plan and JP Morgan
Chase subsequent to an Offer, such communication
will not involve advice regarding whether the Plan
should accept the Offer.
PO 00000
Frm 00005
Fmt 4701
Sfmt 4703
77597
of the affected ARS, plus any accrued
but unpaid interest or dividends, and
such value is readily ascertainable. The
Applicant represents further that
JPMorgan Chase will maintain the
records necessary to enable the
Department and Plan fiduciaries, among
others, to determine whether the
conditions of this exemption, if granted,
have been met.
11. In summary, the Applicant
represents that the transactions
described herein satisfy the statutory
criteria of section 408(a) of the Act
because, among other things:
(a) Except in the case of a JPMorgan
Chase Plan, each Covered Sale shall be
made pursuant to a written Offer;
(b) Each Covered Sale shall be for no
consideration other than cash payment
against prompt delivery of the ARS;
(c) The amount of each Covered Sale
shall equal the par value of the ARS,
plus any accrued but unpaid interest or
dividends;
(d) Plans will not waive any rights or
claims in connection with any Covered
Sale;
(e) Except in the case of a JPMorgan
Chase Plan or a pooled fund maintained
or advised by JPMorgan Chase:
(1) The decision to accept an Offer or
retain the ARS shall be made by a Plan
fiduciary or Plan participant or IRA
owner who is independent of JPMorgan
Chase; and
(2) Neither JPMorgan Chase nor any
affiliate shall exercise investment
discretion or render investment advice
within the meaning of 29 CFR 2510.3–
21(c) with respect to the decision to
accept the Offer or retain the ARS;
(f) Plans shall not pay any
commissions or transaction costs with
respect to any Covered Sale;
(g) A Covered Sale shall not be part
of an arrangement, agreement or
understanding designed to benefit a
party in interest to the affected Plan;
(h) With respect to any Settlement
Sale, the terms and delivery and timing
of the Offer, and the terms of Settlement
Sale, shall be consistent with the
requirements set forth in the Settlement
Agreement;
(i) JPMorgan Chase shall make
available in connection with an
Unrelated Sale the material terms of the
Unrelated Sale, including the most
recent rate information for the ARS (if
reliable information is available), and
the identity and par value of the ARS;
(j) Each Offer made in connection
with a Settlement Agreement shall
describe the material terms of the
Settlement Sale, including the
following:
(1) Information regarding how the
Plan can determine: The ARS held by
E:\FR\FM\13DEN2.SGM
13DEN2
77598
Federal Register / Vol. 76, No. 239 / Tuesday, December 13, 2011 / Notices
the Plan with JPMorgan Chase, the
number of shares and par value of the
ARS, purchase dates for such ARS, and
(if reliable information is available) the
most recent rate information for the
ARS;
(2) The background of the Offer;
(3) That participating in the Offer will
not result in or constitute a waiver of
any claim of the tendering Plan;
(4) The methods and timing by which
the Plan may accept the Offer;
(5) The purchase dates, or the manner
of determining the purchase dates, for
ARS pursuant to the Offer;
(6) The timing for acceptance by
JPMorgan Chase of tendered ARS;
(7) The timing of payment for ARS
accepted by JPMorgan Chase for
payment;
(8) The methods and timing by which
a Plan may elect to withdraw tendered
ARS from the Offer;
(9) The expiration date of the Offer;
(10) The fact that JPMorgan Chase
may make purchases of ARS outside of
the Offer and may otherwise buy, sell,
hold or seek to restructure, redeem or
otherwise dispose of the ARS;
(11) A description of the risk factors
relating to the Offer as JPMorgan Chase
deems appropriate;
(12) How to obtain additional
information concerning the Offer; and
(13) The manner in which
information concerning material
amendments or changes to the Offer will
be communicated to affected Plans.
srobinson on DSK4SPTVN1PROD with NOTICES2
Notice to Interested Persons
The Applicant represents that the
potentially interested participants and
beneficiaries cannot all be identified
and therefore the only practical means
of notifying such participants and
beneficiaries of this proposed
exemption is by the publication of this
notice in the Federal Register.
Comments and requests for a hearing
must be received by the Department not
later than 30 days from the date of
publication of this notice of proposed
exemption in the Federal Register.
For Further Information Contact:
Chris Motta of the Department,
telephone (202) 693–8544. (This is not
a toll-free number.)
VerDate Mar<15>2010
16:27 Dec 12, 2011
Jkt 226001
Delaware Charter Guarantee & Trust
Co. d\b\a\ Principal Trust Company
(Principal Trust); Principal Life
Insurance Company (Principal Life)
and Any Affiliates, Thereof
(Collectively, Principal or the
Applicants), Located in Wilmington,
Delaware and in Des Moines, Iowa
[Application No. D–11579].
Proposed Exemption
The Department of Labor (the
Department) is considering granting an
exemption under the authority of
section 408(a) of the Act and section
4975(c)(2) of the Code and in
accordance with the procedures set
forth in 29 CFR part 2570, subpart B (55
FR 32836, 32847, August 10, 1990).
Section I—Transactions
If the exemption is granted, the
restrictions of sections 406(a)(1)(D) and
406(b) of the Act and the taxes resulting
from the application of section 4975 of
the Code, by reason of sections
4975(c)(1)(D) through (F) of the Code, 7
shall not apply, as of the effective date
of this proposed exemption, to:
(a) The receipt of a fee by Principal,
as Principal is defined, below, in
Section IV(a), from an open-end
investment company or open-end
investment companies (Affiliated
Fund(s)), as defined, below, in Section
IV(e), in connection with the direct
investment in shares of any such
Affiliated Fund, by an employee benefit
plan or by employee benefit plans
(Client Plan(s)), as defined, below, in
Section IV(b), where Principal serves as
a fiduciary with respect to such Client
Plan, and where Principal:
(1) Provides investment advisory
services, or similar services to any such
Affiliated Fund; and
(2) Provides to any such Affiliated
Fund other services (Secondary
Service(s)), as defined, below, in Section
IV(i); and
(b) In connection with the indirect
investment by a Client Plan in shares of
an Affiliated Fund through investment
in a pooled investment vehicle or
pooled investment vehicles (Collective
Fund(s)),8 as defined, below, in Section
7 For purposes of this proposed exemption
reference to specific provisions of Title I of the Act,
unless otherwise specified, refer also to the
corresponding provisions of the Code.
8 The Department, herein, is expressing no
opinion in this proposed exemption regarding the
reliance of the Applicants on the relief provided by
section 408(b)(8) of the Act with regard to the
purchase and with regard to the sale by a Client
Plan of an interest in a Collective Fund and the
receipt by Principal, thereby, of any investment
management fee, any investment advisory fee, and
any similar fee (a Collective Fund-Level
Management Fee), as defined, below, in Section
PO 00000
Frm 00006
Fmt 4701
Sfmt 4703
IV(j), where Principal serves as a
fiduciary with respect to such Client
Plan, the receipt of fees by Principal
from:
(1) An Affiliated Fund for the
provision of investment advisory
services, or similar services by Principal
to any such Affiliated Fund; and
(2) an Affiliated Fund for the
provision of Secondary Services by
Principal to any such Affiliated Fund;
provided that the conditions, as set
forth, below, in Section II and Section
III, are satisfied, as of the effective date
of this proposed exemption and
thereafter.
Section II—Specific Conditions
(a)(1) Each Client Plan which is
invested directly in shares of an
Affiliated Fund either:
(i) Does not pay to Principal for the
entire period of such investment any
investment management fee, or any
investment advisory fee, or any similar
fee at the plan-level (the Plan-Level
Management Fee), as defined, below, in
Section IV(m), with respect to any of the
assets of such Client Plan which are
invested directly in shares of such
Affiliated Fund; or
(ii) pays to Principal a Plan-Level
Management Fee, based on total assets
of such Client Plan under management
by Principal at the plan-level, from
which a credit has been subtracted from
such Plan-Level Management Fee,
where the amount subtracted represents
such Client Plan’s pro rata share of any
investment advisory fee and any similar
fee (the Affiliated Fund-Level Advisory
Fee), as defined, below, in Section IV(o),
paid by such Affiliated Fund to
Principal.
If, during any fee period, in the case
of a Client Plan invested directly in
shares of an Affiliated Fund, such Client
Plan has prepaid its Plan-Level
Management Fee, and such Client Plan
purchases shares of an Affiliated Fund
directly, the requirement of this Section
II(a)(1)(ii) shall be deemed met with
respect to such prepaid Plan-Level
Management Fee, if, by a method
reasonably designed to accomplish the
same, the amount of the prepaid PlanLevel Management Fee that constitutes
the fee with respect to the assets of such
Client Plan invested directly in shares of
an Affiliated Fund:
(A) Is anticipated and subtracted from
the prepaid Plan-Level Management Fee
IV(n), where Principal serves as an investment
manager or investment adviser with respect to such
Collective Fund and also serves as a fiduciary with
respect to such Client Plan, nor is the Department
offering any view as to whether the Applicants
satisfy the conditions, as set forth in section
408(b)(8) of the Act.
E:\FR\FM\13DEN2.SGM
13DEN2
srobinson on DSK4SPTVN1PROD with NOTICES2
Federal Register / Vol. 76, No. 239 / Tuesday, December 13, 2011 / Notices
at the time of the payment of such fee;
or
(B) is returned to such Client Plan, no
later than during the immediately
following fee period; or
(C) is offset against the Plan-Level
Management Fee for the immediately
following fee period or for the fee period
immediately following thereafter.
For purposes of Section II(a)(1)(ii), a
Plan-Level Management Fee shall be
deemed to be prepaid for any fee period,
if the amount of such Plan-Level
Management Fee is calculated as of a
date not later than the first day of such
period.
(2) Each Client Plan invested in a
Collective Fund the assets of which are
not invested in shares of an Affiliated
Fund:
(i) Does not pay to Principal for the
entire period of such investment any
Plan-Level Management Fee with
respect to any assets of such Client Plan
invested in such Collective Fund.
The requirements of this Section
II(a)(2)(i) do not preclude the payment
of a Collective Fund-Level Management
Fee by such Collective Fund to
Principal, based on the assets of such
Client Plan invested in such Collective
Fund; or
(ii) does not pay to Principal for the
entire period of such investment any
Collective Fund-Level Management Fee
with respect to any assets of such Client
Plan invested in such Collective Fund.
The requirements of this Section
II(a)(2)(ii) do not preclude the payment
of a Plan-Level Management Fee by
such Client Plan to Principal, based on
total assets of such Client Plan under
management by Principal at the planlevel; or
(iii) such Client Plan pays to Principal
a Plan-Level Management Fee, based on
total assets of such Client Plan under
management by Principal at the planlevel, from which a credit has been
subtracted from such Plan-Level
Management Fee (the ‘‘Net’’ Plan-Level
Management Fee), where the amount
subtracted represents such Client Plan’s
pro rata share of any Collective FundLevel Management Fee paid by such
Collective Fund to Principal.
The requirements of this Section
II(a)(2)(iii) do not preclude the payment
of a Collective Fund-Level Management
Fee by such Collective Fund to
Principal, based on the assets of such
Client Plan invested in such Collective
Fund.
(3) Each Client Plan invested in a
Collective Fund the assets of which are
invested in shares of an Affiliated Fund:
(i) Does not pay to Principal for the
entire period of such investment any a
Plan-Level Management Fee (including
VerDate Mar<15>2010
16:27 Dec 12, 2011
Jkt 226001
any ‘‘Net’’ Plan-Level Management Fee,
as described, above, in Section
II(a)(2)(iii)), and does not pay to
Principal for the entire period of such
investment any Collective Fund-Level
Management Fee with respect to the
assets of such Client Plan which are
invested in such Affiliated Fund; or
(ii) pays to Principal a Collective
Fund-Level Management Fee, in
accordance with Section II(a)(2)(i),
above, based on the total assets of such
Client Plan invested in such Collective
Fund, from which a credit has been
subtracted from such Collective FundLevel Management Fee, where the
amount subtracted represents such
Client Plan’s pro rata share of any
Affiliated Fund-Level Advisory Fee paid
to Principal by such Affiliated Fund;
and does not pay to Principal for the
entire period of such investment any
Plan-Level Management Fee with
respect to any assets of such Client Plan
invested in such Collective Fund; or
(iii) pays to Principal a Plan-Level
Management Fee, in accordance with
Section II(a)(2)(iii), above, based on the
total assets of such Client Plan under
management by Principal at the planlevel, from which a credit has been
subtracted from such Plan-Level
Management Fee, where the amount
subtracted represents such Client Plan’s
pro rata share of any Affiliated FundLevel Advisory Fee paid to Principal by
such Affiliated Fund; and does not pay
to Principal for the entire period of such
investment any Collective Fund-Level
Management Fee with respect to any
assets of such Client Plan invested in
such Collective Fund; or
(iv) pays to Principal a ‘‘Net’’ PlanLevel Management Fee, in accordance
with Section II(a)(2)(iii), above, from
which a further credit has been
subtracted from such ‘‘Net’’ Plan-Level
Management Fee, where the amount of
such further credit which is subtracted
represents such Client Plan’s pro rata
share of any Affiliated Fund-Level
Advisory Fee paid to Principal by such
Affiliated Fund.
Provided that the conditions of this
proposed exemption are satisfied, the
requirements of Section II(a)(1)(i), (ii),
and Section II(a)(3)(i)–(iv) do not
preclude the payment of an Affiliated
Fund-Level Advisory Fee by an
Affiliated Fund to Principal under the
terms of an investment advisory
agreement adopted in accordance with
section 15 of the Investment Company
Act of 1940 (the Investment Company
Act). Further, the requirements of
Section II(a)(1)(i)–(ii), and Section
II(a)(3)(i)–(iv) do not preclude the
payment of a fee by an Affiliated Fund
to Principal for the provision by
PO 00000
Frm 00007
Fmt 4701
Sfmt 4703
77599
Principal of Secondary Services to such
Affiliated Fund under the terms of a
duly adopted agreement between
Principal and such Affiliated Fund.
For the purpose of Section II(a)(1)(ii),
and Section II(a)(3)(ii)–(iv), in
calculating a Client Plan’s pro rata share
of an Affiliated Fund-Level Advisory
Fee, Principal must use an amount
representing the ‘‘gross’’ advisory fee
paid to Principal by such Affiliated
Fund. For purposes of this paragraph,
the ‘‘gross’’ advisory fee is the amount
paid to Principal by such Affiliated
Fund, including the amount paid by
such Affiliated Fund to sub-advisers.
(b) The purchase price paid and the
sales price received by a Client Plan for
shares in an Affiliated Fund purchased
or sold directly, and the purchase price
paid and the sales price received by a
Client Plan for shares in an Affiliated
Fund purchased or sold indirectly
through a Collective Fund, is the net
asset value per share (NAV), as defined,
below, in Section IV(f), at the time of the
transaction, and is the same purchase
price that would have been paid and the
same sales price that would have been
received for such shares by any other
shareholder of the same class of shares
in such Affiliated Fund at that time.9
(c) Principal, including any officer
and any director of Principal, does not
purchase any shares of an Affiliated
Fund from and does not sell any shares
of an Affiliated Fund to any Client Plan
which invests directly in such Affiliated
Fund, and Principal, including any
officer and director of Principal, does
not purchase any shares of any
Affiliated Fund from and does not sell
any shares of an Affiliated Fund to any
Collective Fund in which a Client Plan
invests indirectly in shares of such
Affiliated Fund.
(d) No sales commissions, no
redemption fees, and no other similar
fees are paid in connection with any
purchase and in connection with any
sale by a Client Plan directly in shares
of an Affiliated Fund, and no sales
commissions, no redemption fees, and
no other similar fees are paid by a
Collective Fund in connection with any
purchase and in connection with any
sale of shares in an Affiliated Fund by
a Client Plan indirectly through such
9 The selection of a particular class of shares of
an Affiliated Fund as an investment for a Client
Plan indirectly through a Collective Fund is a
fiduciary decision that must be made in accordance
with the provisions of section 404(a) of the Act. In
this proposed exemption, the Department is not
providing any relief for any fiduciary violations,
pursuant to section 404 of the Act, or violations of
the prohibited transaction provisions, as set forth in
section 406 of the Act that may arise from the
selection of one class of shares of an Affiliated Fund
over another class of shares.
E:\FR\FM\13DEN2.SGM
13DEN2
srobinson on DSK4SPTVN1PROD with NOTICES2
77600
Federal Register / Vol. 76, No. 239 / Tuesday, December 13, 2011 / Notices
Collective Fund. However, this Section
II(d) does not prohibit the payment of a
redemption fee, if:
(1) Such redemption fee is paid only
to an Affiliated Fund; and
(2) The existence of such redemption
fee is disclosed in the summary
prospectus for such Affiliated Fund in
effect both at the time of any purchase
of shares in such Affiliated Fund and at
the time of any sale of such shares.
(e) The combined total of all fees
received by Principal is not in excess of
reasonable compensation within the
meaning of section 408(b)(2) of the Act,
for services provided:
(1) By Principal to each Client Plan;
(2) By Principal to each Collective
Fund in which a Client Plan invests;
and
(3) By Principal to each Affiliated
Fund in which a Client Plan invests
directly in shares of such Affiliated
Fund, and
(4) By Principal to each Affiliated
Fund in which a Client Plan invests
indirectly in shares of such Affiliated
Fund through a Collective Fund.
(f) Principal does not receive any fees
payable pursuant to Rule 12b–1 under
the Investment Company Act in
connection with the transactions
covered by this proposed exemption;
(g) No Client Plan is an employee
benefit plan sponsored or maintained by
Principal.
(h)(1) In the case of a Client Plan
investing directly in shares of an
Affiliated Fund, a second fiduciary (the
Second Fiduciary), as defined, below, in
Section IV(h), acting on behalf of such
Client Plan, receives, in writing, in
advance of any investment by such
Client Plan directly in shares of such
Affiliated Fund, a full and detailed
disclosure via first class mail or via
personal delivery of (or, if the Second
Fiduciary consents to such means of
delivery, through electronic email, in
accordance with Section II(q), as set
forth, below) of information concerning
such Affiliated Fund, including but not
limited to the items listed, below:
(i) A current summary prospectus
issued by each such Affiliated Fund;
(ii) A statement describing the fees,
including the nature and extent of any
differential between the rates of such
fees for:
(A) Investment advisory and similar
services to be paid to Principal by each
Affiliated Fund;
(B) Secondary Services to be paid to
Principal by each such Affiliated Fund;
and
(C) All other fees to be charged by
Principal to such Client Plan and to
each such Affiliated Fund and all other
fees to be paid to Principal by each such
VerDate Mar<15>2010
16:27 Dec 12, 2011
Jkt 226001
Client Plan and by each such Affiliated
Fund;
(iii) The reasons why Principal may
consider investment directly in shares
of such Affiliated Fund by such Client
Plan to be appropriate for such Client
Plan;
(iv) A statement describing whether
there are any limitations applicable to
Principal with respect to which assets of
such Client Plan may be invested
directly in shares of such Affiliated
Fund, and if so, the nature of such
limitations; and
(v) Upon the request of the Second
Fiduciary acting on behalf of such
Client Plan, a copy of the Notice of
Proposed Exemption (the Notice), a
copy of the final exemption, if granted,
and any other reasonably available
information regarding the transactions
which are the subject of this proposed
exemption.
(2) In the case of a Client Plan whose
assets are proposed to be invested in a
Collective Fund after such Collective
Fund has begun investing in shares of
an Affiliated Fund, a Second Fiduciary,
acting on behalf of such Client Plan,
receives, in writing, in advance of any
investment by such Client Plan in such
Collective Fund, a full and detailed
disclosure via first class mail or via
personal delivery (or, if the Second
Fiduciary consents to such means of
delivery, through electronic email, in
accordance with Section II(q), as set
forth, below) of information concerning
such Collective Fund and information
concerning each such Affiliated Fund in
which such Collective Fund is invested,
including but not limited to the items
listed, below:
(i) A current summary prospectus
issued by each such Affiliated Fund;
(ii) A statement describing the fees,
including the nature and extent of any
differential between the rates of such
fees for:
(A) Investment advisory and similar
services to be paid to Principal by each
Affiliated Fund;
(B) Secondary Services to be paid to
Principal by each such Affiliated Fund;
and
(C) All other fees to be charged by
Principal to such Client Plan, to such
Collective Fund, and to each such
Affiliated Fund and all other fees to be
paid to Principal by such Client Plan, by
such Collective Fund, and by each such
Affiliated Fund;
(iii) The reasons why Principal may
consider investment by such Client Plan
in shares of each such Affiliated Fund
indirectly through such Collective Fund
to be appropriate for such Client Plan;
(iv) A statement describing whether
there are any limitations applicable to
PO 00000
Frm 00008
Fmt 4701
Sfmt 4703
Principal with respect to which assets of
such Client Plan may be invested
indirectly in shares of each such
Affiliated Fund through such Collective
Fund, and if so, the nature of such
limitations;
(v) Upon the request of the Second
Fiduciary, acting on behalf of such
Client Plan, a copy of the Notice, a copy
of the final exemption, if granted, and
any other reasonably available
information regarding the transactions
which are the subject of this proposed
exemption; and
(vi) A copy of the organizational
documents of such Collective Fund
which expressly provide for the
addition of one or more Affiliated Funds
to the portfolio of such Collective Fund.
(3) In the case of a Client Plan whose
assets are proposed to be invested in a
Collective Fund before such Collective
Fund has begun investing in shares of
any Affiliated Fund, a Second
Fiduciary, acting on behalf of such
Client Plan, receives, in writing, in
advance of any investment by such
Client Plan in such Collective Fund, a
full and detailed disclosure via first
class mail or via personal delivery (or,
if the Second Fiduciary consents to such
means of delivery, through electronic
email, in accordance with Section II(q),
as set forth, below) of information,
concerning such Collective Fund,
including but not limited to the items
listed, below:
(i) A statement describing the fees,
including the nature and extent of any
differential between the rates of such
fees for all fees to be charged by
Principal to such Client Plan and to
such Collective Fund and all other fees
to be paid to Principal by such Client
Plan, and by such Collective Fund;
(ii) Upon the request of the Second
Fiduciary, acting on behalf of such
Client Plan, a copy of the Notice, a copy
of the final exemption, if granted, and
any other reasonably available
information regarding the transactions
which are the subject of this proposed
exemption; and
(iii) A copy of the organizational
documents of such Collective Fund
which expressly provide for the
addition of one or more Affiliated Funds
to the portfolio of such Collective Fund.
(i) On the basis of the information
described, above, in Section II(h), a
Second Fiduciary, acting on behalf of a
Client Plan:
(1) Authorizes in writing the
investment of the assets of such Client
Plan, as applicable:
(i) Directly in shares of an Affiliated
Fund;
(ii) Indirectly in shares of an
Affiliated Fund through a Collective
E:\FR\FM\13DEN2.SGM
13DEN2
srobinson on DSK4SPTVN1PROD with NOTICES2
Federal Register / Vol. 76, No. 239 / Tuesday, December 13, 2011 / Notices
Fund where such Collective Fund has
already invested in shares of an
Affiliated Fund; and
(iii) In a Collective Fund which is not
yet invested in shares of an Affiliated
Fund but whose organizational
document expressly provides for the
addition of one or more Affiliated Funds
to the portfolio of such Collective Fund;
and
(2) Authorizes in writing; as
applicable:
(i) The Affiliated Fund-Level
Advisory Fee received by Principal for
investment advisory services and
similar services provided by Principal to
such Affiliated Fund;
(ii) The fee received by Principal for
Secondary Services provided by
Principal to such Affiliated Fund;
(iii) The Collective Fund-Level
Management Fee received by Principal
for investment management, investment
advisory, and similar services provided
by Principal to such Collective Fund in
which such Client Plan invests;
(iv) The Plan-Level Management Fee
received by Principal for investment
management and similar services
provided by Principal to such Client
Plan at the plan-level; and
(v) The selection by Principal of the
applicable fee method, as described,
above, in Section II(a)(1)–(3).
All authorizations made by a Second
Fiduciary, pursuant to this Section II(i),
must be consistent with the
responsibilities, obligations, and duties
imposed on fiduciaries by Part 4 of Title
I of the Act;
(j)(1) Any authorization, described,
above, in Section II(i), and any
authorization made pursuant to negative
consent, as described, below, in Section
II(k) and in Section II(l), made by a
Second Fiduciary, acting on behalf of a
Client Plan, shall be terminable at will
by such Second Fiduciary, without
penalty to such Client Plan, upon
receipt by Principal via first class mail,
via personal delivery, or via electronic
email of a written notification of the
intent of such Second Fiduciary to
terminate any such authorization.
(2) A form (the Termination Form)
expressly providing an election to
terminate any authorization, described,
above, in Section II(i), or to terminate
any authorization made pursuant to
negative consent, as described, below,
in Section II(k) and in Section II(l), with
instructions on the use of such
Termination Form must be provided to
such Second Fiduciary at least annually,
either in writing via first class mail or
via personal delivery (or if such Second
Fiduciary consents to such means of
delivery, through electronic email, in
accordance with Section II(q), as set
VerDate Mar<15>2010
16:27 Dec 12, 2011
Jkt 226001
forth, below). However, if a Termination
Form has been provided to such Second
Fiduciary, pursuant to Section II(k) or
pursuant to Section II(l), below, then a
Termination Form need not be provided
again, pursuant to this Section II(j), until
at least six (6) months but no more than
twelve (12) months have elapsed, since
a Termination Form was provided;
(3) The instructions for the
Termination Form must include the
following statements:
(i) Any authorization, described,
above, in Section II(i), and any
authorization made pursuant to negative
consent, as described, below, in Section
II(k) or in Section II(l), is terminable at
will by a Second Fiduciary, acting on
behalf of a Client Plan, without penalty
to such Client Plan, upon receipt by
Principal via first class mail or via
personal delivery or via electronic email
of the Termination Form, or some other
written notification of the intent of such
Second Fiduciary to terminate such
authorization;
(ii) Within 30 days from the date the
Termination Form is sent to such
Second Fiduciary by Principal, the
failure by such Second Fiduciary to
return such Termination Form or the
failure by such Second Fiduciary to
provide some other written notification
of the Client Plan’s intent to terminate
any authorization, described in Section
II(i), or intent to terminate any
authorization made pursuant to negative
consent, as described, below, in Section
II(k) or in Section II(l), will be deemed
to be an approval by such Second
Fiduciary;
(4) In the event that a Second
Fiduciary, acting on behalf of a Client
Plan, at any time returns a Termination
Form or returns some other written
notification of intent to terminate any
authorization, as described, above, in
Section II(i), or intent to terminate any
authorization made pursuant to negative
consent, as described, below, in Section
II(k) or in Section II(l);
(i)(A) In the case of a Client Plan
which invests directly in shares of an
Affiliated Fund, the termination will be
implemented by the withdrawal of all
investments made by such Client Plan
in the affected Affiliated Fund, and such
withdrawal will be effected by Principal
within one (1) Business day of the date
that Principal receives such
Termination Form or receives from the
Second Fiduciary, acting on behalf of
such Client Plan, some other written
notification of intent to terminate any
such authorization;
(B) From the date a Second Fiduciary,
acting on behalf of a Client Plan that
invests directly in shares of an Affiliated
Fund, returns a Termination Form or
PO 00000
Frm 00009
Fmt 4701
Sfmt 4703
77601
returns some other written notification
of intent to terminate such Client Plan’s
investment in such Affiliated Fund,
such Client Plan will not be subject to
pay a pro rata share of any Affiliated
Fund-Level Advisory Fee and will not
be subject to pay any fees for Secondary
Services paid to Principal by such
Affiliated Fund;
(ii)(A) In the case of a Client Plan
which invests in a Collective Fund, the
termination will be implemented by the
withdrawal of such Client Plan from all
investments in such affected Collective
Fund, and such withdrawal will be
implemented by Principal within such
time as may be necessary for withdrawal
in an orderly manner that is equitable to
the affected withdrawing Client Plan
and to all non-withdrawing Client
Plans, but in no event shall such
withdrawal be implemented by
Principal more than five business (5)
days after the day Principal receives
from the Second Fiduciary, acting on
behalf of such withdrawing Client Plan,
a Termination Form or receives some
other written notification of intent to
terminate the investment of such Client
Plan in such Collective Fund; and
(B) Principal will pay to such
withdrawing Client Plan interest on the
settlement amount calculated at the
prevailing Federal funds rate plus two
percent (2%) for the period from the day
Principal receives from the Second
Fiduciary, acting on behalf of such
withdrawing Client Plan, a Termination
Form or receives some other written
notification of intent to terminate the
investment of such Client Plan in such
Collective Fund, to the date Principal
pays such settlement amount in cash,
with interest thereon, to such
withdrawing Client Plan;
(C) From the date a Second Fiduciary,
acting on behalf of a Client Plan that
invests in a Collective Fund, returns a
Termination Form or returns some other
written notification of intent to
terminate such Client Plan’s investment
in such Collective Fund, such Client
Plan will not be subject to pay a pro rata
share of any Collective Fund-Level
Management Fee, nor will such Client
Plan be subject to any other changes to
the portfolio of such Collective Fund,
including a pro rata share of any
Affiliated Fund-Level Advisory Fee
arising from the investment by such
Collective Fund in an Affiliated Fund.
(k)(1) Principal, at least thirty (30)
days in advance of the implementation
of each fee increase (Fee Increase(s)), as
defined, below, in Section IV(l), must
provide, in writing via first class mail or
via personal delivery (or if the Second
Fiduciary consents to such means of
delivery, through electronic email, in
E:\FR\FM\13DEN2.SGM
13DEN2
srobinson on DSK4SPTVN1PROD with NOTICES2
77602
Federal Register / Vol. 76, No. 239 / Tuesday, December 13, 2011 / Notices
accordance with Section II(q), as set
forth, below), a notice of change in fees
(the Notice of Change in Fees) (which
may take the form of a proxy statement,
letter, or similar communication which
is separate from the summary
prospectus of such Affiliated Fund) and
which explains the nature and the
amount of such Fee Increase to the
Second Fiduciary of each affected Client
Plan. Such Notice of Change in Fees
shall be accompanied by a Termination
Form and by instructions on the use of
such Termination Form, as described,
above, in Section II(j)(3);
(2) For each Client Plan affected by a
Fee Increase, Principal may implement
such Fee Increase without waiting for
the expiration of the 30-day period,
described, above, in Section II(k)(1),
provided Principal does not begin
implementation of such Fee Increase
before the first day of the 30-day period,
described, above in Section II(k)(1), and
provided further that the following
conditions are satisfied:
(i) Principal delivers, in the manner
described in Section II(k)(1), to the
Second Fiduciary for each affected
Client Plan, the Notice of Change of
Fees, as described in Section II(k)(1),
accompanied by the Termination Form
and by instructions on the use of such
Termination Form, as described, above,
in Section II(j)(3);
(ii) Each affected Client Plan receives
from Principal a credit in cash equal to
each such Client Plan’s pro rata share of
such Fee Increase to be received by
Principal for the period from the date of
the implementation of such Fee Increase
to the earlier of:
(A) The date when an affected Client
Plan, pursuant to Section II(j),
terminates any authorization, as
described, above, in Section II(i), or,
terminates any negative consent
authorization, as described, in Section
II(k) or in Section II(l); or
(B) The 30th day after the day that
Principal delivers to the Second
Fiduciary of each affected Client Plan
the Notice of Change of Fees, described
in Section II(k)(1), accompanied by the
Termination Form and by the
instructions on the use of such
Termination Form, as described, above,
in Section II(j)(3).
(iii) Principal pays to each affected
Client Plan the cash credit, described,
above, in Section II(k)(2)(ii), with
interest thereon, no later than five (5)
business days following the earlier of:
(A) the date such affected Client Plan,
pursuant to Section II(j), terminates any
authorization, as described, above, in
Section II(i), or terminates, any negative
consent authorization, as described, in
Section II(k) or in Section II(l); or
VerDate Mar<15>2010
16:27 Dec 12, 2011
Jkt 226001
(B) the 30th day after the day that
Principal delivers to the Second
Fiduciary of each affected Client Plan,
the Notice of Change of Fees, described
in Section II(k)(1), accompanied by the
Termination Form and instructions on
the use of such Termination Form, as
described, above, in Section II(j)(3);
(iv) Interest on the credit in cash is
calculated at the prevailing Federal
funds rate plus two percent (2%) for the
period from the day Principal first
implements the Fee Increase to the date
Principal pays such credit in cash, with
interest thereon, to each affected Client
Plan;
(v) An independent accounting firm
(the Auditor) at least annually audits the
payments made by Principal to each
affected Client Plan, audits the amount
of each cash credit, plus the interest
thereon, paid to each affected Client
Plan, and verifies that each affected
Client Plan received the correct amount
of cash credit and the correct amount of
interest thereon;
(vi) Such Auditor issues an audit
report of its findings no later than six (6)
months after the period to which such
audit report relates, and provides a copy
of such audit report to the Second
Fiduciary of each affected Client Plan;
and
(3) Within 30 days from the date
Principal sends to the Second Fiduciary
of each affected Client Plan, the Notice
of Change of Fees and the Termination
Form, the failure by such Second
Fiduciary to return such Termination
Form and the failure by such Second
Fiduciary to provide some other written
notification of the Client Plan’s intent to
terminate the authorization, described
in Section II(i), or to terminate the
negative consent authorization, as
described, in Section II(k) or in Section
II(l), will be deemed to be an approval
by such Second Fiduciary of such Fee
Increase.
(l) Effective on the date the final
exemption is granted, in the case of a
Client Plan which has received the
disclosures, as set forth, above, in
Section II(h)(2)(i), II(h)(2)(ii)(A),
II(h)(2)(ii)(B), II(h)(2)(ii)(C), II(h)(2)(iii),
II(h)(2)(iv), II(h)(2)(v), and II(h)(2)(vi),
and has authorized the investment by a
Client Plan in a Collective Fund, in
accordance with Section II(i)(1)(ii),
above; and, as applicable, effective on
the date the final exemption is granted,
in the case of a Client Plan which has
received the disclosures, as set forth,
above, in Section II(h)(3)(i), II(h)(3)(ii),
and II(h)(3)(iii), and has authorized the
investment by a Client Plan in a
Collective Fund, in accordance with
Section II(i)(1)(iii), above, then, the
authorization, pursuant to negative
PO 00000
Frm 00010
Fmt 4701
Sfmt 4703
consent, in accordance with this Section
II(l), applies to:
(1) the proposed purchase, as an
addition to the portfolio of such
Collective Fund, of shares of an
Affiliated Fund (a New Affiliated Fund)
where such New Affiliated Fund has not
been previously authorized, pursuant to
Section II(i)(1)(ii) or, as applicable,
Section II(i)(1)(iii), above, and such
Collective Fund may commence
investing in such New Affiliated Fund
without further written authorization
from the Second Fiduciary of each
Client Plan invested in such Collective
Fund provided that:
(i) The organizational documents of
such Collective Fund expressly provide
for the addition of one or more
Affiliated Funds to the portfolio of such
Collective Fund, and such documents
were disclosed in writing via first class
mail or via personal delivery (or, if the
Second Fiduciary consents to such
means of delivery, through electronic
email, in accordance with Section II(q),
as set forth, below) to the Second
Fiduciary of each such Client Plan
invested in such Collective Fund, in
advance of any investment by such
Client Plan in such Collective Fund;
(ii) At least thirty (30) days in advance
of the purchase by a Client Plan of
shares of such New Affiliated Fund
indirectly through a Collective Fund,
Principal provides, either in writing via
first class or via personal delivery (or if
the Second Fiduciary consents to such
means of delivery, through electronic
email, in accordance with Section II(q),
as set forth, below), to the Second
Fiduciary of each Client Plan having an
interest in such Collective Fund, full
and detailed disclosures about such
New Affiliated Fund, including but not
limited to:
(A) A notice of Principal’s intent to
add a New Affiliated Fund to the
portfolio of such Collective Fund. Such
notice may take the form of a proxy
statement, letter, or similar
communication that is separate from the
summary prospectus of such New
Affiliated Fund to the Second Fiduciary
of each affected Client Plan;
(B) Such notice of Principal’s intent to
add a New Affiliated Fund to the
portfolio of such Collective Fund shall
be accompanied by the information, as
described, above, in Section II(h)(2)(i),
II(h)(2)(ii)(A), II(h)(2)(ii)(B),
II(h)(2)(ii)(C), II(h)(2)(iii), II(h)(2)(iv),
and II(2)(v) with respect to each such
New Affiliated Fund proposed to be
added to the portfolio of such Collective
Fund; and
(C) A Termination Form, and
instructions on the use of such
E:\FR\FM\13DEN2.SGM
13DEN2
srobinson on DSK4SPTVN1PROD with NOTICES2
Federal Register / Vol. 76, No. 239 / Tuesday, December 13, 2011 / Notices
Termination Form, as described, above,
in Section II(j)(3); and
(2) Within 30 days from the date
Principal sends to the Second Fiduciary
of each affected Client Plan, the
information described, above, in Section
II(l)(1)(ii), the failure by such Second
Fiduciary to return the Termination
Form or to provide some other written
notification of the Client Plan’s intent to
terminate the authorization, described
in Section II(i)(1)(ii), or, as appropriate,
to terminate the authorization,
described in Section II(i)(1)(iii), or to
terminate any authorization, pursuant to
negative consent, as described, in this
Section II(l), will be deemed to be an
approval by such Second Fiduciary of
the addition of a New Affiliated Fund to
the portfolio of such Collective Fund in
which such Client Plan invests, and will
result in the continuation of the
authorization of Principal to engage in
the transactions which are the subject of
this proposed exemption with respect to
such New Affiliated Fund.
(m) Principal is subject to the
requirement to provide within a
reasonable period of time any
reasonably available information
regarding the covered transactions that
the Second Fiduciary of such Client
Plan requests Principal to provide.
(n) All dealings between a Client Plan
and an Affiliated Fund, including all
such dealings when such Client Plan is
invested directly in shares of such
Affiliated Fund and when such Client
Plan is invested indirectly in such
shares of such Affiliated Fund through
a Collective Fund, are on a basis no less
favorable to such Client Plan, than
dealings between such Affiliated Fund
and other shareholders of the same class
of shares in such Affiliated Fund.
(o) In the event a Client Plan invests
directly in shares of an Affiliated Fund,
and, as applicable, in the event a Client
Plan invests indirectly in shares of an
Affiliated Fund through a Collective
Fund, if such Affiliated Fund places
brokerage transactions with Principal,
Principal will provide to the Second
Fiduciary of each such Client Plan, so
invested, at least annually a statement
specifying:
(1) The total, expressed in dollars of
brokerage commissions that are paid to
Principal by each such Affiliated Fund;
(2) The total, expressed in dollars, of
brokerage commissions that are paid by
each such Affiliated Fund to brokerage
firms unrelated to Principal;
(3) The average brokerage
commissions per share, expressed as
cents per share, paid to Principal by
each such Affiliated Fund; and
(4) The average brokerage
commissions per share, expressed as
VerDate Mar<15>2010
16:27 Dec 12, 2011
Jkt 226001
cents per share, paid by each such
Affiliated Fund to brokerage firms
unrelated to Principal.
(p)(1) Principal provides to the
Second Fiduciary of each Client Plan
invested directly in shares of an
Affiliated Fund, with the disclosures, as
set forth, below, and at the times set
forth below, in Section II(p)(1)(i),
II(p)(1)(ii), II(p)(1)(iii), II(p)(1)(iv), and
II(p)(1)(v), either in writing via first
class mail or via personal delivery (or if
the Second Fiduciary consents to such
means of delivery, through electronic
email, in accordance with Section II(q),
as set forth, below);
(i) Annually, with a copy of the
current summary prospectus for each
Affiliated Fund in which such Client
Plan invests directly in shares of such
Affiliated Fund;
(ii) Upon the request of such Second
Fiduciary, a copy of the statement of
additional information for each
Affiliated Fund in which such Client
Plan invests directly in shares of such
Affiliated Fund which contains a
description of all fees paid by such
Affiliated Fund to Principal;
(iii) With regard to any Fee Increase
received by Principal, pursuant to
Section II(k)(2), above, a copy of the
audit report referred to in Section
II(k)(2)(v), above, within sixty (60) days
of the completion of such audit report;
(iv) Oral or written responses to the
inquiries posed by the Second Fiduciary
of such Client Plan, as such inquiries
arise; and
(v) Annually, with a Termination
form, as described in Section II(j)(1),
and instructions on the use of such
form, as described in Section II(j)(3),
except that if a Termination Form has
been provided to such Second
Fiduciary, pursuant to Section II(k) or
pursuant to Section II(l), above, then a
Termination Form need not be provided
again, pursuant to this Section
II(p)(1)(v), until at least six (6) months
but no more than twelve (12) months
have elapsed, since a Termination Form
was provided.
(2) Principal provides to the Second
Fiduciary of each Client Plan invested
in a Collective Fund, with the
disclosures, as set forth, below, and at
the times set forth below, in Section
II(p)(2)(i), II(p)(2)(ii), II(p)(2)(iii),
II(p)(2)(iv), II(p)(2)(v), II(p)(2)(vi),
II(p)(2)(vii), and II(p)(2)(viii), either in
writing via first class mail or via
personal delivery (or if the Second
Fiduciary consents to such means of
delivery, through electronic email, in
accordance with Section II(q), as set
forth, below);
(i) Annually, with a copy of the
current summary prospectus for each
PO 00000
Frm 00011
Fmt 4701
Sfmt 4703
77603
Affiliated Fund in which such Client
Plan invests indirectly in shares of such
Affiliated Fund thorough each such
Collective Fund;
(ii) Upon the request of such Second
Fiduciary, a copy of the statement of
additional information for each
Affiliated Fund in which such Client
Plan invests indirectly in shares of such
Affiliated Fund thorough each such
Collective Fund which contains a
description of all fees paid by such
Affiliated Fund to Principal;
(iii) Annually, with a statement of the
Collective Fund-Level Management Fee
for investment management, investment
advisory or similar services paid to
Principal by each such Collective Fund,
regardless of whether such Client Plan
invests in shares of an Affiliated Fund
through such Collective Fund;
(iv) A copy of the annual financial
statement of each such Collective Fund
in which such Client Plan invests,
regardless of whether such Client Plan
invests in shares of an Affiliated Fund
through such Collective Fund, within
sixty (60) days of the completion of such
financial statement;
(v) With regard to any Fee Increase
received by Principal, pursuant to
Section II(k)(2), above, a copy of the
audit report referred to in Section
II(k)(2)(v), above, within sixty (60) days
of the completion of such audit report;
(vi) Oral or written responses to the
inquiries posed by the Second Fiduciary
of such Client Plan, as such inquiries
arise;
(vii) For each Client Plan invested
indirectly in shares of an Affiliated
Fund through a Collective Fund, a
statement of the approximate percentage
(which may be in the form of a range)
on an annual basis of the assets of such
Collective Fund that was invested in
Affiliated Funds during the applicable
year; and
(viii) Annually, with a Termination
form, as described in Section II(j)(1),
and instructions on the use of such
form, as described in Section II(j)(3),
except that if a Termination Form has
been provided to such Second
Fiduciary, pursuant to Section II(k) or
pursuant to Section II(l), above, then a
Termination Form need not be provided
again, pursuant to this Section
II(p)(2)(viii), until at least six (6) months
but no more than twelve (12) months
have elapsed, since a Termination Form
was provided.
(q) Any disclosure required, herein, to
be made by Principal to a Second
Fiduciary may be delivered by
electronic email containing direct
hyperlinks to the location of each such
document required to be disclosed,
E:\FR\FM\13DEN2.SGM
13DEN2
77604
Federal Register / Vol. 76, No. 239 / Tuesday, December 13, 2011 / Notices
srobinson on DSK4SPTVN1PROD with NOTICES2
which are maintained on a Web site by
Principal, provided:
(1) Principal obtains from such
Second Fiduciary prior consent in
writing to the receipt by such Second
Fiduciary of such disclosure via
electronic email;
(2) Such Second Fiduciary has
provided to Principal a valid email
address; and
(3) The delivery of such electronic
email to such Second Fiduciary is
provided by Principal in a manner
consistent with the relevant provisions
of the Department’s regulations at 29
CFR 2520.104b–1(c) (substituting the
word, ‘‘Principal,’’ for the word,
‘‘administrator,’’ as set forth therein,
and substituting the phrase, ‘‘Second
Fiduciary,’’ for the phrase, ‘‘the
participant, beneficiary or other
individual,’’ as set forth therein).
Section III—General Conditions
(a) Principal maintains for a period of
six (6) years the records necessary to
enable the persons described, below, in
Section III(b) to determine whether the
conditions of this proposed exemption
have been met, except that:
(1) A prohibited transaction will not
be considered to have occurred, if solely
because of circumstances beyond the
control of Principal, the records are lost
or destroyed prior to the end of the sixyear period; and
(2) No party in interest other than
Principal shall be subject to the civil
penalty that may be assessed under
section 502(i) of the Act or to the taxes
imposed by section 4975(a) and (b) of
the Code, if the records are not
maintained or are not available for
examination as required by Section
III(b); below.
(b)(1) Except as provided in Section
III(b)(2) and notwithstanding any
provisions of section 504(a)(2) of the
Act, the records referred to in Section
III(a) are unconditionally available at
their customary location for
examination during normal business
hours by—
(i) Any duly authorized employee or
representative of the Department or the
Internal Revenue Service, or the
Securities & Exchange Commission;
(ii) Any fiduciary of a Client Plan
invested directly in shares of an
Affiliated Fund, any fiduciary of a
Client Plan who has the authority to
acquire or to dispose of the interest in
a Collective Fund in which a Client Plan
invests, any fiduciary of a Client Plan
invested indirectly in an Affiliated Fund
through a Collective Fund where such
fiduciary has the authority to acquire or
to dispose of the interest in such
Collective Fund, and any duly
VerDate Mar<15>2010
16:27 Dec 12, 2011
Jkt 226001
authorized employee or representative
of such fiduciary; and
(iii) Any participant or beneficiary of
a Client Plan invested directly in shares
of an Affiliated Fund or invested in a
Collective Fund, and any participant or
beneficiary of a Client Plan invested
indirectly in shares of an Affiliated
Fund through a Collective Fund, and
any representative of such participant or
beneficiary; and
(2) None of the persons described in
Section III(b)(1)(ii) and (iii) shall be
authorized to examine trade secrets of
Principal, or commercial or financial
information which is privileged or
confidential.
Section IV—Definitions
For purposes of this proposed
exemption:
(a) The term, ‘‘Principal,’’ means
Principal Trust, Principal Life, and any
affiliate thereof, as defined, below, in
Section IV(c).
(b) The term, ‘‘Client Plan(s),’’ means
a 401(k) plan(s), an individual
retirement account(s), other taxqualified plan(s), and other plan(s) as
defined in the Act and Code, but does
not include any employee benefit plan
sponsored or maintained by Principal,
as defined, above, in Section IV(a).
(c) An ‘‘affiliate’’ of a person includes:
(1) Any person directly or indirectly,
through one or more intermediaries,
controlling, controlled by, or under
common control with the person;
(2) Any officer, director, employee,
relative, or partner in any such person;
and
(3) Any corporation or partnership of
which such person is an officer,
director, partner, or employee.
(d) The term, ‘‘control,’’ means the
power to exercise a controlling
influence over the management or
policies of a person other than an
individual.
(e) The term, ‘‘Affiliated Fund(s),’’
means Principal Funds, Inc., a series of
mutual funds managed by Principal
Management Corporation (PMC), an
affiliate of Principal, as defined, above
in Section IV(c), and any other
diversified open-end investment
company or companies registered with
the Securities and Exchange
Commission under the Investment
Company Act and operated in
accordance with Rule 2a–7 under the
Investment Company Act, as amended,
established and maintained by Principal
now or in the future for which Principal
serves as an investment adviser.
(f) The term, ‘‘net asset value per
share,’’ and the term, ‘‘NAV,’’ means the
amount for purposes of pricing all
purchases and sales of shares of an
PO 00000
Frm 00012
Fmt 4701
Sfmt 4703
Affiliated Fund, calculated by dividing
the value of all securities, determined
by a method as set forth in the summary
prospectus for such Affiliated Fund and
in the statement of additional
information, and other assets belonging
to such Affiliated Fund or portfolio of
such Affiliated Fund, less the liabilities
charged to each such portfolio or each
such Affiliated Fund, by the number of
outstanding shares.
(g) The term, ‘‘relative,’’ means a
relative as that term is defined in
section 3(15) of the Act (or a member of
the family as that term is defined in
section 4975(e)(6) of the Code), or a
brother, a sister, or a spouse of a brother
or a sister.
(h) The term, ‘‘Second Fiduciary,’’
means the fiduciary of a Client Plan
who is independent of and unrelated to
Principal. For purposes of this proposed
exemption, the Second Fiduciary will
not be deemed to be independent of and
unrelated to Principal if:
(1) Such Second Fiduciary, directly or
indirectly, through one or more
intermediaries, controls, is controlled
by, or is under common control with
Principal;
(2) Such Second Fiduciary, or any
officer, director, partner, employee, or
relative of such Second Fiduciary, is an
officer, director, partner, or employee of
Principal (or is a relative of such
person); or
(3) Such Second Fiduciary, directly or
indirectly, receives any compensation or
other consideration for his or her
personal account in connection with
any transaction described in this
proposed exemption.
If an officer, director, partner, or
employee of Principal (or relative of
such person) is a director of such
Second Fiduciary, and if he or she
abstains from participation in:
(i) The decision of a Client Plan to
invest in and to remain invested in
shares of an Affiliated Fund directly, the
decision of a Client Plan to invest in
shares of an Affiliated Fund indirectly
through a Collective Fund, and the
decision of a Client Plan to invest in a
Collective Fund that may in the future
invest in shares of an Affiliated Fund;
(ii) Any authorization in accordance
with Section II(i), and any
authorization, pursuant to negative
consent, as described in Section II(k) or
in Section II(l); and
(iii) The choice of such Client Plan’s
investment adviser; then Section
IV(h)(2), above, shall not apply.
(i) The term, ‘‘Secondary Service(s),’’
means a service or services other than
an investment management service,
investment advisory service, and any
similar service which is provided by
E:\FR\FM\13DEN2.SGM
13DEN2
srobinson on DSK4SPTVN1PROD with NOTICES2
Federal Register / Vol. 76, No. 239 / Tuesday, December 13, 2011 / Notices
Principal to an Affiliated Fund,
including but not limited to custodial,
accounting, administrative services, and
brokerage services. Principal may also
serve as a dividend disbursing agent,
shareholder servicing agent, transfer
agent, fund accountant, or provider of
some other Secondary Service, as
defined, in this Section IV(i).
(j) The term, ‘‘Collective Fund(s),’’
means a separate account of an
insurance company, as defined in
section 2510.3–101(h)(1)(iii) of the
Department’s plan assets regulations,10
maintained by Principal, and a bankmaintained common or collective
investment trust maintained by
Principal.
(k) The term, ‘‘business day,’’ means
any day that
(1) Principal is open for conducting
all or substantially all of its business;
and
(2) The New York Stock Exchange (or
any successor exchange is open for
trading.
(l) The term, ‘‘Fee Increase(s),’’
includes any increase by Principal in a
rate of a fee, previously authorized in
writing by the Second Fiduciary of each
affected Client Plan, pursuant to Section
II(i)(2)(i)–(iv), above, and in addition
includes, but is not limited to:
(1) Any increase in any fee that results
from the addition of a service for which
a fee is charged;
(2) any increase in any fee that results
from a decrease in the number of
services and any increase in any fee that
results from a decrease in the kind of
service(s) performed by Principal for
such fee over an existing rate of fee for
each such service previously authorized
by the Second Fiduciary, in accordance
with Section II(i)(2)(i)–(iv), above; and
(3) any increase in any fee that results
from Principal changing from one of the
fee methods, as described, above, in
Section II(a)(1)–(3), to using another of
the fee methods, as described, above, in
Section II(a)(1)–(3).
(m) The term, ‘‘Plan-Level
Management Fee,’’ includes any
investment management fee, investment
advisory fee, and any similar fee paid by
a Client Plan to Principal for any
investment management services,
investment advisory services, and
similar services provided by Principal to
such Client Plan at the plan-level. The
term, ‘‘Plan-Level Management Fee’’
does not include a separate fee paid by
a Client Plan to Principal for asset
allocation service(s) (Asset Allocation
Service(s)), as defined, below, in Section
10 51
FR 41262 (November 13, 1986).
VerDate Mar<15>2010
16:27 Dec 12, 2011
Jkt 226001
IV(p), provided by Principal to such
Client Plan at the plan-level.11
(n) The term, ‘‘Collective Fund-Level
Management Fee,’’ includes any
investment management fee, investment
advisory fee, and any similar fee paid by
a Collective Fund to Principal for any
investment management services,
investment advisory services, and any
similar services provided by Principal to
such Collective Fund at the collective
fund level.
(o) The term, ‘‘Affiliated Fund-Level
Advisory Fee’’ includes any investment
advisory fee and any similar fee paid by
an Affiliated Fund to Principal under
the terms of an investment advisory
agreement adopted in accordance with
section 15 of the Investment Company
Act.
(p) The term, ‘‘Asset Allocation
Service(s),’’ means a service or services
to a Client Plan relating to the selection
of appropriate asset classes or targetdate ‘‘glidepath,’’ the selection of
specific Collective Funds, and the
selection of specific Affiliated Funds
(subject to the required consent of the
Second Fiduciary) to ‘‘populate’’ the
selected asset classes (including
rebalancing), and the allocation of the
assets of a Client Plan among the
selected funds. Such services do not
include the management of the
underlying assets of a Client Plan, or the
selected Affiliated Funds or Collective
Funds.
Effective Date: If granted, this
proposed exemption will be effective as
of the publication of the final exemption
in the Federal Register.
Summary of Facts and Representations
1. Principal Life was originally
established in 1879. Principal’s
Affiliates have been founded or
acquired from time to time thereafter.
Principal offers a variety of financial
products and services to businesses,
individuals, and institutional clients.
Principal has approximately $236.6
billion in assets under management and
serves 18.8 million customers
worldwide from offices in twelve (12)
countries.
2. The Principal Financial Group is a
trade name/registered trademark under
11 For the receipt by Principal from a Client Plan
of a fee for Asset Allocation Services provided by
Principal to such Client Plan at the plan-level,
Principal relies on the relief provided by the
statutory exemption, as set forth in section 408(b)(2)
of the Act and the Department’s regulations,
pursuant to 29 CFR 2550.408b–2. The Department
is offering no view, herein, as to whether the receipt
by Principal of such an asset allocation fee is
covered by such statutory exemption, nor is the
Department, herein, offering any view as to whether
Principal satisfies the conditions set forth in such
statutory exemption.
PO 00000
Frm 00013
Fmt 4701
Sfmt 4703
77605
which various Principal affiliated
companies operate. Affiliated
companies include Principal Financial
Group, Inc., a public (holding) company
(NYSE: PFG); numerous direct or
indirect subsidiaries including Principal
Life, Delaware Charter Guarantee &
Trust Company d\b\a Principal Trust
Company; PMC, Princor Financial
Services Corporation, Principal
Financial Services, Inc., Principal
Global Investors, LLC, and many other
affiliated entities.
3. It is represented that certain
Affiliates within Principal make
investments available, either directly or
indirectly through Collective Funds to
Client Plans. Principal has requested
that the proposed exemption apply to
any Client Plan for which Principal
serves as investment fiduciary and for
which Principal causes such Client Plan
to invest in shares of Affiliated Funds,
either directly or indirectly through a
Collective Fund. It is represented that
Principal places no limits on the
minimum or maximum portion of the
total assets of each Client Plan that may
be invested directly in shares of an
Affiliated Fund or invested indirectly in
an Affiliated Fund through a Collective
Fund.
4. Section 406(a)(1)(D) of the Act
prohibits a fiduciary with respect to a
plan from causing such plan to engage
in a transaction, if he knows or should
know, that such transaction constitutes
a transfer to, or use by or for the benefit
of, a party in interest, of any assets of
such plan.
Sections 3(14)(A) and (B) of the Act
define the term, ‘‘party in interest,’’ to
include, respectively, any fiduciary of a
plan and any person providing services
to a plan. Under section 3(21)(A)(i) of
the Act, a person is a fiduciary with
respect to a plan to the extent such
person exercises authority or control
with respect to the management or
disposition of the assets of a plan.
Under section 3(21)(A)(ii) a person is a
fiduciary with respect to a plan to the
extent such person renders investment
advice for a fee or other compensation,
direct or indirect, with respect to any
moneys or other property of a plan or
has any authority or responsibility to do
so.
Under section 406(b) of the Act, a
fiduciary with respect to a plan may not:
(1) Deal with the assets of a plan in his
own interest or for his own account,
(2) in his individual or in any other
capacity act in any transaction involving
a plan on behalf of a party (or represent
a party) whose interests are adverse to
the interests of such plan or the interests
of its participants or beneficiaries, or
(3) receive any consideration for his
E:\FR\FM\13DEN2.SGM
13DEN2
srobinson on DSK4SPTVN1PROD with NOTICES2
77606
Federal Register / Vol. 76, No. 239 / Tuesday, December 13, 2011 / Notices
own personal account from any party
dealing with a plan in connection with
a transaction involving the assets of
such plan.
Principal entities may currently serve,
and may in the future serve, as
investment advisors, investment
managers, trustees, or other fiduciaries
with respect to Client Plans.
Accordingly, the Applicants and various
other Principal affiliates may currently
be, or may in the future be, parties in
interest with respect to a Client Plan
which engage in the proposed
transactions. In this regard, where
Principal now or in the future is a
fiduciary with respect to a Client Plan,
the investment of the assets of such
Client Plan in a Collective Fund and/or
in an Affiliated Fund advised by
Principal may raise issues under
sections 406(a)(1)(D), 406(b)(1),
406(b)(2), and 406(b)(3) of the Act, and
the corresponding provisions of the
Code, unless an exemption is available.
5. Principal’s collective investment
vehicles currently include various
pooled separate accounts. In this regard,
Principal Life manages several
insurance company separate accounts
(the Separate Accounts). Principal Life
is a fiduciary with respect to any
Separate Accounts that hold plan assets.
It is represented that none of the
Separate Accounts currently invests in
any Affiliated Fund in a manner that
requires exemptive relief, hereunder.
However, it is represented that existing
Separate Accounts or Separate Accounts
to be established in the future may do
so. Accordingly, the Applicants request
that the proposed exemption apply, as
of the effective date of this proposed
exemption, to Separate Accounts that
hold ‘‘plan assets’’ of investor Client
Plans.
6. Principal’s collective investment
vehicles also currently include various
bank-maintained collective investment
trusts. Any or all of Principal’s
collective investment vehicles may rely
upon one or more statutory or class
exemptions in connection with their
activities. Principal represents that the
proposed exemption, if granted, will
apply to Collective Funds, as defined,
above, in Section IV(j).
7. It is represented that in 2009,
Principal Trust established certain target
date collective funds (the Target Date
Funds). The Target Date Funds are used
as investment options in participantdirected Client Plans. The Target Date
Funds are deemed to hold ‘‘plan assets’’
of such investing Client Plans. It is
represented that although a Second
Fiduciary, as defined, above, in Section
IV(h), will select the Target Date Funds
as designated investment options, the
VerDate Mar<15>2010
16:27 Dec 12, 2011
Jkt 226001
actual decision to invest in any Target
Date Funds is made by individual plan
participants, unless such fund is
selected by a Second Fiduciary as a
qualified default investment option.
The Target Date Funds are bankmaintained collective investment trusts.
The Target Date Funds are currently
comprised of eleven (11) portfolios.
Principal Trust acts as trustee and
investment manager for the Target Date
Funds. As such, Principal Trust has
discretion over the investment of the
assets of the Target Date Funds.
Principal Trust manages the portfolios
of the Target Date Funds in accordance
with its own investment objectives and
strategies. In this regard, Principal Trust
invests the assets of such Target Date
Funds in Affiliated Funds and other
investments including other Collective
Funds. Principal Trust selects the
underlying investments and allocates
the assets of each of the Target Date
Funds among the underlying
investments based on the time horizon
of each such Target Date Fund and the
expected risk tolerance of those
investors who have chosen that time
horizon. It is represented that the
underlying investments include
investment in Principal Funds Inc., a
series of Affiliated Funds managed by
PMC, or may include other Affiliated
Funds to be formed in the future. It is
represented that the Target Date Funds
are the only Principal Collective Funds
currently invested in Affiliated Funds.
8. The Affiliated Funds are a series of
mutual funds managed by PMC, an
affiliate of Principal, and may include
other Affiliated Funds to be established
in the future by Principal. The Affiliated
Funds are open-end investment
companies registered with the Securities
and Exchange Commission under the
Investment Company Act, as amended
and operated in accordance with Rule
2a–7 under the Investment Company
Act. PMC or Principal serves as an
investment adviser with respect to the
Affiliated Funds. Principal may also
serve as custodian, dividend disbursing
agent, shareholder servicing agent,
transfer agent, fund accountant, or
provider of some other Secondary
Services, including brokerage services,
to an Affiliated Fund.
Prohibited Transaction Exemption 77–4
(PTE 77–4)
9. It is represented that all of the
Principal entities to which the proposed
exemption, if granted, would apply are
currently part of the same controlled
group. In this regard, the Applicants
maintain that such Principal entities can
PO 00000
Frm 00014
Fmt 4701
Sfmt 4703
rely on the relief provided pursuant to
PTE 77–4.12
PTE 77–4 provides an exemption from
section 406 of the Act and section 4975
of the Code for the purchase and for the
sale by a plan of shares of a registered,
open-ended investment company where
the investment adviser of such fund: (1)
Is a plan fiduciary or affiliated with a
plan fiduciary; and (2) is not an
employer of employees covered by the
plan. The conditions of PTE 77–4
prohibit the payment of commissions by
a plan, limit the payment of redemption
fees by such plan, require prior
disclosures (e.g., fee information and a
current prospectus) to a second
fiduciary and written authorization from
such second fiduciary who is generally
the sponsor or other named fiduciary or
trustee of such plan, and prohibit the
payment of double investment advisory
fees and similar fees with respect to
plan assets invested in such shares for
the entire period of such investment. In
addition, PTE 77–4 requires advance
written approval from a second
fiduciary for any changes in the fund fee
rates.
10. The Applicants represent that the
requested relief is essentially the same
as that afforded by PTE 77–4, except for
the use of a ‘‘negative consent’’
procedure, as discussed in the
paragraphs, below, for:
(1) Approving Fee Increases received
by Principal, and
(2) approving in advance the addition
of Affiliated Funds (not previously
authorized) as investments ‘‘inside’’ a
Principal Collective Fund, subject to
notice and a right to terminate the
original approval at the time a new
Affiliated Fund is proposed to be added.
Principal maintains that obtaining
advance written approval from a Second
Fiduciary can be difficult, particularly
in the case of a Collective Fund, such as
a Target Date Fund, where a Second
Fiduciary from every investing Client
Plan must provide written approval
before fees payable to Principal by an
Affiliated Fund in which such Client
Plans invest indirectly via a Collective
Fund can be increased, or before a new
investment in an Affiliated Fund that
was not previously authorized can be
made. If advance written approval is not
obtained from the Second Fiduciary of
each affected Client Plan, then PTE 77–
4 may not apply and Principal may
violate the restrictions of section 406(a)
and 406(b) of the Act.
12 The Department, herein, is expressing no
opinion in this proposed exemption regarding the
reliance of the Applicants on the relief provided by
PTE 77–4, nor is the Department offering any view
as to whether the Applicants satisfy the conditions,
as set forth in PTE 77–4.
E:\FR\FM\13DEN2.SGM
13DEN2
srobinson on DSK4SPTVN1PROD with NOTICES2
Federal Register / Vol. 76, No. 239 / Tuesday, December 13, 2011 / Notices
Negative Consent for Fee Increases
11. In order to avoid the
administrative burden of obtaining
advance written approval from a Second
Fiduciary of each affected Client Plan,
the Applicants request an individual
administrative exemption which would
allow for a negative consent procedure
for obtaining the approval from a
Second Fiduciary for Fee Increases
payable to Principal. Fee Increases are
defined in Section IV(l) and include: (1)
Any increase in the rate of a fee
previously authorized in writing by the
Second Fiduciary of an affected Client
Plan, (2) any increase in any fee that
results from an addition of services for
which a fee is charged, (3) any increase
in any fee that results from a decrease
in the number or kind of services
performed for such fee over an existing
rate for such service previously
authorized by the Second Fiduciary,
and (3) any increase in a fee that results
from Principal changing from one of the
fee methods, as described, above, in
Section II(a)(1)–(3), to using another of
the fee methods, as described, above, in
Section II(a)(1)–(3).
In order to obtain the negative consent
authorization from the Second
Fiduciary of each affected Client Plan
with regard to a Fee Increase, Principal
will have to comply with the provisions,
set forth in Section II(k). In this regard,
the proposed exemption would require
Principal to provide to the Second
Fiduciary of a Client Plan invested
directly in shares of an Affiliated Fund
or indirectly through a Collective Fund
certain disclosures in writing thirty (30)
days in advance of any proposed Fee
Increase, including but not limited to
any Fee Increase for Secondary Services,
as such services are described, below.
The disclosures are delivered by regular
mail or personal delivery (or if the
Second Fiduciary consents by electronic
means), and are accompanied by a
Termination Form and instructions on
the use of such form.
Notwithstanding the requirement for
thirty (30) days advance notice of a Fee
Increase, the proposed exemption
would permit Principal to implement a
Fee Increase, without waiting until the
expiration of the 30 day period;
provided that implementation of such
Fee Increase does not start before
Principal delivers to each affected Client
Plan the Notice of Intent of Change of
Fees, as described in Section II(k), and
provided further that any affected Client
Plan receives a cash credit equal to its
pro rata share of such Fee Increase, for
the period from the date of the
implementation of such Fee Increase to
the earlier of the date of the termination
VerDate Mar<15>2010
16:27 Dec 12, 2011
Jkt 226001
of the investment or the thirtieth (30th)
day after the date Principal delivers the
Notice of Change of Fee to the Second
Fiduciary of each affected Client Plan.
In addition, Principal must pay to each
affected Client Plan interest on such
cash credit. An Auditor on at least an
annual basis will verify the proper
crediting of the pro rata share of each
such Fee Increase and interest. An audit
report shall be completed by such
Auditor no later than six (6) months
after the period to which it relates.
Failure of the Second Fiduciary to
return the Termination Form or to
provide some other written notification
of the intent to terminate within a
certain period of time will be deemed to
be approval of the proposed Fee
Increase, including but not limited to an
increase in the fee for Secondary
Services.
Negative Consent for New Affiliated
Funds
12. Principal further requests that the
proposed exemption permit a Principal
Collective Fund holding the assets of a
Client Plan, such as a Target Date Fund,
to purchase shares of an Affiliated Fund
not previously affirmatively authorized
by the Second Fiduciary of such Client
Plan; provided: (1) The organizational
document of such Collective Fund
expressly provides for the addition of
one or more Affiliated Funds to the
portfolio of such Collective Fund and
such organizational document is
disclosed initially to such Client Plan;
and (2) Principal satisfies the
requirements of the negative consent
procedure for obtaining the approval of
the Second Fiduciary for each Client
Plan invested in such Collective Fund at
the time Principal proposes to add an
Affiliated Fund to such Collective
Fund’s portfolio.
Specifically, the negative consent
procedure would entail that the Second
Fiduciary of each Client Plan invested
in such Collective Fund receives in
advance: (i) A notice of Principal’s
intent to add an Affiliated Fund to the
portfolio of such Collective Fund; and
(ii) certain disclosures in writing,
including a summary prospectus of such
Affiliated Fund. The disclosures are
delivered by regular mail or personal
delivery (or if the Second Fiduciary
consents by electronic means), and are
accompanied by a Termination Form
and instructions on the use of such
form.
Failure of the Second Fiduciary to
return the Termination Form or to
provide some other written notification
of the intent to terminate within a
certain period of time will be deemed to
PO 00000
Frm 00015
Fmt 4701
Sfmt 4703
77607
be approval of the investment by such
Collective Fund in such Affiliated Fund.
13. Principal represents that the
negative consent procedures, described
in the paragraphs, above, are more
efficient, cost effective, and
administratively feasible than the
advance written approval from the
Second Fiduciary, as described in PTE
77–4. It is represented that the negative
consent procedure avoids the
administrative delays that would result
if advance written approval from the
Second Fiduciary were required.
It is further represented that because
the Second Fiduciary of each Client
Plan will receive all of the necessary
disclosures and will have an
opportunity to terminate the investment
in any Affiliated Fund without penalty,
such Client Plan and its participants
and beneficiaries are adequately
protected. Further, to the extent that
Principal may find it desirable from
time to time to create an Affiliated Fund
with new investment goals, the negative
consent procedure will facilitate the
addition of an Affiliated Fund into the
portfolios of Principal’s Collective
Funds.
Electronic Disclosures
14. Principal intends to utilize
electronic mail with hyperlinks to
documents required to be disclosed by
this proposed exemption. Principal
agrees that it will ‘‘actively’’ satisfy the
various disclosure requirements of this
proposed exemption by transmitting
emails, rather than relying on ‘‘passive’’
postings on a Web site. It is represented
that this method of disclosure will be
consistent with the Department’s
regulations at 29 CFR section
2520.104b–1. Client Plans which do not
authorize electronic delivery will
receive in advance hard copies of the
documents required to be disclosed, and
hard copies of documents will also be
available on request.
Termination
15. A Client Plan invested directly in
shares of an Affiliated Fund or invested
indirectly through a Collective Fund
will have an opportunity to terminate
and withdraw from investment in such
Affiliated Fund, and, as applicable, to
terminate and withdraw from
investment in such Collective Fund in
the event of a Fee Increase and in the
event of the addition of an Affiliated
Fund to the portfolio of a Collective
Fund.
In this regard, a Second Fiduciary will
be provided with a Termination Form at
least annually and may terminate the
authorization to invest directly in shares
of an Affiliated Fund or indirectly
E:\FR\FM\13DEN2.SGM
13DEN2
77608
Federal Register / Vol. 76, No. 239 / Tuesday, December 13, 2011 / Notices
srobinson on DSK4SPTVN1PROD with NOTICES2
through a Collective Fund, at will,
without penalty to a Client Plan.
Termination of the authorization by the
Second Fiduciary of a Client Plan
investing directly in shares of an
Affiliated Fund will result in such
Client Plan withdrawing from such
Affiliated Fund. Termination of the
authorization by the Second Fiduciary
of a Client Plan investing indirectly in
shares of an Affiliated Fund through a
Collective Fund will result in such
Client Plan withdrawing from such
Collective Fund.
Generally, Principal will process
timely requests for withdrawal from an
Affiliated Fund within one (1) Business
day. Withdrawal from a Collective Fund
will generally be processed within the
same time frame, subject to rules
designed to ensure orderly withdrawals
and fairness for the withdrawing Client
Plans and non-withdrawing Client
Plans, but in no event shall such
withdrawal be implemented by
Principal more than five business (5)
days after receipt by Principal of a
termination form or other written
notification of intent to terminate
investment in such Collective Fund
from the Second Fiduciary acting on
behalf of the withdrawing Client Plan.
Principal will pay interest on the
settlement amount for the period from
receipt by Principal of a termination
form or other written notification of
intent to terminate from the Second
Fiduciary, acting on behalf of the
withdrawing Client Plan, to the date
Principal pays the settlement amount,
plus interest thereon.
From the date a Client Plan terminates
its investment in an Affiliated Fund,
such Client Plan will not be subject to
pay a pro rata share of the fees received
by Principal from such Affiliated Fund.
Likewise, from the date a Client Plan
terminates its investment in a Collective
Fund, such Client Plan will not be
subject to pay a pro rata share of the
fees received by Principal from such
Collective Fund, nor will such Client
Plan be subject to changes in the
portfolio of such Collective Fund,
including a pro rate share of any
Affiliated Fund-Level Advisory Fee
arising from the investment by such
Collective Fund in an Affiliated Fund.
Receipt of Fees Pursuant to the Fee
Methods
16. The exemption, if granted,
includes conditions which detail
various methods which ensure that
Principal complies with the prohibition
against a Client Plan paying double
investment management fees,
investment advisory, and similar fees
for the assets of Client Plans invested
VerDate Mar<15>2010
16:27 Dec 12, 2011
Jkt 226001
directly in shares of an Affiliated Fund
or invested indirectly in shares of an
Affiliated Fund though a Collective
Fund. These methods are described in
Section II(a)(1)–(3) of this proposed
exemption.
Plan-Level Fees
17. It is represented that currently to
the extent that Principal provides
discretionary investment management
services 13 to any Client Plan that
invests directly in shares of an Affiliated
Fund or indirectly through a Collective
Fund, Principal does not charge any
investment management fee, any
investment advisory fee, or any similar
fee directly to such Client Plan.14 If in
the future, Principal were to do so, this
proposed exemption would require
Principal to use the methods, as
described in Section II(a) of this
exemption, as applicable, so as to avoid
receiving ‘‘double’’ investment
management, investment advisory, and
similar fees.
Also, services provided by Principal
for which a fee is charged involve planlevel and participant-level
recordkeeping and administrative
services, custody, and other clerical and
administrative functions.15 It is
represented that a Second Fiduciary
typically will select Principal’s
Collective Funds in connection with a
decision to retain Principal as a service
provider to such Client Plan, usually as
part of a ‘‘bundled’’ arrangement. It is
also possible that a Second Fiduciary of
a Client Plan that already uses
Principal’s products and services may
wish to add additional Collective Funds
to its investment line-up.
The Collective Fund-Level Management
Fee
18. With regard to the Collective
Fund-Level Management Fee, it is
represented that the only Collective
Funds over which Principal currently
exercises fiduciary discretion to invest
in Affiliated Funds are the Target Date
Funds. Principal currently charges no
investment advisory and no similar fees
‘‘inside’’ the Target Date Funds. Fees
charged by the Target Date Funds
13 Investment management services do not
include Asset Allocation Services, as defined,
above, in Section IV(p).
14 The Department, herein, is not providing relief
for the receipt by Principal of a Plan-Level
Management Fee for investment management
services provided at the plan-level by Principal to
a Client Plan.
15 The Applicants have not requested and the
Department, herein, is not providing any relief for
the receipt by Principal at the plan-level of fees for
providing recordkeeping and administrative
services, custody, and other clerical and
administrative functions to a Client Plan.
PO 00000
Frm 00016
Fmt 4701
Sfmt 4703
presently are limited to: (i) Four (4)
basis points charged by Principal Trust
for non-advisory, custodial and
administrative services (Collective Fund
Administrative Services); 16 and (ii)
depending on the specific class of units
selected by a sponsor of a Client Plan,
certain additional ‘‘services fees’’ 17 that
the plan sponsor may direct to be paid
over to other plan service providers for
services such as recordkeeping, custody,
and distribution.18
However, it is represented that in the
future, Principal may decide to charge
investment advisory fees or may decide
to charge similar fees ‘‘inside’’ a
collective investment vehicle. In that
event, Principal will utilize the
methods, described in Section II(a)(2)
and in Section II(a)(3), as applicable so
as to avoid charging ‘‘double’’
investment advisory and similar fees.
The Affiliated Fund-Level Advisory Fee
19. The Affiliated Fund-Level
Advisory Fees are described in the
summary prospectus for an Affiliated
Fund and include fees for investment
advisory services and fees for similar
services which Principal receives as
compensation for the provision of such
services to such Affiliated Fund.
As noted, above, Principal currently
waives the Plan-Level Management Fees
and Collective Fund-Level Management
Fees for the provision of investment
management services, investment
advisory services, and similar services
and retains the fees paid to Principal by
an Affiliated Fund with regard to a
Client Plan that invests directly in
shares of such Affiliated Fund or
indirectly in shares of such Affiliated
Fund through a Collective Fund.
Notwithstanding this fact, it is
represented that Principal in the future
may cease to waive Plan-Level
Management Fees and Collective FundLevel Management Fees. In that event,
in order to avoid receiving double fees,
Principal must comply with the
16 The Department, herein, is not providing relief
for the receipt by Principal of fees from a Collective
Fund for providing Collective Fund Administrative
Services to such Collective Fund.
17 For example, a sponsor of a Client Plan can
select a ‘‘share’’ class of a Collective Fund that is
subject to a four (4) basis point trustee fee, or may
elect to utilize a share class of a Collective Fund
that pays (by way of example) fourteen (14) basis
points, four (4) basis points of which are paid to
Principal Trust and ten (10) basis points of which
the sponsor of such Client Plan may direct Principal
Trust to pay to such Client Plan’s recordkeeper or
other service providers.
18 The Department, herein, is not providing relief
for any other additional ‘‘services fees’’ received by
Principal that the sponsor of a Client Plan may
direct to be paid over to other service providers to
such Client Plan.
E:\FR\FM\13DEN2.SGM
13DEN2
Federal Register / Vol. 76, No. 239 / Tuesday, December 13, 2011 / Notices
srobinson on DSK4SPTVN1PROD with NOTICES2
conditions, as set forth in Section II(a)
of this exemption, as applicable.
Receipt of Fees for Secondary Services
20. Principal also receives from an
Affiliated Fund various fees and
expenses for custody, transfer agency,
and similar services, including
brokerage services. It is represented that
all such services are treated as
‘‘Secondary Services.’’ The term,
‘‘Secondary Services,’’ is defined, above,
in Section IV(i), to mean a service other
than an investment management
service, an investment advisory service,
and any similar service, which is
provided by Principal to an Affiliated
Fund, including but not limited to
custodial, accounting, administrative,
brokerage, and other services. It is
represented that all fees for Secondary
Services received by Principal at this
time are paid to Principal directly by the
Affiliated Funds. The negative consent
procedure applicable for a Fee Increase
for Secondary Services is discussed,
above, in paragraph 11.
In addition, Principal affiliates may
receive commissions for the
performance of brokerage services for
the mutual funds. Under the conditions
of this proposed exemption, if an
Affiliated Fund places brokerage
transactions with Principal, Principal
will provide the Second Fiduciary of
each such Client Plan, at least annually
with the disclosure described in Section
II(o) of this proposed exemption.
21. The Applicants represent that
proposed exemption is in the interest of
Client Plans, because it will allow
Principal to efficiently manage or advise
with respect to the assets of such Client
Plans invested in shares of an Affiliated
Fund, either directly or indirectly
through a Collective Fund, in a timely
manner and on terms that might not
otherwise be available without
exemptive relief.
22. It is represented that the proposed
exemption contains sufficient
safeguards for the protection of the
Client Plans invested in shares of an
Affiliated Fund either directly or
indirectly through a Collective Fund.
Prior to any investment by a Client Plan
directly or indirectly in shares of an
Affiliated Fund, such investment must
be authorized by the Second Fiduciary
of such Client Plan, based on full and
detailed written disclosure concerning
such Affiliated Fund.
It is further represented that the
proposed exemption is protective of the
rights of Client Plans, because any Fee
Increase or the addition of an Affiliated
Fund to the portfolio of a Collective
Fund will be on terms monitored and
approved by the Second Fiduciary who
VerDate Mar<15>2010
16:27 Dec 12, 2011
Jkt 226001
will have the ability to avoid the effect
of such Fee Increase and the effect of the
addition of an Affiliated Fund to the
portfolio of a Collective Fund.
Furthermore, each investment of the
assets of a Client Plan in shares of an
Affiliated Fund, either directly, or
indirectly through a Collective Fund,
will be subject to the ongoing ability of
the Second Fiduciary of such Client
Plan to terminate the investment in such
Affiliated Fund and to terminate the
investment in such Collective Fund,
without penalty to such Client Plan at
any time upon written notice of
termination to Principal.
In addition to the initial disclosures,
Principal provides to such Second
Fiduciary ongoing disclosures regarding
such Affiliated Funds. Further,
Principal will respond to inquiries from
a Second Fiduciary and will provide
any other reasonably available
information to a Second Fiduciary upon
request.
23. It is represented that the proposed
exemption is administratively feasible,
because the subject transactions will not
require continued monitoring or other
involvement on behalf of the
Department or the Internal Revenue
Service. The use of a Termination Form
will provide both a record and a regular
reminder to the Second Fiduciary of a
`
Client Plan of such plan’s rights vis-avis investing in Affiliated Funds, either
directly or indirectly through a
Collective Fund.
24. In summary, the Applicants
represent that the proposed transactions
satisfy the statutory criteria for an
exemption under section 408(a) of the
Act for the following reasons:
(a) The Affiliated Funds will provide
Client Plans with effective investment
vehicles;
(b) The receipt by Principal of an
Affiliated Fund-Level Advisory Fee, and
the receipt of a fee by Principal for
Secondary Services will require an
authorization in writing in advance by
a Second Fiduciary for each such Client
Plan after receipt of full written
disclosure;
(c) Any authorization made by a
Second Fiduciary, acting on behalf of a
Client Plan will be terminable at will by
such Second Fiduciary, without penalty
to such Client Plan, following receipt by
Principal of a Termination Form or any
other written notice of termination from
such Second Fiduciary of a Client Plan
invested directly in shares of an
Affiliated Fund or indirectly through a
Collective Fund;
(d) The Termination Form will be
supplied to such Second Fiduciary at
least annually;
PO 00000
Frm 00017
Fmt 4701
Sfmt 4703
77609
(e) No sales commissions will be paid
by Client Plans in connection with the
acquisition or in connection with the
sale of shares of the Affiliated Funds
either directly or through a Collective
Fund, and only redemption fees
disclosed in the summary prospectus of
an Affiliated Fund will be paid by a
Client Plan;
(f) All dealings among a Client Plan,
any Affiliated Fund, and Principal will
be on a basis no less favorable to such
Client Plan than such dealings with the
other shareholders of such Affiliated
Fund;
(g) The purchase price paid and the
sales price received by a Client Plan for
shares in an Affiliated Fund purchased
or sold directly, and the purchase price
paid and the sales price received by a
Client Plan for shares in an Affiliated
Fund purchased or sold indirectly
through a Collective Fund, will be the
NAV at the time of the transaction, and
will be the same purchase price paid
and the same sales price received for
such shares by any other shareholder of
the same class of shares in such
Affiliated Fund at that time;
(h) A Client Plan investing in shares
of an Affiliated Fund, either directly or
indirectly, through a Collective Fund,
will not pay ‘‘double fees’’ for
investment management, investment
advisory, and similar fees with respect
to the assets of such Client Plan so
invested; and
(i) An Auditor on at least an annual
basis will verify the proper crediting of
any Fee Increase and interest, received
by a Client Plan, pursuant to Section
II(k)(2), and an audit report shall be
completed by such Auditor no later than
six (6) months after the period to which
it relates.
Notice to Interested Persons
Those persons who may be interested
in the publication in the Federal
Register of the Notice include each
Client Plan invested directly in shares of
an Affiliated Fund, each Client Plan
invested indirectly in shares of an
Affiliated Fund through a Collective
Fund, and each plan for which Principal
provides discretionary management
services, via the Target Date Funds or
otherwise at the time the proposed
exemption is published in the Federal
Register.
It is represented that notification will
be provided to each of these interested
persons by first class mail, within
fifteen (15) calendar days of the date of
the publication of the Notice in the
Federal Register. Such mailing will
contain a copy of the Notice, as it
appears in the Federal Register on the
date of publication, plus a copy of the
E:\FR\FM\13DEN2.SGM
13DEN2
77610
Federal Register / Vol. 76, No. 239 / Tuesday, December 13, 2011 / Notices
Supplemental Statement, as required,
pursuant to 29 CFR 2570.43(b)(2), which
will advise such interested persons of
their right to comment and to request a
hearing.
The Department must receive all
written comments and requests for a
hearing no later than forty-five (45) days
from the date of the publication of the
Notice in the Federal Register.
For further information contact:
Angelena C. Le Blanc of the Department,
telephone (202) 693–8540 (This is not a
toll-free number.)
Aztec Well Servicing Company &
Related Companies Medical Plan Trust
Fund (the Plan), Located in Aztec, New
Mexico
[Application No. D–11628]
srobinson on DSK4SPTVN1PROD with NOTICES2
Proposed Exemption
The Department of Labor (the
Department) is considering granting an
exemption under the authority of
section 408(a) of the Act in accordance
with procedures set forth in 29 CFR part
2570, Subpart B (55 FR 32836, 32847,
August 10, 1990).
Section I
If the proposed exemption is granted,
the restrictions of sections 406(a)(1)(A),
(C) and (D), 406(b)(1), and 406(b)(2) of
the Act shall not apply to the payment
by the Plan to Basin Occupational &
Urgent Care, LLC (BOUC), a party in
interest with respect to the Plan, for the
on-site provision to the Plan of urgent
medical care and wellness services by a
nurse-practitioner and a wellness
coordinator employed by BOUC,
provided that the following conditions
are satisfied:
(a) An independent, qualified
fiduciary (I/F), with expertise in plans
providing health and welfare benefits
under the Act and the fiduciary
obligations thereunder, acting on behalf
of the Plan, determines prior to entering
into the transaction that the transaction
is feasible, in the interest of, and
protective of the Plan and the
participants and beneficiaries of the
Plan;
(b) Before the Plan enters into the
proposed transaction, the I/F reviews
the transaction, ensures that the terms of
the transaction are at least as favorable
to the Plan as an arm’s length
transaction with an unrelated party, and
determines whether or not to approve
the transaction, in accordance with the
fiduciary provisions of the Act;
(c) The I/F monitors compliance with
the terms and conditions of this
proposed exemption, as described
herein, and ensures that such terms and
conditions are at all times satisfied;
VerDate Mar<15>2010
16:27 Dec 12, 2011
Jkt 226001
(d) The I/F monitors compliance with
the terms of the written license
agreement (the License) between the
Plan and AWS, and takes any and all
steps necessary to ensure that the Plan
is protected, including, but not limited
to, exercising its authority to terminate
the License on 10 days’ written notice;
and
(e) The subject transaction is, in fact,
on terms and at all times remains on
terms that are at least as favorable to the
Plan as those that would have been
negotiated under similar circumstances
at arm’s-length with an unrelated third
party.
Section II
If the proposed exemption is granted,
the restrictions of sections 406(a)(1)(A),
(C) and (D), 406(b)(1), and 406(b)(2) of
the Act shall not apply, effective July 1,
2010, to: (1) The payment by the Plan’s
participants to BOUC for medical
services provided as a result of the
inclusion of BOUC’s clinic, located in
Farmington, New Mexico, as a network
provider in the BlueCross BlueShield of
New Mexico (BCBSNM) Network of
Health Care Providers; and (2) the
payment by the Plan to BCBSNM of the
difference between BOUC’s fee and the
participant’s co-pay, which difference is
then transmitted by BCBSNM to BOUC,
provided that the following conditions
are satisfied:
(a) The terms of the medical services
provided by BOUC to Plan participants
are at least as favorable to the
participants as those they could obtain
in similar transactions with an
unrelated party;
(b) the Plan participants will have
access to all of the providers in
BCBSNM’s network and will be free to
choose whether or not to use BOUC’s
clinic;
(c) at least 99% of the providers
participating in the BCBSNM are
unrelated to the companies whose
employees participate in the Plan, or
any other party in interest with respect
to the Plan;
(d) BOUC will be treated no more
favorably than any other provider
participating in the BCBSNM; and
(e) the transactions are not part of an
agreement, arrangement or
understanding designed to benefit
BOUC or any other party in interest
with respect to the Plan.
Summary of Facts and Representations
1. Aztec Well Servicing Company
(AWS) is a family-owned business that
has operated in San Juan County, in
northwestern New Mexico, near the
Four Corners, since 1963. In 2007, AWS
decided to self-insure its medical
PO 00000
Frm 00018
Fmt 4701
Sfmt 4703
benefits and established the Aztec Well
Servicing Company & Related
Companies Medical Plan Trust Fund
(the Plan). The Plan covers the
employees of six companies (together,
the Companies) with common
ownership: Totah Rental and Equipment
Company, Inc., Triple S Trucking
Company, Inc., Double M Mud
Company, Inc., Basin Disposal, Inc., and
Roadrunner Fuels, as well as AWS. All
six of these companies operate in the
well drilling and servicing industry in
and around San Juan County. As of May
31, 2011, there were approximately 344
participants in the Plan. The Plan and
its related trust fund are governed by a
three-member Board of Trustees (the
Trustees) that consists of Jerry Sandel,
the President of the Companies, his son
Jason Sandel, Vice-President and
Treasurer, and Stewart Peterson, VicePresident.
2. The Trustees contract with
BCBSNM for access to the BCBSNM
network of health care providers and for
claims adjudication and related
services. However, even with access to
that network, there is a dearth of
primary and urgent care providers in
San Juan County. Along with many
members of the community, the
Trustees have been concerned about the
lengthy waiting times for urgent care
and the general inaccessibility of health
care in this rural area.
3. In order to address this problem,
Trustee Jason Sandel, along with his
sister Michelle Sandel, formed a health
care clinic, Basin Occupational & Urgent
Care LLC (BOUC), which was organized
under the laws of the State of New
Mexico as a for-profit limited liability
corporation. No Plan assets were used in
the formation of BOUC, and its services
are available to the general public.
Currently, AWS has an arrangement
with BOUC under which BOUC
provides the services of a nursepractitioner to the Plan participants and
their dependents. The services consist
of non-occupational urgent care,
wellness exams, and preventive care
advice and are available on AWS’
campus during working hours without
charge to the individual. BOUC also
provides a wellness coordinator who
oversees the Plan’s exercise facility,
which is also available without charge
to the Plan’s participants and their
eligible dependents. BOUC has also
joined the Plan as a sponsoring
employer and its employees have the
opportunity to participate in the Plan on
the same terms as all other employees
of participating employers.
4. The applicant represents that AWS
set up the Plan in order to provide
medical benefits. The Trustees of the
E:\FR\FM\13DEN2.SGM
13DEN2
srobinson on DSK4SPTVN1PROD with NOTICES2
Federal Register / Vol. 76, No. 239 / Tuesday, December 13, 2011 / Notices
Plan consider access to the nursepractitioner and the wellness
coordinator to be an important part of
such benefits. The applicant represents
that it was always intended that the
Plan would provide these benefits; AWS
is currently furnishing them to avoid
violating the prohibited transaction
rules. The applicant has requested relief
to permit the Plan to enter into an
agreement (the Agreement) with BOUC
to provide the same services, on the
same terms and conditions (i.e., the Plan
will pay BOUC for providing the
services of the nurse-practitioner and
the wellness coordinator). The services
would continue to be available to all
Plan participants without charge. AWS
represents that if the Plan were to
provide medical services directly to its
participants, it would have to comply
with a number of state laws, including
medical facility and provider licensing,
as well as state and federal employment
laws. It would also have to insure
against medical malpractice liability.
Because the Plan is so small, the
Trustees have decided that it is more
cost-effective to the Plan to contract out
these services to an entity that can take
care of the licensing, insurance,
employment and legal and regulatory
compliance issues in the context of a
larger book of business.
5. The nurse-practitioner and the
wellness coordinator, who are
employees of BOUC, will be providing
their services to the Plan in a building
(Building) owned by AWS. AWS has
entered into a licensing agreement (the
License) with the Plan under which the
Plan can use the Building free of charge.
The Plan purchased exercise equipment
from an unrelated party, The Fitness
Superstore, a national chain that sells
sports equipment. The equipment,
which the Plan has put into the
Building, includes treadmills, elliptical
trainers, stationary bicycles, weight
machines, exercise mats, and the like,
none of which is affixed to the real
property and all of which could either
be moved to a new location or sold on
the open market by the Plan. The
License does not contain a specific
number of years, but simply provides
that it will remain in effect until
terminated by either party (on 10 days’
written notice). The License provides
that the Plan will retain ownership of
any alterations, remodeling, and/or
improvements funded by the Plan. In
the event of termination, AWS and the
Plan will apply to the Department for a
separate prohibited transaction
exemption to permit the Plan to sell to
AWS any alterations, remodeling or
VerDate Mar<15>2010
16:27 Dec 12, 2011
Jkt 226001
improvements the Plan makes to the
Building.
6. An independent, qualified
fiduciary has been retained by the Plan
and has conducted a study regarding the
proposed transaction. The independent
fiduciary is Maureen Sanders, of
Albuquerque, New Mexico. Ms. Sanders
represents that she has been the attorney
for the New Mexico Medical Insurance
Pool (the Pool) since the late 1980s. The
Pool was created by the legislature to
ensure that health insurance is available
for purchase for those with pre-existing
conditions. Ms. Sanders represents that
because of that affiliation, she has
become very aware of the importance of
preventive measures to assist
individuals with their health needs. She
is also aware of the costs of health care,
the lack of providers in the Four Corners
area, and the need for options for those
working in the oil fields. Since she has
left full-time teaching, Ms. Sanders has
continued to teach insurance law at the
University of New Mexico School of
Law as an adjunct professor. She
represents that she regularly represents
clients who have been denied medical
and other welfare benefits by their fullyinsured ERISA plans and is familiar
with the fiduciary obligations imposed
by ERISA. She further represents that
less than 1% of her annual income has
been and will be derived from her role
as independent fiduciary for the Plan.
7. Ms. Sanders has reviewed the
proposed transaction and determined
that it is appropriate for the Plan and in
the best interest of its participants and
beneficiaries. She states that the
proposed arrangement would provide
several benefits to the Plan participants,
including worksite medical services and
a fitness center. Under the Agreement,
BOUC will furnish the worksite medical
services to the Plan’s participants and
beneficiaries at no additional out-ofpocket costs to them. The services will
include wellness services and urgent
care triage and treatment. However,
participants and beneficiaries will be
referred to their primary care physicians
for routine and on-going treatment. The
services of the nurse-practitioner will be
made available to all of the participants
and beneficiaries, on site and free of
charge. BOUC will also furnish a
wellness coordinator to assist in the
administration of wellness programs
and activities designed to improve
employee health and well-being. It is
expected that the Fitness Center will
support healthy lifestyles for the
participants and beneficiaries.
8. Ms. Sanders further represents that
she reviewed the proposed rates and
fees to be paid by the Plan for the
services to be rendered by BOUC, and
PO 00000
Frm 00019
Fmt 4701
Sfmt 4703
77611
determined that they were reasonable.
In reaching that determination, Ms.
Sanders reviewed compensation for
non-physician providers both nationally
and for the western states. She also
looked at cost to customers generally
and at the anticipated cost to BOUC for
the non-physician providers. She
additionally reviewed the actual or
anticipated BOUC operating expenses
for both a wellness clinic and a fitness
center. In comparing that information
with the proposed fees to be paid by the
Plan to BOUC, she determined that the
proposed fees were reasonable. She
represents that her conclusion is
especially true given the dearth of
facilities and providers in the Four
Corners area.
9. On July 1, 2010, BOUC joined the
BCBSNM provider network. BCBSNM is
the largest provider network in New
Mexico. In order to operate
competitively and establish itself
financially, it had no choice
economically but to join a number of
preferred provider networks, including
BCBSNM, the largest. The benefits to
BOUC of such an arrangement are those
that attract other providers; relatively
fast and streamlined claims payment in
exchange for lower reimbursement fees
that are set by BCBSNM. BCBSNM is
not affiliated with the Plan nor any of
the Companies, other than as a service
provider for network access, claims
adjudication and related services to the
Plan.
10. The Plan has contracted annually
with BCBSNM for the use of its provider
network and claims adjudication
services since August 1, 2007. The
Trustees’ selection of the BCBSNM
network occurred after they had an
insurance broker carry out a competitive
search of area provider networks before
BOUC was formed or contemplated. It is
anticipated that some Plan participants,
as well as the participants in plans
sponsored by other unrelated employers
and the general public will use the
BOUC clinic located in Farmington,
New Mexico. The Plan would pay
claims for the services that BOUC
provides at the rates specified in its
provider agreement with BCBSNM.19
The Plan participants will not be
required to use the BOUC clinic; they
will be able to choose any health care
facilities that are in the BCBSNM
network. The applicant represents that
there are 20,730 health care providers in
19 For example, if a Plan participant visits a
member of the BCBSNM network, including the
BOUC clinic, the participant pays the co-pay, and
the provider bills BCBSNM for the difference
between the negotiated fee amount and the co-pay.
BCBSNM would pay the provider that difference,
and then bill that amount to the Plan.
E:\FR\FM\13DEN2.SGM
13DEN2
srobinson on DSK4SPTVN1PROD with NOTICES2
77612
Federal Register / Vol. 76, No. 239 / Tuesday, December 13, 2011 / Notices
the BCBSNM network, so the BOUC
clinic represents less than .05% of the
providers in the network from which
the participants are free to choose. The
applicant further represents that there
are 774 providers in the BCBSNM
network who are located in San Juan
County.
11. BOUC is a member of the San Juan
Independent Practice Association
(SJIPA), which negotiates provider
reimbursement rates with BCBSNM on
behalf of its members. SJIPA also
negotiates with most, if not all, of the
other medical provider networks that
operate in San Juan County, such as
Presbyterian Health Plan, Aetna, Cigna,
United Health Care, and Lovelace
Health Plan. SJIPA credentials its
members through a lengthy application
process that includes site visits,
verification of provider licensure, and
regulatory agency standing. Providers
such as BOUC then have the
opportunity to enter into a written
agreement directly with one of the
provider networks at the negotiated
master rates.
12. Providers such as BOUC pay a
per-practitioner membership fee to
SJIPA of $1,000 for the first year, $225
per quarter during the second year, and
$100 per quarter for all subsequent
years. The providers do not pay any fee
to BCBSNM. The Plan pays an
administrative fee to BCBSNM for
access to the BCBSNM network (and
thus the negotiated discounted rates for
providers) and for other administrative
services, such as adjudication and
processing of claims, but that fee has not
changed and will not change due to the
presence of BOUC in the network. None
of the Companies have received or will
receive any direct or indirect fees as a
result of BOUC joining the BCBSNM
network.
13. The applicant represents that the
Plan has been trying to encourage its
participants to use urgent care facilities
instead of more expensive emergency
rooms, when medically appropriate. To
that end, the Plan recently reduced its
normal participant co-pay for urgent
care visits to BOUC from $75 to $25,
and BOUC agreed to reduce its rates by
the difference. The BCBSNM
reimbursement that BOUC receives
remains at the negotiated BCBSNM rate
for all similar services, and the Plan
does not make any additional payment
to BOUC; the urgent care facility simply
absorbs the loss. The Plan’s Trustees
recently negotiated the same reduced
co-pay amount with a new urgent care
facility in Aztec called Aztec Urgent
Care, which is unrelated to BOUC, any
of the Trustees, and any of the
Companies.
VerDate Mar<15>2010
16:27 Dec 12, 2011
Jkt 226001
14. In summary, the applicant
represents that the proposed transaction
meets the statutory criteria for an
exemption under section 408(a) of the
Act because:
(a) An independent, qualified
fiduciary (I/F), acting on behalf of the
Plan, has determined prior to entering
into the proposed transaction that the
transaction is administratively feasible,
in the interest of, and protective of the
Plan and the participants and
beneficiaries of the Plan;
(b) The I/F has reviewed the
transaction to ensure that its terms are
at least as favorable to the Plan as an
arm’s-length transaction with an
unrelated party, and has determined to
approve the transaction, in accordance
with the fiduciary provisions of the Act;
(c) The I/F will monitor compliance
with the terms and conditions of this
proposed exemption, as described
herein, and ensure that such terms and
conditions are at all times satisfied;
(d) The I/F will monitor compliance
with the terms of the License, and take
any and all steps necessary to ensure
that the Plan is protected, including, but
not limited to, exercising her authority
to terminate the License on 10 days’
written notice; and
(e) The transaction is, in fact, on terms
and at all times remains on terms that
are at least as favorable to the Plan as
those that would have been negotiated
under similar circumstances at arm’slength with an unrelated third party;
(f) The terms of the medical services
provided by BOUC to Plan participants
at its Farmington, New Mexico clinic
are at least as favorable to the
participants as those they could obtain
in similar transactions with an
unrelated party;
(g) The Plan participants will have
access to all of the providers in
BCBSNM’s network and will be free to
choose whether or not to use BOUC’s
clinic;
(h) At least 99% of the providers
participating in the BCBSNM are
unrelated to the companies whose
employees participate in the Plan, or
any other party in interest with respect
to the Plan;
(i) BOUC will be treated no more
favorably than any other provider
participating in the BCBSNM; and
(j) The transactions are not part of an
agreement, arrangement or
understanding designed to benefit
BOUC or any other party in interest
with respect to the Plan.
For Further Information Contact: Gary
H. Lefkowitz of the Department,
telephone (202) 693–8546 (This is not a
toll-free number.)
PO 00000
Frm 00020
Fmt 4701
Sfmt 4703
Genzyme Corporation 401(k) Plan (the
Plan or the Applicant), Located in
Cambridge, MA
[Application No. D–11669]
Proposed Exemption
The Department is considering
granting an exemption under the
authority of section 408(a) of the Act (or
ERISA) and section 4975(c)(2) of the
Code, and in accordance with the
procedures set forth in 29 CFR Part
2570, Subpart B (55 FR 32836, 32847,
August 10, 1990).20 If the proposed
exemption is granted, the restrictions of
sections 406(a), 406(b)(1) and (b)(2) and
section 407(a) of the Act and the
sanctions resulting from the application
of section 4975 of the Code, by reason
of section 4975(c)(1)(A) through (E) of
the Code, shall not apply, effective April
4, 2011, to (1) the acquisition by the
Plan of contingent value rights (CVRs)
as a result of the Plan’s ownership of
certain common stock (Genzyme
Common Stock) in Genzyme
Corporation (Genzyme), the Plan
sponsor, in connection with (a) The
purchase of shares (Shares) of Genzyme
Common Stock pursuant to an exchange
offer (the Exchange Offer) and a
subsequent offer to the Exchange Offer
(the Subsequent Exchange Offer) by GC
Merger Corp. (the Purchaser), a whollyowned subsidiary of sanofi-aventis
(Sanofi), a party in interest with respect
to the Plan, and (b) the ‘‘short-form’’
merger (the Merger) of Sanofi into
Genzyme (together, the Transactions);
(2) the continued holding of CVRs by
the Plan; and (3) the resale of the CVRs
by the Plan to Sanofi, pursuant to the
exercise of repurchase rights (the
Repurchase Rights) available under
certain circumstances specified in the
Contingent Value Rights Agreement (the
CVR Agreement).
This proposed exemption is subject to
the following conditions:
(a) Plan participants holding Genzyme
Common Stock received one CVR for
each Share on the effective date of the
tender or cancellation of their Shares, in
connection with the Transactions.
(b) The acquisition of CVRs by the
Plan occurred in connection with the
Transactions on the same terms and in
the same manner as the acquisition of
CVRs by all other holders of Genzyme
Common Stock, other than Sanofi, the
Purchaser, Genzyme and dissenting
shareholders.
(c) The Plan’s acquisition of CVRs
resulted either (1) from a decision by a
20 For purposes of this proposed exemption,
references to section 406 of the Act should be read
to refer as well to the corresponding provisions of
section 4975 of the Code.
E:\FR\FM\13DEN2.SGM
13DEN2
Federal Register / Vol. 76, No. 239 / Tuesday, December 13, 2011 / Notices
participant or beneficiary to tender
Shares allocated to his or her account or
(2) following a decision by a participant
or beneficiary not to tender Shares by
reason of the Merger.
(d) The Plan did not pay any fees or
commissions in connection with the
acquisition of the CVRs, nor does it pay
any fees or commissions in connection
with the holding or sale of CVRs to
Sanofi pursuant to an exercise of
Sanofi’s repurchase right under the CVR
Agreement.
(e) Credit Suisse Securities (USA) LLC
(Credit Suisse Securities) and Goldman
Sachs & Co (Goldman Sachs) advised
Genzyme that the consideration
received by Genzyme shareholders
(Genzyme Shareholders), including Plan
participants, in exchange for their
Shares was ‘‘fair,’’ from a financial point
of view.
(f) The Plan does not acquire or hold
CVRs other than those acquired in
connection with the Transactions.
(g) Plan participants have the same
rights with respect to CVRs allocated to
their accounts under the Plan (including
with respect to any repurchase of CVRs
by Sanofi) as unrelated parties have
with respect to CVRs not held under the
Plan, and they may direct the Plan’s
trustee (the Trustee) to sell CVRs
allocated to their respective accounts at
any time.
(h) For so long as CVRs remain a
permissible Plan investment, the
retention or disposition by the Plan of
CVRs allocated to a participant’s or
beneficiary’s account is administered in
accordance with the provisions of the
Plan that are in effect for individuallydirected investment of participant
accounts.
Effective Date: If granted, this
proposed exemption will be effective as
of April 4, 2011.
Summary of Facts and Representations
srobinson on DSK4SPTVN1PROD with NOTICES2
The Plan
1. The Plan, which is sponsored and
maintained by Genzyme, is an
individual account plan intended to
qualify under section 401(a) of the Code
that includes a qualified cash or
deferred arrangement described in
section 401(k) of the Code. The Plan
allows participants to direct the
investment of their accounts under the
Plan in various investment alternatives
available under the Plan, including,
during periods prior to the Transactions
described herein, Genzyme Common
Stock.
As of April 4, 2011, the Plan had
7,537 participants and assets having an
aggregate fair market value of
$738,806,554. As of the same date,
VerDate Mar<15>2010
16:27 Dec 12, 2011
Jkt 226001
646,922.56 Shares were held by the Plan
in accounts maintained for 2,933
participants, representing
approximately 39% of the participants
in the Plan. These Shares had an
aggregate fair market value on April 4,
2011 of $49,366,660, or approximately
6.7% of the aggregate fair market value
of the Plan’s total assets, and
represented approximately 0.2437% of
the 265,485,712 Shares that were issued
and outstanding as of that date.
According to the Applicant, the Plan’s
Shares constituted qualifying employer
securities within the meaning of section
407(d)(5) of the Act.21
The Plan is funded through a trust of
which Prudential Bank & Trust, FSB,
serves as the Trustee. The Trustee is a
directed trustee. Under the Genzyme
Corporation 401(k) Plan Trust
Agreement (the Trust Agreement)
executed between the Trustee and
Genzyme, the Trustee accepted
employer securities (i.e., Genzyme
Common Stock), as defined in the Plan,
as a plan asset with Genzyme’s
understanding and approval that the
employer securities would be held by
Prudential Investment Management
Services LLC.
The Plan is administered by the
Genzyme Benefit Plan Committee (the
Committee), which was appointed by
Genzyme. The Committee is responsible
for making all investment decisions
related to the Plan, other than decisions
made by the participants and decisions
with regard to investments provided for
as a design feature in the Plan
document, such as investments in
employer securities. Genzyme, as Plan
sponsor, is responsible for decisions
relating to the availability of specified
investments as a feature of the Plan’s
design. The Committee has engaged
CapTrust Advisors (CapTrust), an
independent financial advisor with its
primary office located in Raleigh, North
Carolina, to provide financial services to
the Committee and to Plan participants.
Genzyme
2. Genzyme, a Massachusetts
corporation with its principal offices
located in Cambridge, Massachusetts, is
a global biotechnology company
engaged in the research, development,
manufacturing and marketing of
products to address unmet medical
needs. As of December 31, 2010,
Genzyme had total assets of
approximately $10.91 billion and total
stockholders’ equity of approximately
21 Section
407(d)(5) of the Act generally defines
the term ‘‘qualifying employer security’’ as an
employer security which is (a) stock, (b) a
marketable obligation, or (c) an interest in an
existing publicly traded partnership.
PO 00000
Frm 00021
Fmt 4701
Sfmt 4703
77613
$7.59 billion. As of the same date, there
were approximately 261.5 million
Shares outstanding.
Sanofi
´ ´
3. Sanofi, a French societe anonyme 22
with its headquarters located in Paris,
France, is a global pharmaceutical group
engaged in the research, development,
manufacture and marketing of
healthcare products. As of December 31,
2010, Sanofi had total assets of
approximately Ö85.26 billion and total
stockholders’ equity of approximately
Ö53.3 billion.
The Purchaser
4. The Purchaser, a Massachusetts
corporation incorporated on July 29,
2010, is a direct wholly-owned
subsidiary of Sanofi. The Purchaser was
organized by Sanofi to acquire Genzyme
and has not conducted any unrelated
activities since its organization. All
outstanding shares of the capital stock
of the Purchaser are owned by Sanofi.
Acquisition of Genzyme by Sanofi
5. On April 8, 2011, Sanofi completed
its acquisition of Genzyme. The
acquisition occurred pursuant to an
Agreement and Plan of Merger dated
February 16, 2011 (the Merger
Agreement) executed by Sanofi, the
Purchaser and Genzyme, wherein all of
the outstanding Shares of Genzyme
Common Stock were acquired by the
Purchaser. The Share acquisition
transaction was consummated by the
Purchaser through both an Exchange
Offer and a Subsequent Exchange Offer
for all of the outstanding Shares
(together, the Exchange Offers). The
Exchange Offers were followed by a
‘‘short-form’’ merger (i.e., the Merger) of
the Purchaser with and into Genzyme
that did not require a Genzyme
Shareholder vote.
As a result of the Transactions (i.e.,
the Share acquisition transaction and
the Merger), Genzyme survives as a
direct wholly-owned subsidiary of
Sanofi. All Shares validly tendered and
not withdrawn in either the Exchange
Offer or the Subsequent Exchange Offer
(except for Shares held by Sanofi,
Genzyme and their subsidiaries, and
Shares held by shareholders who
properly perfected appraisal rights
under Massachusetts law) were
converted into the right to receive (a)
$74.00 in cash, less any applicable
withholding for taxes and without
22 The Applicant states that a societe anonyme is
´ ´
a stock company or limited company. The
Applicant further states that the ‘‘S.A.’’ that follows
´ ´
the name of a French societe anonyme is
comparable to the ‘‘Inc.’’ that follows the name of
a U.S. corporation.
E:\FR\FM\13DEN2.SGM
13DEN2
77614
Federal Register / Vol. 76, No. 239 / Tuesday, December 13, 2011 / Notices
interest (the Cash Consideration), per
Share, and (b) one CVR per Share
(together with the Cash Consideration,
the Merger Consideration). All Shares
not tendered were converted into the
right to receive the same Merger
Consideration. The Merger
Consideration was paid by the
Purchaser and delivered by
Computershare Trust Company, N.A.,
the exchange agent for the Exchange
Offers (the Exchange Agent), to
tendering Shareholders in the Exchange
Offer and the Subsequent Exchange
Offer on April 4, 2011.
The terms of the Transactions were
negotiated on an arm’s length basis by
the parties and approved by the Boards
of Directors of Sanofi, the Purchaser,
and Genzyme. In connection with
Genzyme’s consideration of the
Exchange Offer and the Subsequent
Exchange Offer and Merger, fairness
opinions were prepared by Credit Suisse
Securities and Goldman Sachs. Notice
of the Transactions was provided by
Genzyme to Genzyme Shareholders.
Also, Plan participants were given the
same consideration as all other holders
of Shares.23 More details about the
Transactions are presented below.
srobinson on DSK4SPTVN1PROD with NOTICES2
The Exchange Offer
6. On April 4, 2011, the Purchaser
accepted for exchange all Shares that
were tendered and actually delivered.
The exchange for such Shares was made
in accordance with the terms of the
Exchange Offer, which commenced on
March 7, 2011 and ended on April 1,
2011 at 11:59 p.m., unless extended by
the Purchaser. The Exchange Agent
advised Sanofi and the Purchaser that
224,528,469 Shares were validly
tendered and not properly withdrawn
pursuant to the Exchange Offer by
Genzyme Shareholders. The tendered
Shares represented approximately
84.6% of all the outstanding Shares as
of the April 1, 2011 expiration date of
the Exchange Offer. However,
43,285,259 of those Shares were offered
up with a guarantee by an ‘‘eligible
guarantor institution’’ 24 that they would
23 While this statement is generally accurate, the
Applicant notes that Sanofi, the Purchaser and
Genzyme did not receive the Merger Consideration
for their Shares. Further, dissenting shareholders
who perfected their appraisal rights were not
entitled to receive the CVRs, but they generally
received $74 in cash for each Share they owned,
plus interest.
24 The Applicant represents that ‘‘eligible
guarantor institutions,’’ as defined in Rule 17Ad–
15 of the Securities Exchange Act of 1934 (the 1934
Act), include banks, brokers, dealers, credit unions,
national securities exchanges, registered securities
associations, clearing agencies, and savings
associations. The Applicant states that, typically,
the delivery guarantee would have been made by
a broker.
VerDate Mar<15>2010
16:27 Dec 12, 2011
Jkt 226001
be delivered within a short period of
time, and the related Shares (i.e., the
Shares for which the guarantor
guaranteed delivery of a Share
certificate or book-entry confirmation)
were not actually accepted for exchange
at the expiration of the Exchange Offer.
The number of Shares actually delivered
and accepted for exchange at the end of
the Exchange Offer was 181,243,210
(224,528,469 Shares minus 43,285,259
Shares). Accordingly, following the
acceptance of the Shares validly
tendered and not properly withdrawn in
the Exchange Offer (excluding the
Shares subject to guarantees of
delivery), Sanofi and the Purchaser
owned approximately 68.3% of the
outstanding Shares or approximately
62% of the total Shares on a fullydiluted basis (i.e., the number of Shares
actually outstanding plus the number of
additional Shares that would be
outstanding if Shares were issued
pursuant to all outstanding stock rights).
As a result of such acceptance of Shares
in the Exchange Offer, a change in
control of Genzyme occurred.
Of the total Shares tendered during
the Exchange Offer, 320,294 Shares
were tendered by 971 Plan participants.
In return for their Shares, Plan
participants received cash consideration
of $23,701,756 in the aggregate, and a
total of 320,294 CVRs with a value of
$2.35 per Share, or an aggregate value of
$752,690.90, as of the close of trading
on April 4, 2011.25
The Subsequent Exchange Offer
7. The Purchaser commenced a
Subsequent Exchange Offer on April 4,
2011 for all remaining untendered
Shares. The Subsequent Exchange Offer
expired at 6 p.m., New York City time,
on April 7, 2011, in accordance with the
applicable rules and regulations of the
U.S. Securities and Exchange
Commission (the SEC) and the Merger
Agreement. Following the close of the
Subsequent Exchange Offer, the
Exchange Agent advised Sanofi and the
Purchaser that 56,069,616 Shares were
validly tendered. The tendered Shares
represented 21.1% of the issued and
outstanding Shares. The Shares
included both (a) Shares delivered for
exchange pursuant to delivery
guarantees made during the Exchange
Offer, and (b) Shares newly tendered
and delivered for exchange in the
25 The Applicant notes that the CVRs in which
the Plan acquired an ownership interest on April
4, 2011 were received by the Plan on April 7, 2011.
The Applicant further notes that the value of the
CVRs at the close of trading on April 7, 2011 was
$2.41 per CVR, or $771,908.54 for all CVRs received
on that date.
PO 00000
Frm 00022
Fmt 4701
Sfmt 4703
Subsequent Exchange Offer.26 Together
with the 181,243,210 Shares delivered
and accepted for exchange in the
Exchange Offer, the 56,069,616 Shares
delivered and accepted in the
Subsequent Exchange Offer brought the
total Shares acquired by Sanofi in the
two offering periods to 237,312,826, or
approximately 89.4% of the issued and
outstanding Shares.
Of the total Shares tendered in the
Subsequent Exchange Offer, 14,567
Shares were exchanged by 66 Plan
participants, who received aggregate
cash consideration of $1,077,958, and a
total of 14,567 CVRs with a value of
$2.41 per CVR, or an aggregate value of
$35,106.47, as of the close of trading on
April 7, 2011, the acceptance date of the
Subsequent Exchange Offer.27
Steps Taken by Genzyme Prior to the
Transactions
8. Genzyme took certain steps prior to
the Transactions in preparation for the
acquisition of CVRs by the Plan. In this
regard, certain provisions of the Plan
and the Trust Agreement relating to
employer securities were amended to
accommodate the acquisition and
holding of the CVRs. In addition, notice
(the Notice) of the Transactions, dated
March 10, 2011, was provided to
Genzyme Shareholders as well as to
each Plan participant and beneficiary
who had invested in Shares through the
Plan. The Notice explained that on the
effective date of the Exchange Offer, the
Plan participant or beneficiary could
elect to provide instructions to the Plan
Trustee to tender all or some of the
Shares held on their behalf under the
Plan. The Notice further explained that
no action was required if a Plan
participant or beneficiary did not wish
to tender any of the Shares allocated to
their account under the Plan in the
Exchange Offer.
Plan participants and beneficiaries
also had the opportunity, on a daily
basis until the second day preceding the
26 The Applicant notes that the Form 8–K filed by
Genzyme with the SEC on April 8, 2011 does not
indicate how many of the 56,069,616 Shares were
Shares delivered pursuant to delivery guarantees
made during the Exchange Offer and how many
were Shares newly tendered and delivered for
exchange. The Applicant also notes that additional
Shares may have been newly offered up during the
Subsequent Exchange Offer with a guarantee that
they would be delivered within a short period of
time, but the Form 8–K does not contain disclosure
regarding such guarantees because the related
Shares had not been accepted for exchange at that
time.
27 The Applicant notes that the CVRs in which
the Plan acquired an ownership interest on April
7, 2011 were received by the Plan on April 8, 2011.
The Applicant further notes that the value of the
CVRs at the close of trading on April 8, 2011 was
$2.32 per CVR or $33,795.44 for all CVRs received
on that date.
E:\FR\FM\13DEN2.SGM
13DEN2
Federal Register / Vol. 76, No. 239 / Tuesday, December 13, 2011 / Notices
closing of the Exchange Offer and the
Subsequent Exchange Offer, to transfer
funds held on their behalf in Genzyme
Common Stock to other investment
funds under the Plan if they did not
wish to receive interests in CVRs under
the Plan. The Notice furnished to Plan
participants and beneficiaries included
notice of the period of time immediately
preceding the closing of the tender offer
during which they would be unable to
give further instructions regarding the
investment of the portion of their
accounts invested in Genzyme Common
Stock.
srobinson on DSK4SPTVN1PROD with NOTICES2
Top-Up Option
9. In the Merger Agreement, Genzyme
granted an irrevocable option (i.e., the
Top-Up Option) to the Purchaser to
purchase newly-issued Shares directly
from Genzyme. On April 8, 2011,
subsequent to the acceptance of Shares
in the Subsequent Exchange Offer, the
Purchaser exercised the Top-Up Option
granted to the Purchaser to purchase
newly issued Shares directly from
Genzyme in accordance with the Merger
Agreement. The Purchaser purchased
16,245,894 newly issued Shares at a
price of $76.33 per Share and paid the
purchase price (a) By issuing a
promissory note to Genzyme in the
amount of $1,239,886,631 and (b) by
paying $162,459 in cash to Genzyme.
Subsequent to the exercise of the TopUp Option, Sanofi and the Purchaser
had an aggregate ownership of over 90%
of the outstanding Shares.
Short-Form Merger and Cancellation of
Shares
10. Sanofi completed its acquisition of
Genzyme by effecting a ‘‘short-form
merger,’’ which did not require a
shareholder vote, pursuant to section
11.05 of the Massachusetts Business
Corporation Act between the Purchaser
and Genzyme. As a result of the Merger,
Genzyme became a direct, whollyowned subsidiary of Sanofi. Any Shares
not tendered in the Exchange Offer or
the Subsequent Exchange Offer (other
than Shares held in Genzyme’s treasury
or owned by Sanofi, which Shares were
cancelled and retired without any
conversion thereof) were cancelled and
converted into the right to receive the
same Merger Consideration that was
paid in the Exchange Offer and the
Subsequent Exchange Offer. The total
number of Shares outstanding on the
effective date of the Merger that became
eligible to be cancelled and converted
into a right to receive the Merger
Consideration was 28,173,190. Of the
total Shares eligible to be cancelled,
308,464.81 Shares were owned by and
allocated to participant accounts under
VerDate Mar<15>2010
16:27 Dec 12, 2011
Jkt 226001
the Plan, for which the Plan received
the Merger Consideration shortly after
the appraisal period expired on May 28,
2011 in the form of cash consideration
of $22,826,395.94, in the aggregate, and
a total of 308,465 CVRs. No specific
action was taken by the Plan to exercise
or relinquish appraisal rights.28
The CVRs
11. The CVRs are general, unsecured,
contingent payment obligations of
Sanofi that rank equally with all
existing and future unsecured
unsubordinated indebtedness of Sanofi
and senior to all subordinated
indebtedness of Sanofi. They were
issued by Sanofi pursuant to a CVR
Agreement that was executed on March
30, 2011 by and between Sanofi and
American Stock Transfer & Trust
Company, LLC (the CVR Trustee), an
unrelated party. In accordance with
requirements of the Trust Indenture Act
of 1939, the CVRs were also issued
under an indenture with the CVR
Trustee, which was appointed to protect
and enforce the rights of the CVR
holders. The indenture trust that holds
the CVRs is not a plan asset vehicle. The
CVR Trustee (a) Will receive from
Sanofi amounts due under the CVRs and
promptly remit payment to the CVR
holders, (b) may demand payment and
institute legal proceedings to collect
amounts due and unpaid if Sanofi fails
to pay amounts due under the CVRs, (c)
must transmit notice to the CVR holders
of breaches under the CVR Agreement,
subject to certain conditions and
expectations, and (d) may institute legal
proceedings to protect and enforce the
rights of the CVR holders upon the
occurrence of a breach under the CVR
Agreement.
The CVR Trustee also performs
various administrative functions that
include, but are not limited to, (a)
Serving as the initial Security Registrar
for the purposes of registration and
transfer of the CVRs, (b) notifying the
CVR holders of certain amendments to
the CVR Agreement, and (c) providing
the CVR holders with certain reports
concerning its actions and filing a copy
of each such report with the Nasdaq
Global Market, the SEC and Sanofi.
28 The Applicant represents that, under
Massachusetts law, holders of Shares of Genzyme
Common Stock that were not tendered had the
opportunity to exercise appraisal rights to demand
fair value for their Shares for a specified time after
the Merger. The deadline for the exercise of
appraisal rights was May 28, 2011. However, the
Applicant notes that the Plan did not provide for
appraisal rights to be passed through to
participants, and the Committee did not direct the
Trustee either to exercise such rights or to
relinquish them before they expired. Accordingly,
no participant in the Plan exercised appraisal rights
affecting the disposition of Shares held by the Plan.
PO 00000
Frm 00023
Fmt 4701
Sfmt 4703
77615
Under the CVR Agreement, Sanofi is
required to pay to the CVR Trustee, and
the CVR Trustee is required to pay to
the holders of CVRs, specified amounts
upon achievement of certain milestones,
as described below, up to a maximum
payment of $14 in the aggregate per
CVR. In accordance with the CVR
Agreement, Sanofi is obligated to use
commercially reasonable efforts to
ensure that the CVRs are publicly traded
on a national securities exchange.29
The CVRs were registered under the
Securities Act of 1933 (the 1933 Act), as
required by the CVR Agreement,
effective March 29, 2011. The CVRs
were also registered under the 1934 Act,
effective March 28, 2011. No CVRs may
be issued after the initial issuance in
connection with the Transactions, and
no payments will be due under the CVR
Agreement for any milestones achieved
after the earlier of (a) December 31, 2020
or (b) the date that Product Sales
Milestone #4 (as described below) is
achieved.
12. The CVR Agreement provides for
payments to the holders of CVRs on
attainment of the following production
and development milestones:
• Production Milestone. A payment of
$1.00 per CVR will be made upon the
completion, not later than December 31,
2011, of production and release of specified
quantities of Cerezyme® and Fabrazyme®,
two of Genzyme’s enzyme replacement
therapies, with payment to be made 20
business days following achievement of the
milestone but not earlier than January 3,
2012.
• Approval Milestone. A payment of $1.00
per CVR will be made within 20 business
days following the receipt, not later than
March 31, 2014, of FDA approval for use of
the drug alemtuzumab for treatment of
multiple sclerosis (alemtuzumab MS).
In addition, the CVR Agreement
provides for payments to the holders of
CVRs on attainment of targets for sales
of alemtuzumab MS, as follows.
• Product Sales Milestone #1. A payment
of $2.00 per CVR will be made if sales during
the four calendar quarter period that begins
on the first anniversary of the major market
launch of alemtuzumab MS equal or exceed
$400,000,000.
• Product Sales Milestone #2. A payment
of $3.00 per CVR will be made if sales in any
period of four consecutive calendar quarters
during the term of the CVR Agreement equal
or exceed $1,800,000,000. If Product Sales
Milestone #2 is achieved as a result of sales
of alemtuzumab MS outside of the United
States but the Approval Milestone is not
achieved by March 31, 2014, the Product
Sales Milestone #2 payment will be $4.00 per
CVR rather than $3.00 per CVR.
29 According to the Applicant, the CVRs were
listed on the Nasdaq Stock Market under the
symbol ‘‘GCVRZ’’ on March 31, 2011 at an opening
price of $2.20 per CVR.
E:\FR\FM\13DEN2.SGM
13DEN2
77616
Federal Register / Vol. 76, No. 239 / Tuesday, December 13, 2011 / Notices
srobinson on DSK4SPTVN1PROD with NOTICES2
• Product Sales Milestone #3. A payment
of $4.00 per CVR will be made if sales in any
period of four consecutive calendar quarters
during the term of the CVR Agreement equal
or exceed $2,300,000,000 (excluding any
quarter in which sales were used to
determine whether Product Sales Milestone
#1 or #2 was achieved).
• Product Sales Milestone #4. A payment
of $3.00 per CVR will be made if sales in any
period of four consecutive calendar quarters
during the term of the CVR Agreement equal
or exceed $2,800,000,000 (excluding any
quarter in which sales were used to
determine whether Product Sales Milestone
#1, #2 or #3 was achieved).
Each payment to be made on any of
the Product Sales Milestones is required
to be made within 20 business days
following notice by Sanofi to the CVR
Trustee that the applicable target was
achieved in the most recently ended
calendar quarter, such notice to be
provided within 50 days following the
end of the calendar quarter. All notices
required to be filed with the CVR
Trustee are required to be made
available simultaneously to the holders
of CVRs on Sanofi’s Web site.
In the event Sanofi fails to make
timely payment with respect to any of
the payment milestones, interest will
accrue on unpaid amounts at a rate
equal to the prime rate plus three
percent. The CVR Trustee is empowered
to institute legal or equitable actions in
order to collect amounts that are due
and unpaid. The CVR Trustee can be
directed to exercise its remedies by
action of the holders of 30% or more of
the CVRs.
13. The CVR Agreement also provides
that Sanofi has the right to repurchase,
and subsequently cancel, all
outstanding CVRs on a date on or after
the third anniversary of the launch date
of alemtuzumab MS, if certain
conditions indicating lack of success are
present.30
Specifically, under the Repurchase
Right, Sanofi may purchase all
outstanding CVRs (but not fewer than
all outstanding CVRs) upon providing
notice to the CVR Trustee between 30
and 60 days following the date as of
which both of the following conditions
have occurred: (a) The volume weighted
average trading price per CVR for all
CVRs traded over the previous 45
trading days is less than fifty cents, and
(b) sales of alemtuzumab MS for the four
most recently ended calendar quarters
are less than $1,000,000,000 in the
aggregate. The price at which Sanofi
30 For this purpose, the product launch date is the
first day of the calendar quarter beginning one full
calendar quarter after the end of the calendar
quarter in which a first commercial sale occurs in
the United States, the United Kingdom, France,
Germany, Italy, or Spain.
VerDate Mar<15>2010
16:27 Dec 12, 2011
Jkt 226001
would purchase each outstanding CVR
pursuant to an exercise of this right is
the volume weighted average price paid
per CVR for all CVRs traded over the 45
trading days prior to the fifth trading
day preceding the date Sanofi gives
notice of its intent to exercise its
Repurchase Right.
It is also possible that Sanofi may
purchase CVRs on the open market in
circumstances where the Plan is selling
CVRs into the market. Any such
purchase would be at market price.
14. The CVRs do not provide any
rights that could lapse by reason of a
failure on the part of the holder to take
timely action. Holders of CVRs will
have the right to receive payments over
time upon achievement of one or more
of the above milestones during the term
of the CVR, without the need for the
CVR holder to take action. The rights of
a CVR holder will not change in any
way as a result of any action or inaction
on the part of the holder, but are
expected to remain in effect until all
payment obligations under the CVR
Agreement are satisfied or have
terminated. The only exception would
be if the CVRs are repurchased by
Sanofi pursuant to its Repurchase Right,
in which case, the holders of CVRs
would not see their rights lapse and
become worthless but would receive
value for their CVRs in accordance with
the terms of the Repurchase Right. With
regard to the date on which the CVRs
are scheduled to terminate, if not earlier
repurchased by Sanofi pursuant to the
Repurchase Right, the CVR Agreement
provides that if any milestone has been
achieved prior to December 31, 2020 but
the related payment has not been paid
as of that date, the CVR Agreement and
the rights of CVR holders under the
Agreement will not terminate until the
payment has been made in full.
Fairness Opinions
15. Credit Suisse Securities, an
investment banking firm that operates in
the United States and a subsidiary of
Credit Suisse, advised Genzyme that the
Merger Consideration to be received by
Genzyme Shareholders in exchange for
their Shares was ‘‘fair,’’ from a financial
point of view. In arriving at its opinion,
Credit Suisse Securities, among other
things, (a) Reviewed the Merger
Agreement, a form of the CVR
Agreement and certain publicly
available business and financial
information relating to Genzyme; (b)
reviewed certain other information
relating to Genzyme, including financial
forecasts, provided to or discussed with
Credit Suisse Securities by Genzyme
and have met with Genzyme’s
management to discuss the business and
PO 00000
Frm 00024
Fmt 4701
Sfmt 4703
prospects of Genzyme; (c) considered
certain financial and stock market data
of Genzyme, and Credit Suisse
Securities has compared that data with
similar data for other publicly held
companies in businesses Credit Suisse
Securities has deemed similar to that of
Genzyme and Credit Suisse Securities
has considered, to the extent publicly
available, the financial terms of certain
other business combinations and other
transactions which have recently been
effected; and (d) considered such other
information, financial studies, analyses
and investigations and financial,
economic and market criteria which
Credit Suisse Securities deemed
relevant.
In rendering its opinion, Credit Suisse
Securities did not independently verify
any of the foregoing information and
assumed and relied on such information
being complete and accurate in all
material respects. For example, with
respect to the updated financial
forecasts for Genzyme and the
assessments as to the probability and
estimated timing of achievement of the
Approval Milestone, each of the Product
Sales Milestones and the Production
Milestone provided to Credit Suisse
Securities by Genzyme, the management
of Genzyme advised Credit Suisse
Securities, and Credit Suisse Securities
assumed, that such forecasts and
assessments were reasonably prepared
on bases reflecting the best currently
available estimates and judgments of
Genzyme’s management as to the future
financial performance of Genzyme and
the probability and timing of
achievement of the Approval Milestone,
each of the Product Sales Milestones
and the Production Milestone.
Furthermore, in rendering its opinion,
Credit Suisse addressed only the
fairness of the Merger Consideration to
be received in the Transactions, from a
financial point of view, to the holders of
Genzyme Common Stock (other than
Sanofi and its affiliates). It did not
address any other aspect of the
Transactions or any other agreement,
arrangement or understanding entered
into in connection with the
Transactions, including the fairness of
the amount or nature of any
compensation paid to any officers,
directors or employees of any party to
the Transactions, or class of such
persons, relative to the Merger
Consideration or otherwise. In addition,
Credit Suisse did not express any
opinion as to the price at which the
CVRs would trade at any time or as to
the solvency or viability of Genzyme or
Sanofi or the ability of Genzyme or
Sanofi to pay its obligations, including
E:\FR\FM\13DEN2.SGM
13DEN2
srobinson on DSK4SPTVN1PROD with NOTICES2
Federal Register / Vol. 76, No. 239 / Tuesday, December 13, 2011 / Notices
in respect of the CVRs, when they come
due.
Credit Suisse issued its opinion with
the understanding that the opinion
would be for the information of the
Board of Directors of Genzyme in
connection with its consideration of the
Transactions and would not constitute
advice or a recommendation to any
holder of Genzyme Common Stock as to
whether or not such holder should
tender such Shares in connection with
the Exchange Offers, or how such
stockholder should vote or act on any
matter relating to the proposed Merger
or any other matter. The issuance of the
opinion was approved by an authorized
internal committee of Credit Suisse.
16. Goldman Sachs, a full-service
global investment banking and
securities firm, advised Genzyme that
the Merger Consideration to be received
by Genzyme Shareholders in exchange
for their Shares was also ‘‘fair,’’ from a
financial point of view. In connection
with its opinion, Goldman Sachs
reviewed, among other things, (a) The
Merger Agreement, (b) annual reports to
shareholders and Annual Reports on
Form 10K of Genzyme for the five fiscal
years ended December 31, 2009; (c)
certain interim reports to shareholders
and Quarterly Reports on Form 10–Q of
Genzyme; (d) annual reports to
shareholders and Annual Reports on
Form 20–F of Sanofi for the five fiscal
years ended December 31, 2009; (e)
certain interim reports to shareholders
and quarterly reports included in
Reports on Form 6–K of Sanofi; (f)
certain other communications from
Genzyme and Sanofi to their respective
shareholders; (g) certain publicly
available research analyst reports for
Genzyme and Sanofi; (h) the Tender
Offer Statement on Schedule TO filed
by Sanofi and the Purchaser, with the
SEC on October 4, 2010, as amended
through Amendment No. 14 to the
Tender Offer Statement on Schedule TO
filed by Sanofi and the Purchaser with
the SEC on February 9, 2011; (i) The
Solicitation/Recommendation Statement
of Genzyme filed on Schedule 14D–9
filed by Genzyme with the SEC on
January 31, 2011; (j) and certain
financial analyses and forecasts for
Genzyme prepared by its management,
including management’s updated
forecasts and its assessments as to the
probability and estimated timing of
achievement of the Approval Milestone,
the Product Sales Milestones and the
Production Milestone (each as defined
in the CVR Agreement) approved for
Goldman Sachs’ use by Genzyme (the
Forecasts). Goldman Sachs also (a) Held
discussions with members of the senior
management of Genzyme regarding the
VerDate Mar<15>2010
16:27 Dec 12, 2011
Jkt 226001
past and current business operations,
financial condition and future prospects
of Genzyme; (b) reviewed the reported
price and trading activity for the Shares;
(c) compared certain financial and stock
market information for Genzyme and
Sanofi with similar information for
certain other companies the securities of
which are publicly traded; (d) reviewed
the financial terms of certain recent
business combinations in the
biotechnology industry and in other
industries; and (e) performed such other
studies and analyses, and considered
such other factors, as they deemed
appropriate.
For purposes of rendering its opinion,
Goldman Sachs relied upon and
assumed, without assuming any
responsibility for independent
verification, the accuracy and
completeness of all the financial, legal,
regulatory, tax, accounting and other
information provided to, discussed with
or reviewed by, Goldman Sachs; and
Goldman Sachs does not assume any
responsibility for any such information.
In that regard, Goldman Sachs assumed
with Genzyme’s consent that the
forecasts were reasonably prepared on a
basis reflecting the best currently
available estimates and judgments of the
management of Genzyme. Goldman
Sachs also did not make an independent
evaluation or appraisal of the assets and
liabilities (including any contingent,
derivative or other off-balance-sheet
assets and liabilities) of Genzyme,
Sanofi or any of their respective
subsidiaries and they were not
furnished with any such evaluation or
appraisal. Furthermore, Goldman Sachs
assumed that all governmental,
regulatory or other consents and
approvals necessary for the
consummation of the Transactions
would be obtained without any adverse
effect on Genzyme, Sanofi or on the
expected benefits of the Transactions in
any way meaningful to their analysis.
Finally, Goldman Sachs assumed that
the Transactions would be
consummated on the terms set forth in
the Merger Agreement, without the
waiver or modification of any term or
condition the effect of which would be
in any way meaningful to its analysis.
In rendering its opinion, Goldman
Sachs did not address the underlying
business decision of Genzyme to engage
in the Transactions, or the relative
merits of the Transactions as compared
to any strategic alternatives that may
have been available to Genzyme.
Additionally, Goldman Sachs did not
address any legal, regulatory, tax or
accounting matters. Instead, Goldman
Sachs addressed only the fairness, from
a financial point of view, of the Merger
PO 00000
Frm 00025
Fmt 4701
Sfmt 4703
77617
Consideration to be paid to the holders
of Genzyme Common Stock (other than
Sanofi and any of its affiliates) pursuant
to the Merger Agreement, as of February
16, 2011, the date of its opinion.
In addition, Goldman Sachs did not
express any view on, nor did its opinion
address, any other term or aspect of the
Merger Agreement, the CVR Agreement
or the Transactions, or any term or
aspect of any other agreement or
instrument contemplated by the Merger
Agreement, the CVR Agreement or
entered into or amended in connection
with the Transactions, including,
without limitation, the fairness of the
Transactions to, or any consideration
received in connection therewith by, the
holders of any other class of securities,
creditors, or other constituencies of
Genzyme; nor as to the fairness of the
amount or nature of any compensation
to be paid or payable to any of the
officers, directors or employees of
Genzyme, or class of such persons in
connection with the Transactions.
Further, Goldman Sachs did not express
any opinion as to the price at which the
CVRs would trade at any time or as to
the impact of the Transactions on the
solvency or viability of Genzyme or
Sanofi or the ability of Genzyme or
Sanofi to pay its obligations when they
come due. In sum, Goldman Sachs
based its opinion on economic,
monetary, market and other conditions
in effect on, and the information made
available to it as of, February 16, 2011.
Goldman Sachs assumed no
responsibility for updating, revising or
reaffirming its opinion based on
circumstances, developments or events
occurring after that date.
The advisory services and opinion
expressed by Goldman Sachs were
provided for the information and
assistance of the Board of Directors of
Genzyme in connection with its
consideration of the Transactions, and
such opinion did not constitute a
recommendation as to whether or not
any holder of Genzyme Common Stock
should tender such Shares in
connection with the Exchange Offer or
how any holder of Shares should vote
with respect to the Merger or any other
matter. The opinion of Goldman Sachs
was approved by a fairness committee of
Goldman Sachs.
Request for Exemptive Relief
17. Genzyme has requested an
administrative exemption from the
Department for (a) The acquisition by
the Plan of CVRs as a result of the Plan’s
ownership of Genzyme Common Stock,
in connection with (i) The purchase of
Shares of Genzyme Common Stock
pursuant to the Exchange Offers by the
E:\FR\FM\13DEN2.SGM
13DEN2
srobinson on DSK4SPTVN1PROD with NOTICES2
77618
Federal Register / Vol. 76, No. 239 / Tuesday, December 13, 2011 / Notices
Purchaser, and (ii) the Merger of Sanofi
into Genzyme; (b) the continued holding
of CVRs by the Plan; and (c) the resale
of the CVRs by the Plan to Sanofi,
pursuant to the exercise of the
Repurchase Rights available under
certain circumstances specified in the
CVR Agreement. If granted, the
exemption would be effective as of
April 4, 2011 and it would also apply
to successor plans to the current Plan.
Genzyme concluded that if the CVRs
were to be acquired by the Plan, it
would be advisable to seek exemptive
relief from the Department because the
CVRs would likely be ‘‘employer
securities,’’ but might not constitute
‘‘qualifying employer securities,’’ as
defined in section 407(d)(5) of the Act
(i.e., stock or marketable obligations).
The Applicant states that, as registered
securities issued by Sanofi, the CVRs
would likely be ‘‘employer securities’’
under section 407(d)(1) of the Act
because Sanofi would be an ‘‘affiliate’’
of Genzyme within the meaning of
section 407(d)(7) immediately following
the closing of the tender offer inasmuch
as it would be more than 50% owned by
Sanofi. However, the Applicant further
states that it is not clear whether the
CVRs, although not ‘‘stock,’’ constitute
‘‘marketable obligations’’ within the
meaning of section 407 of the Act.
18. The Applicant represents that if
the CVRs are employer securities, but
not qualifying employer securities, the
Plan’s acquisition and holding of CVRs
would violate sections 406(a)(1)(E),
406(a)(2) and 407(a)(1) of the Act, absent
an administrative exemption. In
addition, the Applicant represents that
if Sanofi were to acquire CVRs from the
Plan pursuant to an exercise of its
Repurchase Right, the transaction
would, absent an exemption, constitute
a sale or exchange of property between
the Plan and a party in interest, in
violation of section 406(a)(1)(A) of the
Act, and a transfer to a party in interest
of assets of the Plan, in violation of
section 406(a)(1)(D) of the Act.
Moreover, the Applicant states that, to
the extent Sanofi or an affiliate is a
fiduciary of the Plan at the time of such
a transaction, such a fiduciary could be
viewed, absent an exemption, as dealing
with Plan assets for the fiduciary’s own
account, in violation of section 406(b)(1)
of the Act, or as acting in a transaction
involving the Plan on behalf of a party
whose interests are adverse to the
interests of the Plan or the interests of
its participants or beneficiaries, in
violation of section 406(b)(2) of the Act.
Finally, the Applicant states that
because the price at which the
Repurchase Right is exercisable is based
on an average trading price for the CVRs
VerDate Mar<15>2010
16:27 Dec 12, 2011
Jkt 226001
over a forty-five day trailing average,
circumstances could exist that might
cause the purchase price to be viewed
as less than ‘‘adequate consideration’’
for purposes of Section 408(e) of the
Act.
Rationale for the Transactions
19. In light of the foregoing
prohibitions, the Applicant represents
that Genzyme considered whether it
would better serve the interests of
participants and beneficiaries in the
Plan to remove Genzyme Common
Stock from the Plan prior to the
Transactions or to retain Genzyme
Common Stock in the Plan and apply
for exemptive relief covering any CVRs
received by the Plan in the
Transactions. According to the
Applicant, Genzyme determined that a
decision to eliminate Genzyme Common
Stock from the Plan would deprive
participants and beneficiaries with
interests in Genzyme Common Stock of
the ability to realize the full value of the
consideration that would be paid to
other shareholders, by forcing a preclosing sale and effectively depriving
participants of investment discretion,
including the discretion to retain an
investment in CVRs.
20. The Applicant believes that an
exemption permitting the Plan to
acquire and hold CVRs in connection
with the Transactions is in the interest
of the Plan’s participants and
beneficiaries because it maximizes their
ability to realize the full value of the
consideration offered in exchange for
their interests in Genzyme Common
Stock by continuing to give them the
discretionary ability to hold or sell the
employer securities allocated to their
accounts. The Applicant represents that
a pre-closing sale of Genzyme Common
Stock by the Plan would preclude Plan
participants from choosing to hold CVRs
within the Plan and thereby retain the
possibility of substantial future payouts,
and would instead force them to settle
for the current implied market value of
the CVRs.
21. The Applicant believes that the
proposed exemption is protective of the
rights of the Plan’s participants and
beneficiaries because it permits them to
realize the same benefits as other
shareholders in connection with the
Transactions. The Applicant states that
the conditions of the exemption would
ensure that the participants have the
same rights with respect to CVRs
allocated to their accounts under the
Plan as other holders of CVRs, including
with respect to any repurchase by
Sanofi. The Applicant further states that
the Plan’s past acquisition of the CVRs
was a one-time transaction and the
PO 00000
Frm 00026
Fmt 4701
Sfmt 4703
proposed exemption is not intended to
cover any future acquisitions of CVRs by
the Plan. However, the Applicant
represents that the Plan would not
prevent participants from investing in
CVRs outside the Plan on the same basis
as unrelated parties.
In addition, the Applicant represents
that all rights available to holders of
CVRs held outside the Plan are available
on the same basis to participants with
respect to CVRs held in accounts under
the Plan. Moreover, the Applicant states
that during the period in which CVRs
remain a Plan investment, the retention
or disposition of CVRs allocated to a
participant’s or beneficiary’s account
will be administered in accordance with
the provisions of the Plan in effect for
individually-directed investment of
participant accounts.
22. The Applicant believes that it is
administratively feasible to grant the
proposed exemption because all
conditions of the exemption either will
have been satisfied prior to the grant of
the exemption or are required to be
satisfied by the documents governing
issuance of the CVRs. In addition, the
Applicant represents that the fact that
the CVRs are registered ensures that the
regulatory scheme under the 1933 Act
and the 1934 Act will apply in full force
to the CVRs.
23. In summary, the Applicant
represents that the proposed
transactions have satisfied or will satisfy
the statutory requirements for an
exemption under section 408(a) of the
Act and section 4975(c)(2) of the Code
because:
(a) Plan participants holding Genzyme
Common Stock received one CVR for
each Share on the effective date of the
tender or cancellation of their Shares, in
connection with the Transactions.
(b) The acquisition of CVRs by the
Plan occurred in connection with the
Transactions on the same terms and in
the same manner as the acquisition of
CVRs by all other holders of Genzyme
Common Stock, other than Sanofi, the
Purchaser, Genzyme and dissenting
shareholders.
(c) The Plan’s acquisition of CVRs
resulted either from a decision by a
participant or beneficiary to tender
Shares allocated to his or her account
or, following a decision by a participant
or beneficiary not to tender Shares, by
reason of the Merger.
(d) The Plan did not pay any fees or
commissions in connection with the
acquisition of the CVRs, nor will it pay
any fees or commissions in connection
with the holding or sale of CVRs to
Sanofi pursuant to an exercise of
Sanofi’s repurchase right under the CVR
Agreement.
E:\FR\FM\13DEN2.SGM
13DEN2
Federal Register / Vol. 76, No. 239 / Tuesday, December 13, 2011 / Notices
(e) Credit Suisse Securities and
Goldman Sachs advised Genzyme that
the consideration to be received by
Genzyme Shareholders, including Plan
participants, in exchange for their
Shares was ‘‘fair,’’ from a financial point
of view.
(f) The Plan has not acquired or held
CVRs, and will not acquire or hold
CVRs, other than those acquired in
connection with the Transactions.
(g) Plan participants have had and
will continue to have the same rights
with respect to CVRs allocated to their
accounts in the Plan (including with
respect to any repurchase of CVRs by
Sanofi) as unrelated parties and they
may direct the Plan Trustee to sell CVRs
allocated to their respective accounts at
any time.
(h) For so long as CVRs remain a
permissible Plan investment, the
retention or disposition by the Plan of
CVRs allocated to a participant’s or
beneficiary’s account has been
administered and will continue to be
administered in accordance with the
provisions of the Plan that are in effect
for individually-directed investment of
participant accounts.
srobinson on DSK4SPTVN1PROD with NOTICES2
Notice to Interesed Persons
Within fifteen (15) days of the date of
publication of the proposed exemption
in the Federal Register, the Applicant
will provide notice of the proposed
exemption (consisting of a copy of the
proposed exemption, as published in
the Federal Register, and the
supplemental statement required by 29
CFR 2570.43(b)(2), (together, the
Notice)) to all current participants and
beneficiaries of the Plan. The Applicant
will provide interested persons with a
copy of the Notice, as well as an
explanatory cover letter, by first class
mail, at its own expense. The Notice
will specify that the Department must
receive all written comments and
requests for a hearing no later than
thirty (30) days from the last date of the
mailing of such Notice. Therefore,
interested persons will have forty-five
(45) days to provide their written
comments and/or hearing requests to
the Department.
For Further Information Contact:
Anna Mpras Vaughan of the
Department, telephone (202) 693–8565.
(This is not a toll-free number.)
Retirement Program for Employees of
EnPro Industries (Plan), Located in
Charlotte, NC
[Application No. D–11662]
Proposed Exemption
The Department is considering
granting an exemption under the
VerDate Mar<15>2010
16:27 Dec 12, 2011
Jkt 226001
authority of section 408(a) of the Act
and section 4975(c)(2) of the Code and
in accordance with the procedures set
forth in 29 CFR Part 2570, Subpart B (55
FR 32836, 32847, August 10, 1990).31 If
the exemption is granted, the
restrictions of sections 406(a)(1)(A) and
406(b)(1) and (b)(2) of the Act and the
sanctions resulting from the application
of section 4975(c)(1)(A) and (E) of the
Code, shall not apply, effective July 15,
2011, to the in kind contribution (the
Contribution) to the Plan of a
guaranteed investment contract (the
Annuity), issued by the Metropolitan
Life Insurance Company (MetLife), an
unrelated party, by EnPro Industries,
Inc. (EnPro or the Applicant); provided
that the following conditions are
satisfied:
(a) A qualified, independent fiduciary
(the Independent Fiduciary), acting on
behalf of the Plan, determined whether
the Contribution was in the interests of
the Plan and protective of the Plan’s
participants and beneficiaries;
(b) The Independent Fiduciary
reviewed, negotiated and approved the
terms of the Contribution on behalf of
the Plan in accordance with the
fiduciary provisions of the Act;
(c) A qualified, independent appraiser
(the Appraiser) determined the fair
market value of the Annuity prior to the
Contribution, and it updated such
valuation on the date of the
Contribution;
(d) The Annuity represented
approximately 19% of the Plan’s assets
at the time of the Contribution;
(e) The Plan incurred no fees,
commissions, or other charges or
expenses in connection with the
Contribution;
(f) The terms of the Contribution were
no less favorable to the Plan than the
terms negotiated at arm’s length under
similar circumstances between
unrelated parties; and
(g) EnPro amended the Investment
Policy Statement for the Plan in
conformity with the recommendations
of the Independent Fiduciary prior to
the Contribution.
Effective Date: If granted, this
proposed exemption will be effective as
of July 15, 2011.
Summary of Facts and Representations
1. EnPro, based in Charlotte, NC, and
its companies manufacture and market
a variety of industrial products. EnPro’s
businesses include: Garlock Sealing
Technology (Garlock), a manufacturer of
31 For purposes of this proposed exemption,
references to the provisions of Title I of the Act,
unless otherwise specified, refer also to the
corresponding provisions of the Code.
PO 00000
Frm 00027
Fmt 4701
Sfmt 4703
77619
gaskets and sealing systems; 32 GGB, a
manufacturer of various types of
lubricated plain bearings; Stemco, a
manufacturer of wheel-end component
parts and long-life systems in the
medium- and heavy-duty truck and
trailer markets; Compressor Products
International, a leading supplier of
sealing components and services for
reciprocating compressors used in
chemical plants, refineries and natural
gas processing and transmission; and
Fairbanks Morse Engine, which
manufacturers diesel and dual fuel
engines and provides parts and services
for such engines. EnPro stock is publicly
traded on the New York Stock Exchange
under the symbol ‘‘NPO.’’ EnPro
operates manufacturing facilities
throughout the world and employs
approximately 5,000 employees. EnPro
also sponsors several employee benefit
plans, including the Plan.
2. The Plan, which is closed to new
participants, is a defined benefit plan
covering U.S.-based hourly and salaried
employees of EnPro. As of January 26,
2011, the Plan had 1,400 active
employees and 1,400 deferred vested
and retirees eligible for benefits under
the Plan.33 As of January 1, 2011, the
Plan had assets of $112,488,412 and
accumulated benefit obligations of
$179,539,776.
The named fiduciary of the Plan is the
EnPro Industries, Inc. Benefits
Committee (the Committee). The
Vanguard Fiduciary Trust Company
serves as the Plan’s trustee. The
Committee appointed Evercore Trust
Company, N.A. (Evercore) to serve as
Independent Fiduciary for the Plan with
respect to the Contribution.
3. The Plan also constitutes a single
plan that is comprised of three separate
plan documents, which reflect different
benefit formulas for (a) The EnPro
Industries, Inc. Retirement Program for
Salaried Employees; (b) the EnPro
Industries, Inc. Retirement Program for
Hourly Employees; and the (c) Pension
32 EnPro represents that Garlock is currently in
Chapter 11 Bankruptcy Proceedings in the
Bankruptcy Court for the Western District of North
Carolina, but operates in the ordinary course under
Bankruptcy Court protection from asbestos claims.
Further, EnPro represents that this bankruptcy
filing will protect EnPro and its other lines of
business while permanently resolving asbestos
claims against Garlock.
33 The Applicant represents that effective January
1, 2007, future benefit accruals under the Plan were
frozen for a significant number of then current
employees of EnPro. As a result, many current
employees of EnPro who were employed on January
1, 2007 are entitled to a future benefit under the
Plan following termination of employment, but no
longer accrue benefits under the Plan. These nonaccruing current employees are included in the
number of deferred vested participants under the
Plan, as well as former employees who are entitled
to future Plan benefits.
E:\FR\FM\13DEN2.SGM
13DEN2
77620
Federal Register / Vol. 76, No. 239 / Tuesday, December 13, 2011 / Notices
Plan Between Quincy Compressor
Division and Lodge 822 of the
International Association of Machinists
and Aerospace Workers.
srobinson on DSK4SPTVN1PROD with NOTICES2
The Origins of the Annuity
4. The Annuity, that is the subject of
this exemption request, was formerly an
asset of a grantor trust (the Grantor
Trust) established by Colt Industries,
Inc. and Colt Industries Operating Corp.
(together, CIOC), predecessors to Coltec
Industries, Inc. (Coltec), a subsidiary of
EnPro. The Grantor Trust (a rabbi trust)
and another trust known as the ‘‘Colt
Midland Retiree Medical Trust’’ (the
CIOC Trust) were established in
connection with the settlement of
litigation in 1985 to retiree benefits
involving Coltec (the CIOC Settlement).
The lawsuit was filed by the United
Steel Workers of America against Colt
Industries Operating Corp. on January 5,
1985. Although the litigation was filed
and settled before EnPro came into
existence as an independent
corporation, the obligations of the
settlement became EnPro’s obligations
when it was spun off from the Goodrich
Corporation in 2002.
5. Under the terms of the CIOC
Settlement, CIOC was required to fund
both the CIOC Trust and the Grantor
Trust, both of which would be managed
by independent parties. The CIOC Trust
was established to fund lifetime retiree
medical benefits for certain CIOC
retirees and their dependents and is a
voluntary employees beneficiary
association. The CIOC Trust was funded
with $14,800,000. An actuary was to
review the funding of the CIOC Trust as
of June 30, 1994, June 30, 2004, and
June 30, 2014 to determine the projected
future costs of providing lifetime
medical benefits as of January 1, 1995,
January 1, 2005 and January 1, 2015,
respectively. If the assets of the CIOC
Trust fell below pre-set levels on those
dates, the CIOC Settlement required
CIOC to provide additional funding to
the CIOC Trust.34
To ensure that the liability of any
additional funding obligations would be
fulfilled, the CIOC Settlement required
CIOC to establish and fund the Grantor
Trust.35 The Grantor Trust would serve
34 Pursuant to the terms of the CIOC Settlement,
Coltec, as successor of CIOC, provided
approximately $2 million of additional funding to
the CIOC Trust following the January 1, 1995
valuation. However, Coltec was not required to
provide additional funding to such trust following
the January 1, 2005 valuation and withdrew a
portion of funds available in the Grantor Trust in
accordance with the terms of the CIOC Settlement.
35 EnPro represents that the assets of the Grantor
Trust have always been assets of EnPro’s corporate
predecessors or EnPro and, as such, they have never
been plan assets.
VerDate Mar<15>2010
16:27 Dec 12, 2011
Jkt 226001
as a supplemental source of funding for
those benefits only if the CIOC Trust
was financially unable to fund its
obligations. The Grantor Trust was
initially funded with a series of MetLife
guaranteed annuity contracts, whose
aggregate funding amount is not known.
The Grantor Trust also held a group
annuity contract that was a predecessor
to the Annuity (the Old Annuity),
having a face value of $13,781,486. The
Old Annuity was issued by MetLife to
the CIOC Trustee on December 11, 1997.
The Old Annuity paid interest at an
effective annual rate of 6.82%. It
permitted the contractholder to
withdraw $8.4 million on December 31,
2004 and no less than $26,209,835.28 on
December 14, 2014, the maturity date.
If no additional funding was
necessary as of January 1, 1995, January
1, 2005 or January 1, 2015, the CIOC
Settlement permitted CIOC to withdraw
a portion of the assets of the Grantor
Trust. Further, any assets remaining in
the Grantor Trust after January 1, 2015,
subject to the fulfillment of any
contribution due to the CIOC Trust,
would revert to CIOC.36
6. On May 25, 2010, Coltec reached an
agreement with the trustees of the CIOC
Trust and the Grantor Trust that would
allow the transfer of ownership of the
Old Annuity to EnPro. The agreement
required that Coltec would make a onetime $900,000 cash payment to the
CIOC Trust to be used by the CIOC
trustees for any purpose permitted
under the CIOC Trust. The parties also
agreed that the Old Annuity would be
split into two contracts. The first
contract would have a value of $2.3
million. It would be transferred to an
escrow account (the Escrow Account) in
the name of Coltec and the CIOC Trust
to ensure that funds would be available
to the CIOC Trust regardless of the
financial condition of Coltec. The
second contract, the current Annuity,
would have a remaining value of
approximately $17.85 million and
would be eventually issued to EnPro.
The parties also agreed that EnPro
would guarantee the performance of
Coltec’s funding obligations with
respect to the CIOC Trust and the
Escrow Account and that it would be
prudent for the parties to seek judicial
36 According to the most recent actuarial
valuations, the CIOC Trust’s assets are more than
sufficient to meet all of it funding needs. Therefore,
Coltec will not be required to provide additional
funding to the CIOC Trust in 2015. Further, in the
unlikely event additional funding would be
required, under an analysis of the ‘‘worst case
scenario,’’ the maximum contribution from the
Grantor Trust would be $2.7 million. This amount
is far below the approximated value of $22 million
held in the Grantor Trust prior to its termination
(See Representation 7).
PO 00000
Frm 00028
Fmt 4701
Sfmt 4703
approval since the process would
involve modification of the CIOC
Settlement.
7. In June 2010, this matter was
presented to the United States District
Court for the Western District of
Pennsylvania (the Court), which had
jurisdiction over the retiree medical
benefits litigation and had retained
jurisdiction over the CIOC and the
Grantor Trusts pursuant to the CIOC
Settlement. As a condition of approval,
the Court required notice to, and an
opportunity to comment from, the CIOC
Trust beneficiaries. Following the notice
period, the Court set a hearing on July
27, 2010. The settlement agreement
transferring ownership of the Annuity to
EnPro and establishment of the Escrow
Account was approved by the Court on
July 27, 2010. As permitted by the
Court’s order, the escrow account was
funded and the Grantor Trust was
terminated. Unencumbered title to the
portion of the Old Annuity not
deposited in the Escrow Account is
vested in EnPro.
The Annuity
8. On January 7, 2011, Metlife issued
a new group annuity contract, the
Annuity, naming EnPro as the
contractholder. The Annuity had a face
value of $17,852,632.22 on the date of
issuance. Under the terms of the
Annuity, Metlife will pay the Annuity’s
contractholder, in a single payout, no
less than $23,214,698.70 on December
31, 2014. Metlife will credit interest,
payable at a fixed rate, on amounts in
the Annuity’s funding account. Such
interest will be credited at a rate
compounded daily equivalent to an
effective annual rate of 6.82%. The
Annuity is fully funded and does not
require any further payments to MetLife
by any person. The Annuity also does
not permit early withdrawal, including
payment of Plan benefits prior to the
final maturity date.
The Transaction
9. On July 15, 2011, EnPro
contributed the Annuity to the Plan in
order to meet its funding obligations
under the Act. Therefore, EnPro
requests an administrative exemption
from the Department for the
Contribution. Absent an exemption, the
Contribution to the Plan by EnPro, a
party in interest, would violate section
406(a)(1)(A) of the Act. Additionally,
because EnPro is also a fiduciary with
respect to the Plan, the Contribution
would violate sections 406(b)(1) and (2)
of the Act.
E:\FR\FM\13DEN2.SGM
13DEN2
Federal Register / Vol. 76, No. 239 / Tuesday, December 13, 2011 / Notices
srobinson on DSK4SPTVN1PROD with NOTICES2
Annuity Appraisals
10. In an April 25, 2011 letter, the
Cognient Group, LLC of Chicago, IL
confirmed and acknowledged its status
as a qualified, independent appraiser on
behalf of Evercore, the Independent
Fiduciary. The Appraiser has also
worked for the Independent Fiduciary
(and its predecessor) on other types of
assignments. However, prior to this
engagement, the Appraiser had not
provided financial advisory services to
EnPro or its retirement plans. The
Appraiser represents that its fee from
this assignment represents less than 1%
of its annual gross income.
The Appraiser states that it has been
involved as an independent financial
adviser to plan fiduciaries for over 25
years in numerous ERISA securities
transactions. Prior to its 2009 formation,
the Appraiser explains that most of its
professionals had spent a majority of
their professional careers at the
financial services and business
valuation firm of Duff & Phelps for
approximately 25 years. The Appraiser’s
professionals have represented
independent fiduciaries and company
plan committees in numerous ERISArelated transactions.
The Appraiser represents that its
ERISA-related work for clients includes
contributions of large blocks of
restricted securities to public company
retirement plans and the sale of
securities to employee stock ownership
plans for both publicly-traded and
closely-held companies. Such securities
have also included certain fixed income
securities, such as guaranteed
investment contracts.
11. In a valuation analysis (the
Appraisal), the Appraiser valued the
Annuity initially at $20,709,088 as of
March 15, 2011. The Appraiser valued
the Annuity based on the expected cash
flows discounted at a rate that
appropriately reflected the risk of the
Contractholder receiving full payment
on the final payment date. For the cash
flow analysis, the Appraiser noted that
the Annuity’s funding account had a
balance of $18,024,481.02 as of February
28, 2011 and that interest accrued on
this balance at a rate, compounded
daily, equivalent to an effective annual
rate of 6.82%. This would result in a
projected funding account balance of
$23,227,291 as of December 31, 2014.
12. In order to select the appropriate
discount rate to apply to the expected
lump sum payment on December 31,
2014, the Appraiser reviewed MetLife’s
credit ratings and recent bond offerings.
The Appraiser noted that the major
credit rating firms currently rate
Metlife’s senior unsecured corporate
VerDate Mar<15>2010
16:27 Dec 12, 2011
Jkt 226001
bonds at investment grade and that
Metlife was rated ‘‘A-’’ by Standard and
Poor’s, ‘‘A3’’ by Moody’s Investors
Service and ‘‘A-’’ by Fitch. The
Appraiser also considered publicly
traded MetLife bonds maturing in 2014
and 2015. The first was a $350 million
bond due on June 30, 2014 with a
coupon rate of 5.5% or current yield to
maturity of 2.59%. The second was a
$1,000 million due June 30, 2015 with
a coupon rate of 5.0% or current yield
to maturity of 2.95%. In addition, the
Appraiser represents that MetLife issued
$1,000 million in new unsecured bonds
due February 6, 2014 at a coupon rate
of 2.375%. Based on this information,
the Appraiser determined that the
appropriate discount rate for the
Annuity, given its maturity date of
December 31, 2014, was 3.02% as of
March 15, 2011. According to the
Appraiser, this discount rate would
reflect current MetLife market bond
yields and the non-publicly traded
nature of the Contract.
The Appraiser then applied the
discount rate to the projected funding
account balance for the annuity of
$23,227,291 as of December 31, 2014.
After applying the discount rate and
considering the Annuity’s time to
maturity from March 15, 2011 to
December 31, 2014 (1,387 days), the
Appraiser determined that the
Annuity’s present value was
$20,709,088 as of March 15, 2011. Thus,
the annuity would represent
approximately 18% of the Plan’s assets.
13. The Appraiser updated the
Appraisal (the Appraisal Update) on the
date of the Contribution. In the
Appraisal Update, the Appraiser placed
the fair market value of the Annuity at
$21,406,713 as of July 15, 2011.
Although the Appraiser utilized the
same valuation methodology in the
Appraisal Update as it had done in the
Appraisal, there were differences in the
amounts previously calculated. For
example, in the cash flow analysis, the
Appraiser noted that the Annuity’s
funding account balance had increased
to $18,426,370.25, in contrast to the
$18,024,418.02 balance originally
determined in the Appraisal. Thus,
because of a change in the daily interest
rate, the projected funding account
balance for the Annuity as of December
31, 2014 in the Appraisal Update would
be $23,223,092, instead of $23,227,291,
as evidenced in the Appraisal.
Additionally, the Appraiser
determined, in the Appraisal Update,
that the appropriate discount rate for the
Annuity was 2.35% instead of 3.02%,
which was the rate set forth in the
Appraisal. In applying the July 15, 2011
discount rate of 2.35% to the Annuity’s
PO 00000
Frm 00029
Fmt 4701
Sfmt 4703
77621
projected funding balance of
$23,223,092 as of December 31, 2014,
and considering the Annuity’s time to
maturity (i.e., 1,265 days instead of
1,387 days), the Appraiser calculated
the Annuity’s fair market value at
$21,406,713 as of July 15, 2011. This
amount represented an increase from
the $20,709,088 fair market value of the
Annuity as of March 15, 2011 that was
set forth in the Appraisal. The fair
market value of the Annuity also
represented approximately 19% of the
Plan’s assets at the time of the
Contribution.
Independent Fiduciary’s
Recommendation
14. Pursuant to engagement letter
executed on October 6, 2010 (the
Engagement Letter), EnPro retained
Evercore as the Independent Fiduciary
to determine whether the proposed
Contribution was in the interests of the
Plan and its participants and
beneficiaries. The Independent
Fiduciary represents that it is
independent of and unrelated to EnPro
and that (a) It does not directly or
indirectly control, is not controlled by,
and is not under common control with
EnPro; (b) neither it, nor any of its
officers, directors, or employees is an
officer, director, partner or employee of
EnPro (or is a relative of such person);
and (c) it does not directly or indirectly
receive any compensation or other
consideration for its own account in
connection with the Contribution,
except that the Independent Fiduciary
may receive compensation from EnPro
for performing the services described in
the Engagement Letter as long as
amount of such payment is not
contingent upon or in any way affected
by the Independent Fiduciary’s ultimate
decision.
The Independent Fiduciary also
represents that its total fee in
connection with the subject exemption
application represents less than 1% of
its 2010 gross business income. The
Independent Fiduciary further
represents that it acknowledges and
understands its duties, responsibilities
and liabilities under the Act in acting as
a fiduciary on behalf of the Plan with
respect to the proposed transaction.
15. The Independent Fiduciary
represents that it is a national trust
bank, chartered by the U.S. Office of the
Comptroller of Currency. The
Independent Fiduciary, which formerly
comprised U.S. Trust’s Special
Fiduciary Services division, states that
it has served as an independent
fiduciary to employee benefit plans
since 1987, including serving as an
independent fiduciary to qualified plans
E:\FR\FM\13DEN2.SGM
13DEN2
srobinson on DSK4SPTVN1PROD with NOTICES2
77622
Federal Register / Vol. 76, No. 239 / Tuesday, December 13, 2011 / Notices
in connection with prior exemptions
granted by the Department. The
Independent Fiduciary also asserts that
it has extensive experience in serving as
an independent fiduciary to defined
benefits plans in connection with
proposed contributions to such plans of
qualifying employer securities.
16. In its Engagement Letter, a March
29, 2011 report, and a July 29, 2011
supplemental report, the Independent
Fiduciary agreed to perform the
following duties on behalf of the Plan:
(a) Determine whether to accept the
proposed Contribution, subject to the
Department’s grant of an exemption; (b)
cause the Appraiser, acting as Evercore’s
independent valuation expert, to
prepare a report as to the fair market
value of the Annuity; 37 (c) negotiate the
terms and conditions of the proposed
Contribution; and (d) render an opinion
suitable for submission to the
Department in connection with this
exemption request.
17. In making its determinations
about the Contribution, the Independent
Fiduciary explains that it considered
several factors. These included the
exemption application, the Annuity, the
Appraisal, the Appraiser’s spreadsheet
analysis of the Annuity, the Plan’s
Investment Annuity Statement,
communications between EnPro and its
outside counsel and a statement from
Towers Watson, the Plan’s actuary, that
the Plan had sufficient assets to cover
benefit payments through December
2014. After reviewing the Appraisal, the
Independent Fiduciary determined that
the Appraiser’s valuation approach was
appropriate.
18. The Independent Fiduciary
represents that the Plan’s assets
declined during the recent recession
and have yet to recover fully. For Plan
Year 2011, the Independent Fiduciary
explains that EnPro owed the Plan
required minimum contributions
totaling approximately $20 million and
that it intended to make a first quarter
cash contribution of $3 million. (On
April 11, 2011, EnPro contributed
$3,478,251 to the Plan.)
The Independent Fiduciary states that
EnPro estimates that it will owe the Plan
annual contributions of $21 to $24
million per year from 2011 through
2014. These contributions, according to
the Independent Fiduciary, could
impact EnPro’s financial strength, limit
its operating goals and impair its ability
to maintain the Plan in its current form.
37 In this regard, the Independent Fiduciary
reviewed and approved the methodology used by
the Appraiser and ensured that such methodology
was properly applied in determining the fair market
value of the Annuity on the date of the
Contribution.
VerDate Mar<15>2010
16:27 Dec 12, 2011
Jkt 226001
19. The Annuity, valued at
$21,406,173 as of July 15, 2011, exceeds
the amount of the required minimum
contribution for Plan Year 2011, the
Independent Fiduciary explains. Once
contributed to the Plan, the Annuity
would provide the Plan with assets in
excess of $24 million. This, in the
Independent Fiduciary’s view, would
give the Plan an incremental benefit of
more than $4 million over its required
minimum contribution for Plan Year
2011.
20. The Independent Fiduciary also
explains that it considered the quality of
the Annuity. In this regard, the
Independent Fiduciary states that the
Annuity is very similar to a zero coupon
bond.38 The Independent Fiduciary
represents that were the Plan to
purchase a zero coupon bond with a
similar time to maturity, from an issuer
with a similar credit profile as MetLife,
the Plan would not likely obtain a better
quality investment. Instead, the Plan
would receive an asset with a face value
of $17,852,632.22 and a fair market
value of $21,406,713 as of July 15, 2011.
Such asset would generate a return of
6.82% from face value and 2.35% from
fair market value until the date of
maturity on December 31, 2014,
according to the Independent Fiduciary.
Were the Plan to invest in a similar
bond, i.e., a bond with a similar time to
maturity from an issuer with a similar
credit profile, the Independent
Fiduciary explains that the return from
fair market value or yield to maturity of
that hypothetical bond would be no
better than the Annuity.
With respect to Plan benefits, the
Independent Fiduciary notes that
should the Department deny this
exemption, one of the options available
to EnPro is to impose benefit restrictions
on Plan participants. However, the
Applicant represents that the
Contribution of the Annuity, in lieu of
cash, should not have a detrimental
effect on the Plan’s ability to pay
benefits from the Contribution date until
the maturity date of the Annuity. The
Independent Fiduciary, after confirming
with the Plan’s actuary, represents that
the Plan is in a position to meet its
benefit obligations from the date of the
Contribution until the maturity date of
the Annuity on December 31, 2014.
38 The Independent Fiduciary explains that zero
coupon bonds make no coupon payments and
investors in such bonds receive par value at the
time of maturity but no interest payments. Such
bonds are issued at prices that are considerably
below par value and the return comes solely from
the difference between the issue price and the
payment of par value at maturity. The holder of the
Annuity, similarly, will receive no interest payment
in installments, but will get a lump sum payment
at maturity.
PO 00000
Frm 00030
Fmt 4701
Sfmt 4703
21. The Independent Fiduciary
represents that based on its review and
analysis of the Contribution and the
Appraisal, the Contribution was in the
interests of the Plan and its participants
and beneficiaries. Furthermore, the
Independent Fiduciary has determined
that the Contribution was fair and
reasonable, and it approved the Plan’s
acceptance of the Annuity.
22. Finally, the Independent
Fiduciary requested that EnPro amend
its Investment Policy Statement for the
Plan (the Investment Policy Statement).
This document was silent with regard to
the Contribution of the Annuity. The
value of the Annuity would have
violated certain diversification
guidelines because the Plan’s
Investment Policy Statement, prior to
the Contribution, limited fixed income
investments (with the exception of fixed
income explicitly guaranteed by the
United States) to less than 5% of the
Plan’s assets. EnPro represents that at
the time of the Contribution, the value
of the Annuity would exceed the
diversification guidelines under the
Plan’s Investment Policy Statement.
Accordingly, the Independent Fiduciary
confirmed that the Plan’s Investment
Policy Statement was amended by
EnPro to permit the Contribution.
Rationale for the Proposed Contribution
23. The Applicant represents that the
Contribution was administratively
feasible because it was a one-time
transaction that would be easy to review
and audit. In addition, the Plan was not
required to pay any fees, commissions
or expenses in connection therewith.
Moreover, the Independent Fiduciary
had been engaged to determine whether
to accept the Annuity, and, if so, the
value of the Annuity for Contribution
and funding purposes. In this regard,
the Independent Fiduciary (a) Reviewed
and approved the methodology used by
the Appraiser, (b) ensured that such
methodology was properly applied in
determining the fair market value of the
Annuity on the date of the Contribution,
and (c) determined whether it was
prudent to go forward with the
transaction. Finally, EnPro would value
the Annuity annually with the
assistance of the Appraiser or another
qualified, independent appraiser.
EnPro states that the Contribution was
also in the interests of the Plan and its
participants and beneficiaries because
the Plan realized an additional
contribution of approximately $4
million above the estimated required
minimum contribution for Plan Year
2011. In addition, the Plan obtained,
with no transaction costs, a high-quality
instrument backed by MetLife. Further,
E:\FR\FM\13DEN2.SGM
13DEN2
Federal Register / Vol. 76, No. 239 / Tuesday, December 13, 2011 / Notices
EnPro states that the Contribution was
protective of the rights of the Plan’s
participants and beneficiaries because
the Plan would be in a position to meet
its benefit obligations from the date of
the Contribution until the maturity date
of the Annuity on December 31, 2014.
EnPro notes that the Annuity pays a
daily effective interest rate equivalent to
a 6.82% annual interest rate and states
that the Plan would not likely find a
zero coupon bond with a better interest
rate.
Summary
srobinson on DSK4SPTVN1PROD with NOTICES2
24. In summary, the Applicant
represents that the Contribution
satisfied the statutory requirements for
an exemption under section 408(a) of
the Act because:
(a) The Independent Fiduciary, acting
on behalf of the Plan, determined
whether the Contribution was in the
interests of the Plan and protective of
the Plan’s participants and beneficiaries;
(b) The Independent Fiduciary
reviewed, negotiated and approved the
terms of the Contribution on behalf of
the Plan in accordance with the
fiduciary provisions of the Act;
(c) The Appraiser determined the fair
market value of the Annuity prior to the
Contribution and it updated such
valuation on the date of the
Contribution;
(d) The Annuity represented
approximately 19% of the Plan’s assets
at the time of the Contribution;
(e) The Plan incurred no fees,
commissions, or other charges or
expenses in connection with the
Contribution;
(f) The terms of the Contribution were
no less favorable to the Plan than the
terms negotiated at arm’s length under
similar circumstances between
unrelated parties; and
VerDate Mar<15>2010
16:27 Dec 12, 2011
Jkt 226001
(g) EnPro amended the Plan’s
Investment Policy Statement in
conformity with the recommendations
of the Independent Fiduciary prior to
the Contribution.
Notice to Interested Parties
Notice of the proposed exemption
will be given to interested persons
within 10 days of the publication of the
notice of proposed exemption in the
Federal Register. The notice will be
given to interested persons by first class
mail or personal delivery. Such notice
will contain a copy of the notice of
proposed exemption, as published in
the Federal Register, and a
supplemental statement, as required
pursuant to 29 CFR 2570.43(b)(2). The
supplemental statement will inform
interested persons of their right to
comment on and/or to request a hearing
with respect to the pending exemption.
Written comments and hearing requests
are due within 40 days of the
publication of the notice of proposed
exemption in the Federal Register.
For Further Information Contact: Mr.
Anh-Viet Ly of the Department at (202)
693–8648. (This is not a toll-free
number.)
General Information
The attention of interested persons is
directed to the following:
(1) The fact that a transaction is the
subject of an exemption under section
408(a) of the Act and/or section
4975(c)(2) of the Code does not relieve
a fiduciary or other party in interest or
disqualified person from certain other
provisions of the Act and/or the Code,
including any prohibited transaction
provisions to which the exemption does
not apply and the general fiduciary
responsibility provisions of section 404
of the Act, which, among other things,
require a fiduciary to discharge his
PO 00000
Frm 00031
Fmt 4701
Sfmt 9990
77623
duties respecting the plan solely in the
interest of the participants and
beneficiaries of the plan and in a
prudent fashion in accordance with
section 404(a)(1)(b) of the Act; nor does
it affect the requirement of section
401(a) of the Code that the plan must
operate for the exclusive benefit of the
employees of the employer maintaining
the plan and their beneficiaries;
(2) Before an exemption may be
granted under section 408(a) of the Act
and/or section 4975(c)(2) of the Code,
the Department must find that the
exemption is administratively feasible,
in the interests of the plan and of its
participants and beneficiaries, and
protective of the rights of participants
and beneficiaries of the plan;
(3) The proposed exemptions, if
granted, will be supplemental to, and
not in derogation of, any other
provisions of the Act and/or the Code,
including statutory or administrative
exemptions and transitional rules.
Furthermore, the fact that a transaction
is subject to an administrative or
statutory exemption is not dispositive of
whether the transaction is in fact a
prohibited transaction; and
(4) The proposed exemptions, if
granted, will be subject to the express
condition that the material facts and
representations contained in each
application are true and complete, and
that each application accurately
describes all material terms of the
transaction which is the subject of the
exemption.
Signed at Washington, DC, this 7th day of
December, 2011.
Ivan Strasfeld,
Director of Exemption Determinations,
Employee Benefits Security Administration,
U.S. Department of Labor.
[FR Doc. 2011–31741 Filed 12–12–11; 8:45 am]
BILLING CODE 4510–29–P
E:\FR\FM\13DEN2.SGM
13DEN2
Agencies
[Federal Register Volume 76, Number 239 (Tuesday, December 13, 2011)]
[Notices]
[Pages 77594-77623]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-31741]
[[Page 77593]]
Vol. 76
Tuesday,
No. 239
December 13, 2011
Part II
Department of Labor
-----------------------------------------------------------------------
Employee Benefits Security Administration
-----------------------------------------------------------------------
Proposed Exemptions From Certain Prohibited Transaction Restrictions;
Notice
Federal Register / Vol. 76, No. 239 / Tuesday, December 13, 2011 /
Notices
[[Page 77594]]
-----------------------------------------------------------------------
DEPARTMENT OF LABOR
Employee Benefits Security Administration
Proposed Exemptions From Certain Prohibited Transaction
Restrictions
AGENCY: Employee Benefits Security Administration, Labor.
ACTION: Notice of Proposed Exemptions.
-----------------------------------------------------------------------
SUMMARY: This document contains notices of pendency before the
Department of Labor (the Department) of proposed exemptions from
certain of the prohibited transaction restrictions of the Employee
Retirement Income Security Act of 1974 (ERISA or the Act) and/or the
Internal Revenue Code of 1986 (the Code). This notice includes the
following proposed exemptions: D-11517, JPMorgan Chase & Co. and its
Current and Future Affiliates and Subsidiaries (JPMorgan Chase); D-
11579, Delaware Charter Guarantee & Trust Co. d\b\a\ Principle Trust
Company (Principle Trust); D-11628, Aztec Well Servicing Company and
Related Companies Medical Plan Trust Fund (the Plan); D-11669, Genzyme
Corporation 401(k) Plan (the Plan or the Applicant); and Retirement
Program for Employees of EnPro Industries (the Plan), D-11662 et al.
DATES: All interested persons are invited to submit written comments or
requests for a hearing on the pending exemptions, unless otherwise
stated in the Notice of Proposed Exemption, within 45 days from the
date of publication of this Federal Register Notice.
ADDRESSES: Comments and requests for a hearing should state: (1) The
name, address, and telephone number of the person making the comment or
request, and (2) the nature of the person's interest in the exemption
and the manner in which the person would be adversely affected by the
exemption. A request for a hearing must also state the issues to be
addressed and include a general description of the evidence to be
presented at the hearing. All written comments and requests for a
hearing (at least three copies) should be sent to the Employee Benefits
Security Administration (EBSA), Office of Exemption Determinations,
Room N-5700, U.S. Department of Labor, 200 Constitution Avenue NW.,
Washington, DC 20210. Attention: Application No.----, stated in each
Notice of Proposed Exemption. Interested persons are also invited to
submit comments and/or hearing requests to EBSA via email or fax. Any
such comments or requests should be sent either by email to:
moffitt.betty@dol.gov, or by fax to (202) 219-0204 by the end of the
scheduled comment period. The applications for exemption and the
comments received will be available for public inspection in the Public
Documents Room of the Employee Benefits Security Administration, U.S.
Department of Labor, Room N-1513, 200 Constitution Avenue NW.,
Washington, DC 20210.
Warning: If you submit written comments or hearing requests, do not
include any personally-identifiable or confidential business
information that you do not want to be publicly-disclosed. All comments
and hearing requests are posted on the Internet exactly as they are
received, and they can be retrieved by most Internet search engines.
The Department will make no deletions, modifications or redactions to
the comments or hearing requests received, as they are public records.
SUPPLEMENTARY INFORMATION:
Notice to Interested Persons
Notice of the proposed exemptions will be provided to all
interested persons in the manner agreed upon by the applicant and the
Department within 15 days of the date of publication in the Federal
Register. Such notice shall include a copy of the notice of proposed
exemption as published in the Federal Register and shall inform
interested persons of their right to comment and to request a hearing
(where appropriate).
The proposed exemptions were requested in applications filed
pursuant to section 408(a) of the Act and/or section 4975(c)(2) of the
Code, and in accordance with procedures set forth in 29 CFR part 2570,
subpart B (55 FR 32836, 32847, August 10, 1990). Effective December 31,
1978, section 102 of Reorganization Plan No. 4 of 1978, 5 U.S.C. App. 1
(1996), transferred the authority of the Secretary of the Treasury to
issue exemptions of the type requested to the Secretary of Labor.
Therefore, these notices of proposed exemption are issued solely by the
Department.
The applications contain representations with regard to the
proposed exemptions which are summarized below. Interested persons are
referred to the applications on file with the Department for a complete
statement of the facts and representations.
JPMorgan Chase & Co. and Its Current and Future Affiliates and
Subsidiaries (JPMorgan Chase), Located in New York, New York
Application Number D-11517
Proposed Exemption
The Department is considering granting an exemption under the
authority of section 408(a) of the Employee Retirement Income Security
Act of 1974 (ERISA or the Act) and section 4975(c)(2) of the Internal
Revenue Code of 1986, as amended (the Code), and in accordance with the
procedures set forth in 29 CFR part 2570, subpart B (55 FR 32836,
32847, August 10, 1990).\1\
---------------------------------------------------------------------------
\1\ For purposes of this proposed exemption, references to
section 406 of ERISA should be read to refer as well to the
corresponding provisions of section 4975 of the Code.
---------------------------------------------------------------------------
Section I. Sales of Auction Rate Securities From Plans to JPMorgan
Chase: Unrelated to a Settlement Agreement
If the proposed exemption is granted, the restrictions of section
406(a)(1)(A) and (D) and section 406(b)(1) and (2) of the Act and the
sanctions resulting from the application of section 4975 of the Code,
by reason of section 4975(c)(1)(A), (D), and (E) of the Code, shall not
apply, effective February 1, 2008, to the sale by a Plan (as defined in
section V(e)) of an Auction Rate Security (as defined in section V(c))
to JPMorgan Chase, where such sale (an Unrelated Sale) is unrelated to,
and not made in connection with, a Settlement Agreement (as defined in
section V(f)), provided that the conditions set forth in section II
have been met.
Section II. Conditions Applicable to Transactions Described in Section
I
(a) The Plan acquired the Auction Rate Security in connection with
brokerage or advisory services provided by JPMorgan Chase;
(b) The last auction for the Auction Rate Security was
unsuccessful;
(c) Except in the case of a Plan sponsored by JPMorgan Chase for
its own employees (a JPMorgan Chase Plan), the Unrelated Sale is made
pursuant to a written offer by JPMorgan Chase (the Offer) containing
all of the material terms of the Unrelated Sale, including, but not
limited to the most recent rate information for the Auction Rate
Security (if reliable information is available). Either the Offer or
other materials available to the Plan provide the identity and par
value of the Auction Rate Security. Notwithstanding the foregoing, in
the case of a pooled
[[Page 77595]]
fund maintained or advised by JPMorgan Chase, this condition shall be
deemed met to the extent each Plan invested in the pooled fund (other
than a JPMorgan Chase Plan) receives written notice regarding the
Unrelated Sale, where such notice contains the material terms of the
Unrelated Sale, including, but not limited to, the material terms
described in the preceding sentence;
(d) The Unrelated Sale is for no consideration other than cash
payment against prompt delivery of the Auction Rate Security;
(e) The sales price for the Auction Rate Security is equal to the
par value of the Auction Rate Security, plus any accrued but unpaid
interest or dividends; \2\
---------------------------------------------------------------------------
\2\ This proposed exemption does not address tax issues. The
Department has been informed by the Internal Revenue Service and the
Department of the Treasury that they are considering providing
limited relief from the requirements of sections 72(t)(4),
401(a)(9), and 4974 of the Code with respect to retirement plans
that hold Auction Rate Securities. The Department has also been
informed by the Internal Revenue Service that if Auction Rate
Securities are purchased from a Plan in a transaction described in
sections I and III at a price that exceeds the fair market value of
those securities, then the excess value would be treated as a
contribution for purposes of applying applicable contribution and
deduction limits under sections 219, 404, 408, and 415 of the Code.
---------------------------------------------------------------------------
(f) The Plan does not waive any rights or claims in connection with
the Unrelated Sale;
(g) The decision to accept the Offer or retain the Auction Rate
Security is made by a Plan fiduciary or Plan participant or IRA owner
who is independent (as defined in section V(d)) of JPMorgan Chase.
Notwithstanding the foregoing: (1) In the case of an individual
retirement account (an IRA, as described in section V(e) below) which
is beneficially owned by an employee, officer, director or partner of
JPMorgan Chase, or a relative of any such persons, the decision to
accept the Offer or retain the Auction Rate Security may be made by
such employee, officer, director, partner, or relative; or (2) in the
case of a JPMorgan Chase Plan or a pooled fund maintained or advised by
JPMorgan Chase, the decision to accept the Offer may be made by
JPMorgan Chase after JPMorgan Chase has determined that such purchase
is in the best interest of the JPMorgan Chase Plan or pooled fund; \3\
---------------------------------------------------------------------------
\3\ The Department notes that the Act's general standards of
fiduciary conduct also would apply to the transactions described
herein. In this regard, section 404 requires, among other things,
that a fiduciary discharge his duties respecting a plan solely in
the interest of the plan's participants and beneficiaries and in a
prudent manner. Accordingly, a plan fiduciary must act prudently
with respect to, among other things, the decision to sell the
Auction Rate Security to JPMorgan Chase for the par value of the
Auction Rate Security, plus any accrued but unpaid interest or
dividends. The Department further emphasizes that it expects Plan
fiduciaries, prior to entering into any of the proposed
transactions, to fully understand the risks associated with this
type of transaction following disclosure by JPMorgan Chase of all
relevant information.
---------------------------------------------------------------------------
(h) Except in the case of a JPMorgan Chase Plan or a pooled fund
maintained or advised by JPMorgan Chase, neither JPMorgan Chase nor any
affiliate exercises investment discretion or renders investment advice
within the meaning of 29 CFR 2510.3-21(c) with respect to the decision
to accept the Offer or retain the Auction Rate Security;
(i) The Plan does not pay any commissions or transaction costs with
respect to the Unrelated Sale;
(j) The Unrelated Sale is not part of an arrangement, agreement or
understanding designed to benefit a party in interest to the Plan;
(k) JPMorgan Chase and its affiliates, as applicable, maintain, or
cause to be maintained, for a period of six (6) years from the date of
the Unrelated Sale, such records as are necessary to enable the persons
described below in paragraph (l)(1), to determine whether the
conditions of this exemption, if granted, have been met, except that--
(1) No party in interest with respect to a Plan which engages in an
Unrelated Sale, other than JPMorgan Chase and its affiliates, as
applicable, shall be subject to a civil penalty under section 502(i) of
the Act or the taxes imposed by section 4975(a) and (b) of the Code, if
such records are not maintained, or not available for examination, as
required, below, by paragraph (l)(1); and
(2) A separate prohibited transaction shall not be considered to
have occurred solely because, due to circumstances beyond the control
of JPMorgan Chase or its affiliates, as applicable, such records are
lost or destroyed prior to the end of the six-year period;
(l)(1) Except as provided below in paragraph (l)(2), and
notwithstanding any provisions of subsections (a)(2) and (b) of section
504 of the Act, the records referred to above in paragraph (k) are
unconditionally available at their customary location for examination
during normal business hours by--
(A) Any duly authorized employee or representative of the
Department, the Internal Revenue Service, or the U.S. Securities and
Exchange Commission; or
(B) Any fiduciary of any Plan, including any IRA owner, that
engages in a Sale, or any duly authorized employee or representative of
such fiduciary; or
(C) Any employer of participants and beneficiaries and any employee
organization whose members are covered by a Plan that engages in the
Unrelated Sale, or any authorized employee or representative of these
entities;
(2) None of the persons described above in paragraph (l)(1)(B)-(C)
shall be authorized to examine trade secrets of JPMorgan Chase, or
commercial or financial information which is privileged or
confidential; and
(3) Should JPMorgan Chase refuse to disclose information on the
basis that such information is exempt from disclosure, JPMorgan Chase
shall, by the close of the thirtieth (30th) day following the request,
provide a written notice advising that person of the reasons for the
refusal and that the Department may request.
Section III. Sales of Auction Rate Securities From Plans to JPMorgan
Chase: Related to a Settlement Agreement
If the proposed exemption is granted, the restrictions of section
406(a)(1)(A) and (D) and section 406(b)(1) and (2) of the Act and the
sanctions resulting from the application of section 4975 of the Code,
by reason of section 4975(c)(1)(A), (D), and (E) of the Code, shall not
apply, effective February 1, 2008, to the sale by a Plan of an Auction
Rate Security to JPMorgan Chase, where such sale (a Settlement Sale) is
related to, and made in connection with, a Settlement Agreement,
provided that the conditions set forth in Section IV have been met.
Section IV. Conditions Applicable to Transactions Described in Section
III
(a) The terms and delivery and timing of the Offer are consistent
with the requirements set forth in the Settlement Agreement;
(b) The Offer or other documents available to the Plan specifically
describe, among other things:
(1) How a Plan may determine: the Auction Rate Securities held by
the Plan with JPMorgan Chase, the purchase dates for the Auction Rate
Securities, and (if reliable information is available) the most recent
rate information for the Auction Rate Securities;
(2) The number of shares and par value of the Auction Rate
Securities available for purchase under the Offer;
(3) The background of the Offer;
(4) That participating in the Offer will not result in or
constitute a waiver of any claim of the tendering Plan;
(5) The methods and timing by which Plans may accept the Offer;
(6) The purchase dates, or the manner of determining the purchase
dates, for
[[Page 77596]]
Auction Rate Securities tendered pursuant to the Offer;
(7) The timing for acceptance by JPMorgan Chase of tendered Auction
Rate Securities;
(8) The timing of payment for Auction Rate Securities accepted by
JPMorgan Chase for payment;
(9) The methods and timing by which a Plan may elect to withdraw
tendered Auction Rate Securities from the Offer;
(10) The expiration date of the Offer;
(11) The fact that JPMorgan Chase may make purchases of Auction
Rate Securities outside of the Offer and may otherwise buy, sell, hold
or seek to restructure, redeem or otherwise dispose of the Auction Rate
Securities;
(12) A description of the risk factors relating to the Offer as
JPMorgan Chase deems appropriate;
(13) How to obtain additional information concerning the Offer; and
(14) The manner in which information concerning material amendments
or changes to the Offer will be communicated to affected Plans;
(c) The terms of the Settlement Sale are consistent with the
requirements set forth in the Settlement Agreement; and
(d) All of the conditions in Section II have been met with respect
to the Settlement Sale.
Section V. Definitions
For purposes of this proposed exemption:
(a) The term ``affiliate'' means: Any person directly or
indirectly, through one or more intermediaries, controlling, controlled
by, or under common control with such other person;
(b) The term ``control'' means: The power to exercise a controlling
influence over the management or policies of a person other than an
individual;
(c) The term ``Auction Rate Security'' means a security that:
(1) Is either a debt instrument (generally with a long-term nominal
maturity) or preferred stock; and
(2) Has an interest rate or dividend that is reset at specific
intervals through a Dutch auction process;
(d) A person is ``independent'' of JPMorgan Chase if the person is:
(1) Not JPMorgan Chase or an affiliate; and (2) not a relative (as
defined in ERISA section 3(15)) of the party engaging in the
transaction;
(e) The term ``Plan'' means: An individual retirement account or
similar account described in section 4975(e)(1)(B) through (F) of the
Code (an IRA); an employee benefit plan as defined in section 3(3) of
ERISA; or an entity holding plan assets within the meaning of 29 CFR
2510.3-101, as modified by ERISA section 3(42); and
(f) The term ``Settlement Agreement'' means: A legal settlement
involving JPMorgan Chase and a U.S. state or federal authority that
provides for the purchase of an Auction Rate Security by JPMorgan Chase
from a Plan.
Effective Date: If granted, this proposed exemption will be
effective as of February 1, 2008.
Summary of Facts and Representations
1. The applicant is JPMorgan Chase & Co. (hereinafter, either
JPMorgan Chase or the Applicant), a financial holding company
incorporated under Delaware law in 1968. JPMorgan Chase is a leading
global financial services firm, with $2.0 trillion in assets, $165.4
billion in stockholders' equity, and operations in more than 60
countries as of December 31, 2009.
2. The Applicant describes Auction Rate Securities (ARS) and the
arrangement by which ARS are bought and sold as follows. ARS are
securities (issued as debt or preferred stock) with an interest rate or
dividend that is reset at periodic intervals pursuant to a process
called a Dutch Auction. Investors submit orders to buy, hold, or sell a
specific ARS to a broker-dealer selected by the entity that issued the
ARS. The broker-dealers, in turn, submit all of these orders to an
auction agent. The auction agent's functions include collecting orders
from all participating broker-dealers by the auction deadline,
determining the amount of securities available for sale, and organizing
the bids to determine the winning bid. If there are any buy orders
placed into the auction at a specific rate, the auction agent accepts
bids with the lowest rate above any applicable minimum rate and then
successively higher rates up to the maximum applicable rate, until all
sell orders and orders that are treated as sell orders are filled. Bids
below any applicable minimum rate or above the applicable maximum rate
are rejected. After determining the clearing rate for all of the
securities at auction, the auction agent allocates the ARS available
for sale to the participating broker-dealers based on the orders they
submitted. If there are multiple bids at the clearing rate, the auction
agent will allocate securities among the bidders at such rate on a pro-
rata basis.
3. The Applicant states that, under a typical Dutch Auction
process, JPMorgan Chase is permitted, but not obligated, to submit
orders in auctions for its own account either as a bidder or a seller
and routinely does so in the auction rate securities market in its sole
discretion. JPMorgan Chase may place one or more bids in an auction for
its own account to acquire ARS for its inventory, to prevent: (a) A
failed auction (i.e., an event where there are insufficient clearing
bids which would result in the auction rate being set at a specified
rate, resulting in no ARS being sold through the auction process); or
(b) an auction from clearing at a rate that JPMorgan Chase believes
does not reflect the market for the particular ARS being auctioned.
4. The Applicant states that for many ARS, JPMorgan Chase has been
appointed by the issuer of the securities to serve as a dealer in the
auction and is paid by the issuer for its services. JPMorgan Chase is
typically appointed to serve as a dealer in the auctions pursuant to an
agreement between the issuer and JPMorgan Chase. That agreement
provides that JPMorgan Chase will receive from the issuer auction
dealer fees based on the principal amount of the securities placed
through JPMorgan Chase.
5. The Applicant states further that JPMorgan Chase may share a
portion of the auction rate dealer fees it receives from the issuer
with other broker-dealers that submit orders through JPMorgan Chase,
for those orders that JPMorgan Chase successfully places in the
auctions. Similarly, with respect to ARS for which broker-dealers other
than JPMorgan Chase act as dealer, such other broker-dealers may share
auction dealer fees with JPMorgan Chase for orders submitted by
JPMorgan Chase.
6. The Applicant represents that since February, 2008, a
significant majority of auctions have been unsuccessful. According to
the Applicant, the current state of the ARS market remains illiquid. As
a result, Plans holding ARS may not have sufficient liquidity to make
benefit payments, mandatory payments and withdrawals and expense
payments when due.\4\
---------------------------------------------------------------------------
\4\ The Department notes that Class Exemption 80-26 (45 FR 28545
(Apr. 29, 1980), as amended at 71 FR 17917 (Apr. 7, 2006)) permits
interest-free loans or other extensions of credit from a party in
interest to a plan if, among other things, the proceeds of the loan
or extension of credit are used only-- (1) For the payment of
ordinary operating expenses of the plan, including the payment of
benefits in accordance with the terms of the plan and periodic
premiums under an insurance or annuity contract, or (2) for a
purpose incidental to the ordinary operation of the plan.
---------------------------------------------------------------------------
7. The Applicant represents further that, in certain instances,
JPMorgan Chase may have previously advised or otherwise caused a Plan
to acquire and hold an ARS.\5\ In connection with JPMorgan Chase's role
in the acquisition and holding of ARS by various JPMorgan Chase
clients, including the
[[Page 77597]]
Plans, JPMorgan Chase entered into Settlement Agreements with certain
U.S. states and federal authorities. Pursuant to these Settlement
Agreements, among other things, JPMorgan Chase was required to send a
written offer to certain Plans that held ARS in connection with the
advice and/or brokerage services provided by JPMorgan Chase. As
described in further detail below, eligible Plans that accepted the
written offer were permitted to sell the ARS to JPMorgan Chase for cash
equal to the par value of such securities, plus any accrued interest
and/or dividends. According to the Applicant, in connection with an
offer issued by JPMorgan Chase pursuant to a Settlement Agreement,
JPMorgan Chase has purchased approximately $2 billion dollars in ARS.
The Applicant states that, prospectively, additional shares of ARS may
be tendered by Plans to JPMorgan Chase pursuant to an offer issued by
JPMorgan Chase pursuant to a Settlement Agreement. Accordingly, the
Applicant is requesting retroactive and prospective relief for the
Settlement Sales. With respect to Unrelated Sales, the Applicant states
that to the best of its knowledge, as of January 1, 2011, no Unrelated
Sale has occurred. However, the Applicant is requesting retroactive
relief (and prospective relief) for Unrelated Sales in the event that a
sale of ARS by a Plan to JPMorgan Chase has occurred outside the
Settlement process. If granted, the exemption would be effective as of
February 1, 2008.
---------------------------------------------------------------------------
\5\ The relief contained in this proposed exemption does not
extend to the fiduciary provisions of section 404 of the Act.
---------------------------------------------------------------------------
8. Specifically, the Applicant is requesting exemptive relief for
the sale of ARS under two different circumstances: (a) Where JPMorgan
Chase initiates the sale by sending to a Plan a written offer to
acquire the ARS, notwithstanding that such offer is not required under
a Settlement Agreement (i.e., an Unrelated Sale); and (b) where
JPMorgan Chase is required under a Settlement Agreement to send to
Plans a written offer to acquire the ARS (i.e., a Settlement Sale). The
Applicant states that the Unrelated Sales and Settlement Sales
(hereinafter, either, a Covered Sale) are in the interests of Plans. In
this regard, the Applicant states that the Covered Sales would permit
Plans to normalize Plan investments. The Applicant represents that each
Covered Sale will be for no consideration other than cash payment
against prompt delivery of the ARS, and such cash will equal the par
value of the ARS, plus any accrued but unpaid interest or dividends.
The Applicant represents further that Plans will not pay any
commissions or transaction costs with respect to any Covered Sale.
9. The Applicant represents that the proposed exemption is
protective of the Plans. The Applicant states that, except in the case
of a Plan sponsored by JPMorgan Chase for its own employees (a JPMorgan
Chase Plan), each Covered Sale will be made pursuant to a written offer
(an Offer); and the decision to accept the Offer or retain the ARS will
be made by a Plan fiduciary or Plan participant or IRA owner who is
independent of JPMorgan Chase. Additionally, each Offer will be
delivered in a manner designed to alert a Plan fiduciary that JPMorgan
Chase intends to purchase ARS from the Plan. In connection with an
Unrelated Sale, the Offer will describe the material terms of the
Unrelated Sale, including the most recent rate information for the ARS
(if reliable information is available). Either the Offer or other
materials available to the Plan will provide the identity and par value
of the ARS. Offers made in connection with a Settlement Agreement will
specifically include, among other things: The background of the Offer;
the method and timing by which a Plan may accept the Offer; the
expiration date of the Offer; a description of certain risk factors
relating to the Offer; how to obtain additional information concerning
the Offer; and the manner in which information concerning material
amendments or changes to the Offer will be communicated to affected
Plans. The Applicant states that, except in the case of a JPMorgan
Chase Plan or a pooled fund maintained or advised by JPMorgan Chase,
neither JPMorgan Chase nor any affiliate will exercise investment
discretion or render investment advice with respect to a Plan's
decision to accept the Offer or retain the ARS.\6\ In the case of a
JPMorgan Chase Plan or a pooled fund maintained or advised by JPMorgan
Chase, the decision to engage in a Covered Sale may be made by JPMorgan
Chase after JPMorgan Chase has determined that such purchase is in the
best interest of the JPMorgan Chase Plan or pooled fund. The Applicant
represents further that Plans will not waive any rights or claims in
connection with any Covered Sale.
---------------------------------------------------------------------------
\6\ The Applicant states that while there may be communication
between a Plan and JP Morgan Chase subsequent to an Offer, such
communication will not involve advice regarding whether the Plan
should accept the Offer.
---------------------------------------------------------------------------
10. The Applicant represents that the proposed exemption, if
granted, would be administratively feasible. In this regard, the
Applicant notes that each Covered Sale will occur at the par value of
the affected ARS, plus any accrued but unpaid interest or dividends,
and such value is readily ascertainable. The Applicant represents
further that JPMorgan Chase will maintain the records necessary to
enable the Department and Plan fiduciaries, among others, to determine
whether the conditions of this exemption, if granted, have been met.
11. In summary, the Applicant represents that the transactions
described herein satisfy the statutory criteria of section 408(a) of
the Act because, among other things:
(a) Except in the case of a JPMorgan Chase Plan, each Covered Sale
shall be made pursuant to a written Offer;
(b) Each Covered Sale shall be for no consideration other than cash
payment against prompt delivery of the ARS;
(c) The amount of each Covered Sale shall equal the par value of
the ARS, plus any accrued but unpaid interest or dividends;
(d) Plans will not waive any rights or claims in connection with
any Covered Sale;
(e) Except in the case of a JPMorgan Chase Plan or a pooled fund
maintained or advised by JPMorgan Chase:
(1) The decision to accept an Offer or retain the ARS shall be made
by a Plan fiduciary or Plan participant or IRA owner who is independent
of JPMorgan Chase; and
(2) Neither JPMorgan Chase nor any affiliate shall exercise
investment discretion or render investment advice within the meaning of
29 CFR 2510.3-21(c) with respect to the decision to accept the Offer or
retain the ARS;
(f) Plans shall not pay any commissions or transaction costs with
respect to any Covered Sale;
(g) A Covered Sale shall not be part of an arrangement, agreement
or understanding designed to benefit a party in interest to the
affected Plan;
(h) With respect to any Settlement Sale, the terms and delivery and
timing of the Offer, and the terms of Settlement Sale, shall be
consistent with the requirements set forth in the Settlement Agreement;
(i) JPMorgan Chase shall make available in connection with an
Unrelated Sale the material terms of the Unrelated Sale, including the
most recent rate information for the ARS (if reliable information is
available), and the identity and par value of the ARS;
(j) Each Offer made in connection with a Settlement Agreement shall
describe the material terms of the Settlement Sale, including the
following:
(1) Information regarding how the Plan can determine: The ARS held
by
[[Page 77598]]
the Plan with JPMorgan Chase, the number of shares and par value of the
ARS, purchase dates for such ARS, and (if reliable information is
available) the most recent rate information for the ARS;
(2) The background of the Offer;
(3) That participating in the Offer will not result in or
constitute a waiver of any claim of the tendering Plan;
(4) The methods and timing by which the Plan may accept the Offer;
(5) The purchase dates, or the manner of determining the purchase
dates, for ARS pursuant to the Offer;
(6) The timing for acceptance by JPMorgan Chase of tendered ARS;
(7) The timing of payment for ARS accepted by JPMorgan Chase for
payment;
(8) The methods and timing by which a Plan may elect to withdraw
tendered ARS from the Offer;
(9) The expiration date of the Offer;
(10) The fact that JPMorgan Chase may make purchases of ARS outside
of the Offer and may otherwise buy, sell, hold or seek to restructure,
redeem or otherwise dispose of the ARS;
(11) A description of the risk factors relating to the Offer as
JPMorgan Chase deems appropriate;
(12) How to obtain additional information concerning the Offer; and
(13) The manner in which information concerning material amendments
or changes to the Offer will be communicated to affected Plans.
Notice to Interested Persons
The Applicant represents that the potentially interested
participants and beneficiaries cannot all be identified and therefore
the only practical means of notifying such participants and
beneficiaries of this proposed exemption is by the publication of this
notice in the Federal Register.
Comments and requests for a hearing must be received by the
Department not later than 30 days from the date of publication of this
notice of proposed exemption in the Federal Register.
For Further Information Contact: Chris Motta of the Department,
telephone (202) 693-8544. (This is not a toll-free number.)
Delaware Charter Guarantee & Trust Co. d\b\a\ Principal Trust Company
(Principal Trust); Principal Life Insurance Company (Principal Life)
and Any Affiliates, Thereof (Collectively, Principal or the
Applicants), Located in Wilmington, Delaware and in Des Moines, Iowa
[Application No. D-11579].
Proposed Exemption
The Department of Labor (the Department) is considering granting an
exemption under the authority of section 408(a) of the Act and section
4975(c)(2) of the Code and in accordance with the procedures set forth
in 29 CFR part 2570, subpart B (55 FR 32836, 32847, August 10, 1990).
Section I--Transactions
If the exemption is granted, the restrictions of sections
406(a)(1)(D) and 406(b) of the Act and the taxes resulting from the
application of section 4975 of the Code, by reason of sections
4975(c)(1)(D) through (F) of the Code, \7\ shall not apply, as of the
effective date of this proposed exemption, to:
---------------------------------------------------------------------------
\7\ For purposes of this proposed exemption reference to
specific provisions of Title I of the Act, unless otherwise
specified, refer also to the corresponding provisions of the Code.
---------------------------------------------------------------------------
(a) The receipt of a fee by Principal, as Principal is defined,
below, in Section IV(a), from an open-end investment company or open-
end investment companies (Affiliated Fund(s)), as defined, below, in
Section IV(e), in connection with the direct investment in shares of
any such Affiliated Fund, by an employee benefit plan or by employee
benefit plans (Client Plan(s)), as defined, below, in Section IV(b),
where Principal serves as a fiduciary with respect to such Client Plan,
and where Principal:
(1) Provides investment advisory services, or similar services to
any such Affiliated Fund; and
(2) Provides to any such Affiliated Fund other services (Secondary
Service(s)), as defined, below, in Section IV(i); and
(b) In connection with the indirect investment by a Client Plan in
shares of an Affiliated Fund through investment in a pooled investment
vehicle or pooled investment vehicles (Collective Fund(s)),\8\ as
defined, below, in Section IV(j), where Principal serves as a fiduciary
with respect to such Client Plan, the receipt of fees by Principal
from:
---------------------------------------------------------------------------
\8\ The Department, herein, is expressing no opinion in this
proposed exemption regarding the reliance of the Applicants on the
relief provided by section 408(b)(8) of the Act with regard to the
purchase and with regard to the sale by a Client Plan of an interest
in a Collective Fund and the receipt by Principal, thereby, of any
investment management fee, any investment advisory fee, and any
similar fee (a Collective Fund-Level Management Fee), as defined,
below, in Section IV(n), where Principal serves as an investment
manager or investment adviser with respect to such Collective Fund
and also serves as a fiduciary with respect to such Client Plan, nor
is the Department offering any view as to whether the Applicants
satisfy the conditions, as set forth in section 408(b)(8) of the
Act.
---------------------------------------------------------------------------
(1) An Affiliated Fund for the provision of investment advisory
services, or similar services by Principal to any such Affiliated Fund;
and
(2) an Affiliated Fund for the provision of Secondary Services by
Principal to any such Affiliated Fund; provided that the conditions, as
set forth, below, in Section II and Section III, are satisfied, as of
the effective date of this proposed exemption and thereafter.
Section II--Specific Conditions
(a)(1) Each Client Plan which is invested directly in shares of an
Affiliated Fund either:
(i) Does not pay to Principal for the entire period of such
investment any investment management fee, or any investment advisory
fee, or any similar fee at the plan-level (the Plan-Level Management
Fee), as defined, below, in Section IV(m), with respect to any of the
assets of such Client Plan which are invested directly in shares of
such Affiliated Fund; or
(ii) pays to Principal a Plan-Level Management Fee, based on total
assets of such Client Plan under management by Principal at the plan-
level, from which a credit has been subtracted from such Plan-Level
Management Fee, where the amount subtracted represents such Client
Plan's pro rata share of any investment advisory fee and any similar
fee (the Affiliated Fund-Level Advisory Fee), as defined, below, in
Section IV(o), paid by such Affiliated Fund to Principal.
If, during any fee period, in the case of a Client Plan invested
directly in shares of an Affiliated Fund, such Client Plan has prepaid
its Plan-Level Management Fee, and such Client Plan purchases shares of
an Affiliated Fund directly, the requirement of this Section
II(a)(1)(ii) shall be deemed met with respect to such prepaid Plan-
Level Management Fee, if, by a method reasonably designed to accomplish
the same, the amount of the prepaid Plan-Level Management Fee that
constitutes the fee with respect to the assets of such Client Plan
invested directly in shares of an Affiliated Fund:
(A) Is anticipated and subtracted from the prepaid Plan-Level
Management Fee
[[Page 77599]]
at the time of the payment of such fee; or
(B) is returned to such Client Plan, no later than during the
immediately following fee period; or
(C) is offset against the Plan-Level Management Fee for the
immediately following fee period or for the fee period immediately
following thereafter.
For purposes of Section II(a)(1)(ii), a Plan-Level Management Fee
shall be deemed to be prepaid for any fee period, if the amount of such
Plan-Level Management Fee is calculated as of a date not later than the
first day of such period.
(2) Each Client Plan invested in a Collective Fund the assets of
which are not invested in shares of an Affiliated Fund:
(i) Does not pay to Principal for the entire period of such
investment any Plan-Level Management Fee with respect to any assets of
such Client Plan invested in such Collective Fund.
The requirements of this Section II(a)(2)(i) do not preclude the
payment of a Collective Fund-Level Management Fee by such Collective
Fund to Principal, based on the assets of such Client Plan invested in
such Collective Fund; or
(ii) does not pay to Principal for the entire period of such
investment any Collective Fund-Level Management Fee with respect to any
assets of such Client Plan invested in such Collective Fund.
The requirements of this Section II(a)(2)(ii) do not preclude the
payment of a Plan-Level Management Fee by such Client Plan to
Principal, based on total assets of such Client Plan under management
by Principal at the plan-level; or
(iii) such Client Plan pays to Principal a Plan-Level Management
Fee, based on total assets of such Client Plan under management by
Principal at the plan-level, from which a credit has been subtracted
from such Plan-Level Management Fee (the ``Net'' Plan-Level Management
Fee), where the amount subtracted represents such Client Plan's pro
rata share of any Collective Fund-Level Management Fee paid by such
Collective Fund to Principal.
The requirements of this Section II(a)(2)(iii) do not preclude the
payment of a Collective Fund-Level Management Fee by such Collective
Fund to Principal, based on the assets of such Client Plan invested in
such Collective Fund.
(3) Each Client Plan invested in a Collective Fund the assets of
which are invested in shares of an Affiliated Fund:
(i) Does not pay to Principal for the entire period of such
investment any a Plan-Level Management Fee (including any ``Net'' Plan-
Level Management Fee, as described, above, in Section II(a)(2)(iii)),
and does not pay to Principal for the entire period of such investment
any Collective Fund-Level Management Fee with respect to the assets of
such Client Plan which are invested in such Affiliated Fund; or
(ii) pays to Principal a Collective Fund-Level Management Fee, in
accordance with Section II(a)(2)(i), above, based on the total assets
of such Client Plan invested in such Collective Fund, from which a
credit has been subtracted from such Collective Fund-Level Management
Fee, where the amount subtracted represents such Client Plan's pro rata
share of any Affiliated Fund-Level Advisory Fee paid to Principal by
such Affiliated Fund; and does not pay to Principal for the entire
period of such investment any Plan-Level Management Fee with respect to
any assets of such Client Plan invested in such Collective Fund; or
(iii) pays to Principal a Plan-Level Management Fee, in accordance
with Section II(a)(2)(iii), above, based on the total assets of such
Client Plan under management by Principal at the plan-level, from which
a credit has been subtracted from such Plan-Level Management Fee, where
the amount subtracted represents such Client Plan's pro rata share of
any Affiliated Fund-Level Advisory Fee paid to Principal by such
Affiliated Fund; and does not pay to Principal for the entire period of
such investment any Collective Fund-Level Management Fee with respect
to any assets of such Client Plan invested in such Collective Fund; or
(iv) pays to Principal a ``Net'' Plan-Level Management Fee, in
accordance with Section II(a)(2)(iii), above, from which a further
credit has been subtracted from such ``Net'' Plan-Level Management Fee,
where the amount of such further credit which is subtracted represents
such Client Plan's pro rata share of any Affiliated Fund-Level Advisory
Fee paid to Principal by such Affiliated Fund.
Provided that the conditions of this proposed exemption are
satisfied, the requirements of Section II(a)(1)(i), (ii), and Section
II(a)(3)(i)-(iv) do not preclude the payment of an Affiliated Fund-
Level Advisory Fee by an Affiliated Fund to Principal under the terms
of an investment advisory agreement adopted in accordance with section
15 of the Investment Company Act of 1940 (the Investment Company Act).
Further, the requirements of Section II(a)(1)(i)-(ii), and Section
II(a)(3)(i)-(iv) do not preclude the payment of a fee by an Affiliated
Fund to Principal for the provision by Principal of Secondary Services
to such Affiliated Fund under the terms of a duly adopted agreement
between Principal and such Affiliated Fund.
For the purpose of Section II(a)(1)(ii), and Section II(a)(3)(ii)-
(iv), in calculating a Client Plan's pro rata share of an Affiliated
Fund-Level Advisory Fee, Principal must use an amount representing the
``gross'' advisory fee paid to Principal by such Affiliated Fund. For
purposes of this paragraph, the ``gross'' advisory fee is the amount
paid to Principal by such Affiliated Fund, including the amount paid by
such Affiliated Fund to sub-advisers.
(b) The purchase price paid and the sales price received by a
Client Plan for shares in an Affiliated Fund purchased or sold
directly, and the purchase price paid and the sales price received by a
Client Plan for shares in an Affiliated Fund purchased or sold
indirectly through a Collective Fund, is the net asset value per share
(NAV), as defined, below, in Section IV(f), at the time of the
transaction, and is the same purchase price that would have been paid
and the same sales price that would have been received for such shares
by any other shareholder of the same class of shares in such Affiliated
Fund at that time.\9\
---------------------------------------------------------------------------
\9\ The selection of a particular class of shares of an
Affiliated Fund as an investment for a Client Plan indirectly
through a Collective Fund is a fiduciary decision that must be made
in accordance with the provisions of section 404(a) of the Act. In
this proposed exemption, the Department is not providing any relief
for any fiduciary violations, pursuant to section 404 of the Act, or
violations of the prohibited transaction provisions, as set forth in
section 406 of the Act that may arise from the selection of one
class of shares of an Affiliated Fund over another class of shares.
---------------------------------------------------------------------------
(c) Principal, including any officer and any director of Principal,
does not purchase any shares of an Affiliated Fund from and does not
sell any shares of an Affiliated Fund to any Client Plan which invests
directly in such Affiliated Fund, and Principal, including any officer
and director of Principal, does not purchase any shares of any
Affiliated Fund from and does not sell any shares of an Affiliated Fund
to any Collective Fund in which a Client Plan invests indirectly in
shares of such Affiliated Fund.
(d) No sales commissions, no redemption fees, and no other similar
fees are paid in connection with any purchase and in connection with
any sale by a Client Plan directly in shares of an Affiliated Fund, and
no sales commissions, no redemption fees, and no other similar fees are
paid by a Collective Fund in connection with any purchase and in
connection with any sale of shares in an Affiliated Fund by a Client
Plan indirectly through such
[[Page 77600]]
Collective Fund. However, this Section II(d) does not prohibit the
payment of a redemption fee, if:
(1) Such redemption fee is paid only to an Affiliated Fund; and
(2) The existence of such redemption fee is disclosed in the
summary prospectus for such Affiliated Fund in effect both at the time
of any purchase of shares in such Affiliated Fund and at the time of
any sale of such shares.
(e) The combined total of all fees received by Principal is not in
excess of reasonable compensation within the meaning of section
408(b)(2) of the Act, for services provided:
(1) By Principal to each Client Plan;
(2) By Principal to each Collective Fund in which a Client Plan
invests; and
(3) By Principal to each Affiliated Fund in which a Client Plan
invests directly in shares of such Affiliated Fund, and
(4) By Principal to each Affiliated Fund in which a Client Plan
invests indirectly in shares of such Affiliated Fund through a
Collective Fund.
(f) Principal does not receive any fees payable pursuant to Rule
12b-1 under the Investment Company Act in connection with the
transactions covered by this proposed exemption;
(g) No Client Plan is an employee benefit plan sponsored or
maintained by Principal.
(h)(1) In the case of a Client Plan investing directly in shares of
an Affiliated Fund, a second fiduciary (the Second Fiduciary), as
defined, below, in Section IV(h), acting on behalf of such Client Plan,
receives, in writing, in advance of any investment by such Client Plan
directly in shares of such Affiliated Fund, a full and detailed
disclosure via first class mail or via personal delivery of (or, if the
Second Fiduciary consents to such means of delivery, through electronic
email, in accordance with Section II(q), as set forth, below) of
information concerning such Affiliated Fund, including but not limited
to the items listed, below:
(i) A current summary prospectus issued by each such Affiliated
Fund;
(ii) A statement describing the fees, including the nature and
extent of any differential between the rates of such fees for:
(A) Investment advisory and similar services to be paid to
Principal by each Affiliated Fund;
(B) Secondary Services to be paid to Principal by each such
Affiliated Fund; and
(C) All other fees to be charged by Principal to such Client Plan
and to each such Affiliated Fund and all other fees to be paid to
Principal by each such Client Plan and by each such Affiliated Fund;
(iii) The reasons why Principal may consider investment directly in
shares of such Affiliated Fund by such Client Plan to be appropriate
for such Client Plan;
(iv) A statement describing whether there are any limitations
applicable to Principal with respect to which assets of such Client
Plan may be invested directly in shares of such Affiliated Fund, and if
so, the nature of such limitations; and
(v) Upon the request of the Second Fiduciary acting on behalf of
such Client Plan, a copy of the Notice of Proposed Exemption (the
Notice), a copy of the final exemption, if granted, and any other
reasonably available information regarding the transactions which are
the subject of this proposed exemption.
(2) In the case of a Client Plan whose assets are proposed to be
invested in a Collective Fund after such Collective Fund has begun
investing in shares of an Affiliated Fund, a Second Fiduciary, acting
on behalf of such Client Plan, receives, in writing, in advance of any
investment by such Client Plan in such Collective Fund, a full and
detailed disclosure via first class mail or via personal delivery (or,
if the Second Fiduciary consents to such means of delivery, through
electronic email, in accordance with Section II(q), as set forth,
below) of information concerning such Collective Fund and information
concerning each such Affiliated Fund in which such Collective Fund is
invested, including but not limited to the items listed, below:
(i) A current summary prospectus issued by each such Affiliated
Fund;
(ii) A statement describing the fees, including the nature and
extent of any differential between the rates of such fees for:
(A) Investment advisory and similar services to be paid to
Principal by each Affiliated Fund;
(B) Secondary Services to be paid to Principal by each such
Affiliated Fund; and
(C) All other fees to be charged by Principal to such Client Plan,
to such Collective Fund, and to each such Affiliated Fund and all other
fees to be paid to Principal by such Client Plan, by such Collective
Fund, and by each such Affiliated Fund;
(iii) The reasons why Principal may consider investment by such
Client Plan in shares of each such Affiliated Fund indirectly through
such Collective Fund to be appropriate for such Client Plan;
(iv) A statement describing whether there are any limitations
applicable to Principal with respect to which assets of such Client
Plan may be invested indirectly in shares of each such Affiliated Fund
through such Collective Fund, and if so, the nature of such
limitations;
(v) Upon the request of the Second Fiduciary, acting on behalf of
such Client Plan, a copy of the Notice, a copy of the final exemption,
if granted, and any other reasonably available information regarding
the transactions which are the subject of this proposed exemption; and
(vi) A copy of the organizational documents of such Collective Fund
which expressly provide for the addition of one or more Affiliated
Funds to the portfolio of such Collective Fund.
(3) In the case of a Client Plan whose assets are proposed to be
invested in a Collective Fund before such Collective Fund has begun
investing in shares of any Affiliated Fund, a Second Fiduciary, acting
on behalf of such Client Plan, receives, in writing, in advance of any
investment by such Client Plan in such Collective Fund, a full and
detailed disclosure via first class mail or via personal delivery (or,
if the Second Fiduciary consents to such means of delivery, through
electronic email, in accordance with Section II(q), as set forth,
below) of information, concerning such Collective Fund, including but
not limited to the items listed, below:
(i) A statement describing the fees, including the nature and
extent of any differential between the rates of such fees for all fees
to be charged by Principal to such Client Plan and to such Collective
Fund and all other fees to be paid to Principal by such Client Plan,
and by such Collective Fund;
(ii) Upon the request of the Second Fiduciary, acting on behalf of
such Client Plan, a copy of the Notice, a copy of the final exemption,
if granted, and any other reasonably available information regarding
the transactions which are the subject of this proposed exemption; and
(iii) A copy of the organizational documents of such Collective
Fund which expressly provide for the addition of one or more Affiliated
Funds to the portfolio of such Collective Fund.
(i) On the basis of the information described, above, in Section
II(h), a Second Fiduciary, acting on behalf of a Client Plan:
(1) Authorizes in writing the investment of the assets of such
Client Plan, as applicable:
(i) Directly in shares of an Affiliated Fund;
(ii) Indirectly in shares of an Affiliated Fund through a
Collective
[[Page 77601]]
Fund where such Collective Fund has already invested in shares of an
Affiliated Fund; and
(iii) In a Collective Fund which is not yet invested in shares of
an Affiliated Fund but whose organizational document expressly provides
for the addition of one or more Affiliated Funds to the portfolio of
such Collective Fund; and
(2) Authorizes in writing; as applicable:
(i) The Affiliated Fund-Level Advisory Fee received by Principal
for investment advisory services and similar services provided by
Principal to such Affiliated Fund;
(ii) The fee received by Principal for Secondary Services provided
by Principal to such Affiliated Fund;
(iii) The Collective Fund-Level Management Fee received by
Principal for investment management, investment advisory, and similar
services provided by Principal to such Collective Fund in which such
Client Plan invests;
(iv) The Plan-Level Management Fee received by Principal for
investment management and similar services provided by Principal to
such Client Plan at the plan-level; and
(v) The selection by Principal of the applicable fee method, as
described, above, in Section II(a)(1)-(3).
All authorizations made by a Second Fiduciary, pursuant to this
Section II(i), must be consistent with the responsibilities,
obligations, and duties imposed on fiduciaries by Part 4 of Title I of
the Act;
(j)(1) Any authorization, described, above, in Section II(i), and
any authorization made pursuant to negative consent, as described,
below, in Section II(k) and in Section II(l), made by a Second
Fiduciary, acting on behalf of a Client Plan, shall be terminable at
will by such Second Fiduciary, without penalty to such Client Plan,
upon receipt by Principal via first class mail, via personal delivery,
or via electronic email of a written notification of the intent of such
Second Fiduciary to terminate any such authorization.
(2) A form (the Termination Form) expressly providing an election
to terminate any authorization, described, above, in Section II(i), or
to terminate any authorization made pursuant to negative consent, as
described, below, in Section II(k) and in Section II(l), with
instructions on the use of such Termination Form must be provided to
such Second Fiduciary at least annually, either in writing via first
class mail or via personal delivery (or if such Second Fiduciary
consents to such means of delivery, through electronic email, in
accordance with Section II(q), as set forth, below). However, if a
Termination Form has been provided to such Second Fiduciary, pursuant
to Section II(k) or pursuant to Section II(l), below, then a
Termination Form need not be provided again, pursuant to this Section
II(j), until at least six (6) months but no more than twelve (12)
months have elapsed, since a Termination Form was provided;
(3) The instructions for the Termination Form must include the
following statements:
(i) Any authorization, described, above, in Section II(i), and any
authorization made pursuant to negative consent, as described, below,
in Section II(k) or in Section II(l), is terminable at will by a Second
Fiduciary, acting on behalf of a Client Plan, without penalty to such
Client Plan, upon receipt by Principal via first class mail or via
personal delivery or via electronic email of the Termination Form, or
some other written notification of the intent of such Second Fiduciary
to terminate such authorization;
(ii) Within 30 days from the date the Termination Form is sent to
such Second Fiduciary by Principal, the failure by such Second
Fiduciary to return such Termination Form or the failure by such Second
Fiduciary to provide some other written notification of the Client
Plan's intent to terminate any authorization, described in Section
II(i), or intent to terminate any authorization made pursuant to
negative consent, as described, below, in Section II(k) or in Section
II(l), will be deemed to be an approval by such Second Fiduciary;
(4) In the event that a Second Fiduciary, acting on behalf of a
Client Plan, at any time returns a Termination Form or returns some
other written notification of intent to terminate any authorization, as
described, above, in Section II(i), or intent to terminate any
authorization made pursuant to negative consent, as described, below,
in Section II(k) or in Section II(l);
(i)(A) In the case of a Client Plan which invests directly in
shares of an Affiliated Fund, the termination will be implemented by
the withdrawal of all investments made by such Client Plan in the
affected Affiliated Fund, and such withdrawal will be effected by
Principal within one (1) Business day of the date that Principal
receives such Termination Form or receives from the Second Fiduciary,
acting on behalf of such Client Plan, some other written notification
of intent to terminate any such authorization;
(B) From the date a Second Fiduciary, acting on behalf of a Client
Plan that invests directly in shares of an Affiliated Fund, returns a
Termination Form or returns some other written notification of intent
to terminate such Client Plan's investment in such Affiliated Fund,
such Client Plan will not be subject to pay a pro rata share of any
Affiliated Fund-Level Advisory Fee and will not be subject to pay any
fees for Secondary Services paid to Principal by such Affiliated Fund;
(ii)(A) In the case of a Client Plan which invests in a Collective
Fund, the termination will be implemented by the withdrawal of such
Client Plan from all investments in such affected Collective Fund, and
such withdrawal will be implemented by Principal within such time as
may be necessary for withdrawal in an orderly manner that is equitable
to the affected withdrawing Client Plan and to all non-withdrawing
Client Plans, but in no event shall such withdrawal be implemented by
Principal more than five business (5) days after the day Principal
receives from the Second Fiduciary, acting on behalf of such
withdrawing Client Plan, a Termination Form or receives some other
written notification of intent to terminate the investment of such
Client Plan in such Collective Fund; and
(B) Principal will pay to such withdrawing Client Plan interest on
the settlement amount calculated at the prevailing Federal funds rate
plus two percent (2%) for the period from the day Principal receives
from the Second Fiduciary, acting on behalf of such withdrawing Client
Plan, a Termination Form or receives some other written notification of
intent to terminate the investment of such Client Plan in such
Collective Fund, to the date Principal pays such settlement amount in
cash, with interest thereon, to such withdrawing Client Plan;
(C) From the date a Second Fiduciary, acting on behalf of a Client
Plan that invests in a Collective Fund, returns a Termination Form or
returns some other written notification of intent to terminate such
Client Plan's investment in such Collective Fund, such Client Plan will
not be subject to pay a pro rata share of any Collective Fund-Level
Management Fee, nor will such Client Plan be subject to any other
changes to the portfolio of such Collective Fund, including a pro rata
share of any Affiliated Fund-Level Advisory Fee arising from the
investment by such Collective Fund in an Affiliated Fund.
(k)(1) Principal, at least thirty (30) days in advance of the
implementation of each fee increase (Fee Increase(s)), as defined,
below, in Section IV(l), must provide, in writing via first class mail
or via personal delivery (or if the Second Fiduciary consents to such
means of delivery, through electronic email, in
[[Page 77602]]
accordance with Section II(q), as set forth, below), a notice of change
in fees (the Notice of Change in Fees) (which may take the form of a
proxy statement, letter, or similar communication which is separate
from the summary prospectus of such Affiliated Fund) and which explains
the nature and the amount of such Fee Increase to the Second Fiduciary
of each affected Client Plan. Such Notice of Change in Fees shall be
accompanied by a Termination Form and by instructions on the use of
such Termination Form, as described, above, in Section II(j)(3);
(2) For each Client Plan affected by a Fee Increase, Principal may
implement such Fee Increase without waiting for the expiration of the
30-day period, described, above, in Section II(k)(1), provided
Principal does not begin implementation of such Fee Increase before the
first day of the 30-day period, described, above in Section II(k)(1),
and provided further that the following conditions are satisfied:
(i) Principal delivers, in the manner described in Section
II(k)(1), to the Second Fiduciary for each affected Client Plan, the
Notice of Change of Fees, as described in Section II(k)(1), accompanied
by the Termination Form and by instructions on the use of such
Termination Form, as described, above, in Section II(j)(3);
(ii) Each affected Client Plan receives from Principal a credit in
cash equal to each such Client Plan's pro rata share of such Fee
Increase to be received by Principal for the period from the date of
the implementation of such Fee Increase to the earlier of:
(A) The date when an affected Client Plan, pursuant to Section
II(j), terminates any authorization, as described, above, in Section
II(i), or, terminates any negative consent authorization, as described,
in Section II(k) or in Section II(l); or
(B) The 30th day after the day that Principal delivers to the
Second Fiduciary of each affected Client Plan the Notice of Change of
Fees, described in Section II(k)(1), accompanied by the Termination
Form and by the instructions on the use of such Termination Form, as
described, above, in Section II(j)(3).
(iii) Principal pays to each affected Client Plan the cash credit,
described, above, in Section II(k)(2)(ii), with interest thereon, no
later than five (5) business days following the earlier of:
(A) the date such affected Client Plan, pursuant to Section II(j),
terminates any authorization, as described, above, in Section II(i), or
terminates, any negative consent authorization, as described, in
Section II(k) or in Section II(l); or
(B) the 30th day after the day that Principal delivers to the
Secon